id	sid	tid	token	lemma	pos
ajlm-975	1	1	abstract	abstract	ADJ
ajlm-975	1	2	introduction	introduction	NOUN
ajlm-975	1	3	methods	method	NOUN
ajlm-975	1	4	results	result	VERB
ajlm-975	1	5	discussion	discussion	NOUN
ajlm-975	1	6	acknowledgements	acknowledgement	NOUN
ajlm-975	1	7	references	reference	NOUN
ajlm-975	1	8	about	about	ADP
ajlm-975	1	9	the	the	DET
ajlm-975	1	10	author(s	author(s	PROPN
ajlm-975	1	11	)	)	PUNCT
ajlm-975	1	12	jude	jude	PROPN
ajlm-975	1	13	o.	o.	PROPN
ajlm-975	1	14	okoye	okoye	PROPN
ajlm-975	1	15	department	department	PROPN
ajlm-975	1	16	of	of	ADP
ajlm-975	1	17	medical	medical	ADJ
ajlm-975	1	18	laboratory	laboratory	NOUN
ajlm-975	1	19	science	science	NOUN
ajlm-975	1	20	,	,	PUNCT
ajlm-975	1	21	school	school	NOUN
ajlm-975	1	22	of	of	ADP
ajlm-975	1	23	public	public	ADJ
ajlm-975	1	24	and	and	CCONJ
ajlm-975	1	25	allied	ally	VERB
ajlm-975	1	26	health	health	NOUN
ajlm-975	1	27	,	,	PUNCT
ajlm-975	1	28	babcock	babcock	PROPN
ajlm-975	1	29	university	university	PROPN
ajlm-975	1	30	,	,	PUNCT
ajlm-975	1	31	ilishan	ilishan	NOUN
ajlm-975	1	32	-	-	PUNCT
ajlm-975	1	33	remo	remo	NOUN
ajlm-975	1	34	,	,	PUNCT
ajlm-975	1	35	ogun	ogun	PROPN
ajlm-975	1	36	state	state	PROPN
ajlm-975	1	37	,	,	PUNCT
ajlm-975	1	38	nigeria	nigeria	PROPN
ajlm-975	1	39	department	department	PROPN
ajlm-975	1	40	of	of	ADP
ajlm-975	1	41	medical	medical	ADJ
ajlm-975	1	42	laboratory	laboratory	NOUN
ajlm-975	1	43	science	science	NOUN
ajlm-975	1	44	,	,	PUNCT
ajlm-975	1	45	faculty	faculty	NOUN
ajlm-975	1	46	of	of	ADP
ajlm-975	1	47	health	health	NOUN
ajlm-975	1	48	sciences	sciences	PROPN
ajlm-975	1	49	and	and	CCONJ
ajlm-975	1	50	technology	technology	NOUN
ajlm-975	1	51	,	,	PUNCT
ajlm-975	1	52	college	college	NOUN
ajlm-975	1	53	of	of	ADP
ajlm-975	1	54	medicine	medicine	NOUN
ajlm-975	1	55	,	,	PUNCT
ajlm-975	1	56	nnamdi	nnamdi	PROPN
ajlm-975	1	57	azikiwe	azikiwe	PROPN
ajlm-975	1	58	university	university	PROPN
ajlm-975	1	59	,	,	PUNCT
ajlm-975	1	60	nnewi	nnewi	NOUN
ajlm-975	1	61	campus	campus	PROPN
ajlm-975	1	62	,	,	PUNCT
ajlm-975	1	63	anambra	anambra	PROPN
ajlm-975	1	64	,	,	PUNCT
ajlm-975	1	65	nigeria	nigeria	PROPN
ajlm-975	1	66	anthony	anthony	PROPN
ajlm-975	1	67	a.	a.	PROPN
ajlm-975	1	68	ngokere	ngokere	PROPN
ajlm-975	1	69	department	department	PROPN
ajlm-975	1	70	of	of	ADP
ajlm-975	1	71	medical	medical	ADJ
ajlm-975	1	72	laboratory	laboratory	NOUN
ajlm-975	1	73	science	science	NOUN
ajlm-975	1	74	,	,	PUNCT
ajlm-975	1	75	faculty	faculty	NOUN
ajlm-975	1	76	of	of	ADP
ajlm-975	1	77	health	health	NOUN
ajlm-975	1	78	sciences	sciences	PROPN
ajlm-975	1	79	and	and	CCONJ
ajlm-975	1	80	technology	technology	NOUN
ajlm-975	1	81	,	,	PUNCT
ajlm-975	1	82	college	college	NOUN
ajlm-975	1	83	of	of	ADP
ajlm-975	1	84	medicine	medicine	NOUN
ajlm-975	1	85	,	,	PUNCT
ajlm-975	1	86	nnamdi	nnamdi	PROPN
ajlm-975	1	87	azikiwe	azikiwe	PROPN
ajlm-975	1	88	university	university	PROPN
ajlm-975	1	89	,	,	PUNCT
ajlm-975	1	90	nnewi	nnewi	NOUN
ajlm-975	1	91	campus	campus	PROPN
ajlm-975	1	92	,	,	PUNCT
ajlm-975	1	93	anambra	anambra	PROPN
ajlm-975	1	94	,	,	PUNCT
ajlm-975	1	95	nigeria	nigeria	PROPN
ajlm-975	1	96	charles	charles	PROPN
ajlm-975	1	97	c.	c.	PROPN
ajlm-975	1	98	onyenekwe	onyenekwe	PROPN
ajlm-975	1	99	department	department	PROPN
ajlm-975	1	100	of	of	ADP
ajlm-975	1	101	medical	medical	ADJ
ajlm-975	1	102	laboratory	laboratory	NOUN
ajlm-975	1	103	science	science	NOUN
ajlm-975	1	104	,	,	PUNCT
ajlm-975	1	105	faculty	faculty	NOUN
ajlm-975	1	106	of	of	ADP
ajlm-975	1	107	health	health	NOUN
ajlm-975	1	108	sciences	sciences	PROPN
ajlm-975	1	109	and	and	CCONJ
ajlm-975	1	110	technology	technology	NOUN
ajlm-975	1	111	,	,	PUNCT
ajlm-975	1	112	college	college	NOUN
ajlm-975	1	113	of	of	ADP
ajlm-975	1	114	medicine	medicine	NOUN
ajlm-975	1	115	,	,	PUNCT
ajlm-975	1	116	nnamdi	nnamdi	PROPN
ajlm-975	1	117	azikiwe	azikiwe	PROPN
ajlm-975	1	118	university	university	PROPN
ajlm-975	1	119	,	,	PUNCT
ajlm-975	1	120	nnewi	nnewi	NOUN
ajlm-975	1	121	campus	campus	PROPN
ajlm-975	1	122	,	,	PUNCT
ajlm-975	1	123	anambra	anambra	PROPN
ajlm-975	1	124	,	,	PUNCT
ajlm-975	1	125	nigeria	nigeria	PROPN
ajlm-975	1	126	olaposi	olaposi	PROPN
ajlm-975	1	127	omotuyi	omotuyi	PROPN
ajlm-975	1	128	department	department	PROPN
ajlm-975	1	129	of	of	ADP
ajlm-975	1	130	biochemistry	biochemistry	NOUN
ajlm-975	1	131	,	,	PUNCT
ajlm-975	1	132	centre	centre	NOUN
ajlm-975	1	133	for	for	ADP
ajlm-975	1	134	biotechnology	biotechnology	NOUN
ajlm-975	1	135	,	,	PUNCT
ajlm-975	1	136	adekunle	adekunle	PROPN
ajlm-975	1	137	ajasin	ajasin	PROPN
ajlm-975	1	138	university	university	PROPN
ajlm-975	1	139	,	,	PUNCT
ajlm-975	1	140	akungba	akungba	NOUN
ajlm-975	1	141	-	-	PUNCT
ajlm-975	1	142	akoko	akoko	NOUN
ajlm-975	1	143	,	,	PUNCT
ajlm-975	1	144	ondo	ondo	NOUN
ajlm-975	1	145	,	,	PUNCT
ajlm-975	1	146	nigeria	nigeria	PROPN
ajlm-975	1	147	deborah	deborah	PROPN
ajlm-975	1	148	i.	i.	PROPN
ajlm-975	1	149	dada	dada	PROPN
ajlm-975	1	150	department	department	PROPN
ajlm-975	1	151	of	of	ADP
ajlm-975	1	152	medical	medical	ADJ
ajlm-975	1	153	laboratory	laboratory	NOUN
ajlm-975	1	154	science	science	NOUN
ajlm-975	1	155	,	,	PUNCT
ajlm-975	1	156	school	school	NOUN
ajlm-975	1	157	of	of	ADP
ajlm-975	1	158	public	public	ADJ
ajlm-975	1	159	and	and	CCONJ
ajlm-975	1	160	allied	ally	VERB
ajlm-975	1	161	health	health	NOUN
ajlm-975	1	162	,	,	PUNCT
ajlm-975	1	163	babcock	babcock	PROPN
ajlm-975	1	164	university	university	PROPN
ajlm-975	1	165	,	,	PUNCT
ajlm-975	1	166	ilishan	ilishan	NOUN
ajlm-975	1	167	-	-	PUNCT
ajlm-975	1	168	remo	remo	NOUN
ajlm-975	1	169	,	,	PUNCT
ajlm-975	1	170	ogun	ogun	PROPN
ajlm-975	1	171	state	state	PROPN
ajlm-975	1	172	,	,	PUNCT
ajlm-975	1	173	nigeria	nigeria	PROPN
ajlm-975	1	174	citation	citation	PROPN
ajlm-975	1	175	okoye	okoye	PROPN
ajlm-975	1	176	jo	jo	PROPN
ajlm-975	1	177	,	,	PUNCT
ajlm-975	1	178	ngokere	ngokere	NOUN
ajlm-975	1	179	aa	aa	NOUN
ajlm-975	1	180	,	,	PUNCT
ajlm-975	1	181	onyenekwe	onyenekwe	NOUN
ajlm-975	1	182	cc	cc	PROPN
ajlm-975	1	183	,	,	PUNCT
ajlm-975	1	184	omotuyi	omotuyi	NOUN
ajlm-975	1	185	o	o	NOUN
ajlm-975	1	186	,	,	PUNCT
ajlm-975	1	187	dada	dada	PROPN
ajlm-975	1	188	di	di	PROPN
ajlm-975	1	189	.	.	PROPN
ajlm-975	1	190	epstein	epstein	PROPN
ajlm-975	1	191	-	-	PUNCT
ajlm-975	1	192	barr	barr	PROPN
ajlm-975	1	193	virus	virus	PROPN
ajlm-975	1	194	,	,	PUNCT
ajlm-975	1	195	human	human	ADJ
ajlm-975	1	196	papillomavirus	papillomavirus	NOUN
ajlm-975	1	197	and	and	CCONJ
ajlm-975	1	198	herpes	herpe	NOUN
ajlm-975	1	199	simplex	simplex	NOUN
ajlm-975	1	200	virus	virus	NOUN
ajlm-975	1	201	2	2	NUM
ajlm-975	1	202	co	co	NOUN
ajlm-975	1	203	-	-	NOUN
ajlm-975	1	204	presence	presence	NOUN
ajlm-975	1	205	severely	severely	ADV
ajlm-975	1	206	dysregulates	dysregulate	VERB
ajlm-975	1	207	mirna	mirna	NOUN
ajlm-975	1	208	expression	expression	NOUN
ajlm-975	1	209	.	.	PUNCT
ajlm-975	2	1	afr	afr	PROPN
ajlm-975	2	2	j	j	PROPN
ajlm-975	2	3	lab	lab	PROPN
ajlm-975	2	4	med	med	PROPN
ajlm-975	2	5	.	.	PUNCT
ajlm-975	3	1	2021;10(1	2021;10(1	NUM
ajlm-975	3	2	)	)	PUNCT
ajlm-975	3	3	,	,	PUNCT
ajlm-975	3	4	a975	a975	PROPN
ajlm-975	3	5	.	.	PUNCT
ajlm-975	4	1	https://doi.org/10.4102/ajlm.v10i1.975	https://doi.org/10.4102/ajlm.v10i1.975	PROPN
ajlm-975	4	2	brief	brief	PROPN
ajlm-975	4	3	report	report	PROPN
ajlm-975	4	4	epstein	epstein	PROPN
ajlm-975	4	5	-	-	PUNCT
ajlm-975	4	6	barr	barr	PROPN
ajlm-975	4	7	virus	virus	PROPN
ajlm-975	4	8	,	,	PUNCT
ajlm-975	4	9	human	human	ADJ
ajlm-975	4	10	papillomavirus	papillomavirus	NOUN
ajlm-975	4	11	and	and	CCONJ
ajlm-975	4	12	herpes	herpe	NOUN
ajlm-975	4	13	simplex	simplex	NOUN
ajlm-975	4	14	virus	virus	NOUN
ajlm-975	4	15	2	2	NUM
ajlm-975	4	16	co	co	NOUN
ajlm-975	4	17	-	-	NOUN
ajlm-975	4	18	presence	presence	NOUN
ajlm-975	4	19	severely	severely	ADV
ajlm-975	4	20	dysregulates	dysregulate	VERB
ajlm-975	4	21	mirna	mirna	PROPN
ajlm-975	4	22	expression	expression	PROPN
ajlm-975	4	23	jude	jude	PROPN
ajlm-975	4	24	o.	o.	PROPN
ajlm-975	4	25	okoye	okoye	PROPN
ajlm-975	4	26	,	,	PUNCT
ajlm-975	4	27	anthony	anthony	PROPN
ajlm-975	4	28	a.	a.	PROPN
ajlm-975	4	29	ngokere	ngokere	PROPN
ajlm-975	4	30	,	,	PUNCT
ajlm-975	4	31	charles	charles	PROPN
ajlm-975	4	32	c.	c.	PROPN
ajlm-975	4	33	onyenekwe	onyenekwe	NOUN
ajlm-975	4	34	,	,	PUNCT
ajlm-975	4	35	olaposi	olaposi	NOUN
ajlm-975	4	36	omotuyi	omotuyi	NOUN
ajlm-975	4	37	,	,	PUNCT
ajlm-975	4	38	deborah	deborah	PROPN
ajlm-975	4	39	i.	i.	PROPN
ajlm-975	4	40	dada	dada	PROPN
ajlm-975	4	41	received	receive	VERB
ajlm-975	4	42	:	:	PUNCT
ajlm-975	4	43	20	20	NUM
ajlm-975	4	44	jan	jan	PROPN
ajlm-975	4	45	.	.	PROPN
ajlm-975	4	46	2019	2019	NUM
ajlm-975	4	47	;	;	PUNCT
ajlm-975	4	48	accepted	accept	VERB
ajlm-975	4	49	:	:	PUNCT
ajlm-975	4	50	20	20	NUM
ajlm-975	4	51	oct	oct	PROPN
ajlm-975	4	52	.	.	PROPN
ajlm-975	4	53	2020	2020	NUM
ajlm-975	4	54	;	;	PUNCT
ajlm-975	4	55	published	publish	VERB
ajlm-975	4	56	:	:	PUNCT
ajlm-975	4	57	16	16	NUM
ajlm-975	4	58	mar	mar	PROPN
ajlm-975	4	59	.	.	PROPN
ajlm-975	5	1	2021	2021	NUM
ajlm-975	6	1	copyright	copyright	NOUN
ajlm-975	6	2	:	:	PUNCT
ajlm-975	6	3	©	©	PROPN
ajlm-975	6	4	2021	2021	NUM
ajlm-975	6	5	.	.	PUNCT
ajlm-975	7	1	the	the	DET
ajlm-975	7	2	author(s	author(s	PROPN
ajlm-975	7	3	)	)	PUNCT
ajlm-975	7	4	.	.	PUNCT
ajlm-975	8	1	licensee	licensee	NOUN
ajlm-975	8	2	:	:	PUNCT
ajlm-975	8	3	aosis	aosis	NOUN
ajlm-975	8	4	.	.	PUNCT
ajlm-975	9	1	this	this	PRON
ajlm-975	9	2	is	be	AUX
ajlm-975	9	3	an	an	DET
ajlm-975	9	4	open	open	ADJ
ajlm-975	9	5	access	access	NOUN
ajlm-975	9	6	article	article	NOUN
ajlm-975	9	7	distributed	distribute	VERB
ajlm-975	9	8	under	under	ADP
ajlm-975	9	9	the	the	DET
ajlm-975	9	10	terms	term	NOUN
ajlm-975	9	11	of	of	ADP
ajlm-975	9	12	the	the	DET
ajlm-975	9	13	creative	creative	ADJ
ajlm-975	9	14	commons	common	NOUN
ajlm-975	9	15	attribution	attribution	NOUN
ajlm-975	9	16	license	license	NOUN
ajlm-975	9	17	,	,	PUNCT
ajlm-975	9	18	which	which	PRON
ajlm-975	9	19	permits	permit	VERB
ajlm-975	9	20	unrestricted	unrestricted	ADJ
ajlm-975	9	21	use	use	NOUN
ajlm-975	9	22	,	,	PUNCT
ajlm-975	9	23	distribution	distribution	NOUN
ajlm-975	9	24	,	,	PUNCT
ajlm-975	9	25	and	and	CCONJ
ajlm-975	9	26	reproduction	reproduction	NOUN
ajlm-975	9	27	in	in	ADP
ajlm-975	9	28	any	any	DET
ajlm-975	9	29	medium	medium	NOUN
ajlm-975	9	30	,	,	PUNCT
ajlm-975	9	31	provided	provide	VERB
ajlm-975	9	32	the	the	DET
ajlm-975	9	33	original	original	ADJ
ajlm-975	9	34	work	work	NOUN
ajlm-975	9	35	is	be	AUX
ajlm-975	9	36	properly	properly	ADV
ajlm-975	9	37	cited	cite	VERB
ajlm-975	9	38	.	.	PUNCT
ajlm-975	10	1	abstract	abstract	ADJ
ajlm-975	10	2	this	this	DET
ajlm-975	10	3	cross	cross	ADJ
ajlm-975	10	4	-	-	ADJ
ajlm-975	10	5	sectional	sectional	ADJ
ajlm-975	10	6	study	study	NOUN
ajlm-975	10	7	evaluated	evaluate	VERB
ajlm-975	10	8	the	the	DET
ajlm-975	10	9	expression	expression	NOUN
ajlm-975	10	10	of	of	ADP
ajlm-975	10	11	mir	mir	NOUN
ajlm-975	10	12	-	-	ADJ
ajlm-975	10	13	let-7b	let-7b	PROPN
ajlm-975	10	14	,	,	PUNCT
ajlm-975	10	15	mir-21	mir-21	PROPN
ajlm-975	10	16	,	,	PUNCT
ajlm-975	10	17	mir-125b	mir-125b	NOUN
ajlm-975	10	18	,	,	PUNCT
ajlm-975	10	19	mir-143	mir-143	PROPN
ajlm-975	10	20	,	,	PUNCT
ajlm-975	10	21	mir-145	mir-145	PROPN
ajlm-975	10	22	,	,	PUNCT
ajlm-975	10	23	mir-155	mir-155	NOUN
ajlm-975	10	24	,	,	PUNCT
ajlm-975	10	25	mir-182	mir-182	NOUN
ajlm-975	10	26	,	,	PUNCT
ajlm-975	10	27	mir-200c	mir-200c	NOUN
ajlm-975	10	28	,	,	PUNCT
ajlm-975	10	29	p53	p53	NOUN
ajlm-975	10	30	gene	gene	NOUN
ajlm-975	10	31	,	,	PUNCT
ajlm-975	10	32	ki67	ki67	PROPN
ajlm-975	10	33	,	,	PUNCT
ajlm-975	10	34	scca1	scca1	NOUN
ajlm-975	10	35	and	and	CCONJ
ajlm-975	10	36	cd4	cd4	PROPN
ajlm-975	10	37	+	+	PROPN
ajlm-975	10	38	t	t	PROPN
ajlm-975	10	39	-	-	PUNCT
ajlm-975	10	40	cell	cell	NOUN
ajlm-975	10	41	counts	count	NOUN
ajlm-975	10	42	among	among	ADP
ajlm-975	10	43	319	319	NUM
ajlm-975	10	44	women	woman	NOUN
ajlm-975	10	45	,	,	PUNCT
ajlm-975	10	46	to	to	ADP
ajlm-975	10	47	epstein	epstein	PROPN
ajlm-975	10	48	-	-	PUNCT
ajlm-975	10	49	barr	barr	PROPN
ajlm-975	10	50	virus	virus	PROPN
ajlm-975	10	51	,	,	PUNCT
ajlm-975	10	52	human	human	ADJ
ajlm-975	10	53	papillomavirus	papillomavirus	NOUN
ajlm-975	10	54	and	and	CCONJ
ajlm-975	10	55	herpes	herpe	NOUN
ajlm-975	10	56	simplex	simplex	NOUN
ajlm-975	10	57	virus	virus	NOUN
ajlm-975	10	58	2	2	NUM
ajlm-975	10	59	mono	mono	NOUN
ajlm-975	10	60	-	-	PUNCT
ajlm-975	10	61	infections	infection	NOUN
ajlm-975	10	62	and	and	CCONJ
ajlm-975	10	63	co	co	NOUN
ajlm-975	10	64	-	-	NOUN
ajlm-975	10	65	infections	infection	NOUN
ajlm-975	10	66	,	,	PUNCT
ajlm-975	10	67	using	use	VERB
ajlm-975	10	68	enzyme	enzyme	NOUN
ajlm-975	10	69	-	-	PUNCT
ajlm-975	10	70	linked	link	VERB
ajlm-975	10	71	immunosorbent	immunosorbent	ADJ
ajlm-975	10	72	assay	assay	NOUN
ajlm-975	10	73	and	and	CCONJ
ajlm-975	10	74	reverse	reverse	VERB
ajlm-975	10	75	transcriptase	transcriptase	NOUN
ajlm-975	10	76	-	-	PUNCT
ajlm-975	10	77	polymerase	polymerase	NOUN
ajlm-975	10	78	chain	chain	NOUN
ajlm-975	10	79	reaction	reaction	NOUN
ajlm-975	10	80	methods	method	NOUN
ajlm-975	10	81	.	.	PUNCT
ajlm-975	11	1	this	this	DET
ajlm-975	11	2	study	study	NOUN
ajlm-975	11	3	suggests	suggest	VERB
ajlm-975	11	4	that	that	SCONJ
ajlm-975	11	5	malignancies	malignancy	NOUN
ajlm-975	11	6	associated	associate	VERB
ajlm-975	11	7	with	with	ADP
ajlm-975	11	8	viral	viral	ADJ
ajlm-975	11	9	co	co	NOUN
ajlm-975	11	10	-	-	NOUN
ajlm-975	11	11	infection	infection	NOUN
ajlm-975	11	12	could	could	AUX
ajlm-975	11	13	be	be	AUX
ajlm-975	11	14	diagnosed	diagnose	VERB
ajlm-975	11	15	early	early	ADV
ajlm-975	11	16	by	by	ADP
ajlm-975	11	17	monitoring	monitor	VERB
ajlm-975	11	18	cluster	cluster	NOUN
ajlm-975	11	19	of	of	ADP
ajlm-975	11	20	differentiation	differentiation	NOUN
ajlm-975	11	21	4	4	NUM
ajlm-975	11	22	+	+	NUM
ajlm-975	11	23	t	t	NOUN
ajlm-975	11	24	-	-	PUNCT
ajlm-975	11	25	cell	cell	NOUN
ajlm-975	11	26	counts	count	NOUN
ajlm-975	11	27	and	and	CCONJ
ajlm-975	11	28	serum	serum	NOUN
ajlm-975	11	29	expression	expression	NOUN
ajlm-975	11	30	of	of	ADP
ajlm-975	11	31	mir-145	mir-145	NOUN
ajlm-975	11	32	and	and	CCONJ
ajlm-975	11	33	mir-182	mir-182	NOUN
ajlm-975	11	34	.	.	PUNCT
ajlm-975	12	1	keywords	keyword	NOUN
ajlm-975	12	2	:	:	PUNCT
ajlm-975	12	3	epstein	epstein	PROPN
ajlm-975	12	4	-	-	PUNCT
ajlm-975	12	5	barr	barr	PROPN
ajlm-975	12	6	virus	virus	PROPN
ajlm-975	12	7	;	;	PUNCT
ajlm-975	12	8	human	human	ADJ
ajlm-975	12	9	papilloma	papilloma	NOUN
ajlm-975	12	10	virus	virus	NOUN
ajlm-975	12	11	;	;	PUNCT
ajlm-975	12	12	herpes	herpe	NOUN
ajlm-975	12	13	simplex	simplex	NOUN
ajlm-975	12	14	virus	virus	NOUN
ajlm-975	12	15	2	2	NUM
ajlm-975	12	16	;	;	PUNCT
ajlm-975	12	17	epithelial	epithelial	ADJ
ajlm-975	12	18	-	-	PUNCT
ajlm-975	12	19	mesenchymal	mesenchymal	NOUN
ajlm-975	12	20	transition	transition	NOUN
ajlm-975	12	21	;	;	PUNCT
ajlm-975	12	22	micrornas	microrna	NOUN
ajlm-975	12	23	.	.	PUNCT
ajlm-975	13	1	introduction	introduction	NOUN
ajlm-975	13	2	evidence	evidence	NOUN
ajlm-975	13	3	shows	show	VERB
ajlm-975	13	4	that	that	SCONJ
ajlm-975	13	5	epstein	epstein	PROPN
ajlm-975	13	6	-	-	PUNCT
ajlm-975	13	7	barr	barr	PROPN
ajlm-975	13	8	virus	virus	PROPN
ajlm-975	13	9	(	(	PUNCT
ajlm-975	13	10	ebv	ebv	NOUN
ajlm-975	13	11	)	)	PUNCT
ajlm-975	13	12	infection	infection	NOUN
ajlm-975	13	13	favours	favour	VERB
ajlm-975	13	14	human	human	ADJ
ajlm-975	13	15	papillomavirus	papillomavirus	NOUN
ajlm-975	13	16	(	(	PUNCT
ajlm-975	13	17	hpv	hpv	NOUN
ajlm-975	13	18	)	)	PUNCT
ajlm-975	13	19	fusion	fusion	NOUN
ajlm-975	13	20	to	to	ADP
ajlm-975	13	21	host	host	NOUN
ajlm-975	13	22	genome	genome	NOUN
ajlm-975	13	23	resulting	result	VERB
ajlm-975	13	24	in	in	ADP
ajlm-975	13	25	genetic	genetic	ADJ
ajlm-975	13	26	instability	instability	NOUN
ajlm-975	13	27	,	,	PUNCT
ajlm-975	13	28	initiation	initiation	NOUN
ajlm-975	13	29	and	and	CCONJ
ajlm-975	13	30	amplification	amplification	NOUN
ajlm-975	13	31	of	of	ADP
ajlm-975	13	32	epithelial	epithelial	ADJ
ajlm-975	13	33	-	-	PUNCT
ajlm-975	13	34	mesenchymal	mesenchymal	NOUN
ajlm-975	13	35	transition	transition	NOUN
ajlm-975	13	36	(	(	PUNCT
ajlm-975	13	37	emt	emt	PROPN
ajlm-975	13	38	)	)	PUNCT
ajlm-975	13	39	to	to	ADP
ajlm-975	13	40	cancer	cancer	NOUN
ajlm-975	13	41	in	in	ADP
ajlm-975	13	42	the	the	DET
ajlm-975	13	43	host.1,2	host.1,2	NOUN
ajlm-975	13	44	the	the	DET
ajlm-975	13	45	mechanisms	mechanism	NOUN
ajlm-975	13	46	by	by	ADP
ajlm-975	13	47	which	which	PRON
ajlm-975	13	48	they	they	PRON
ajlm-975	13	49	synergistically	synergistically	ADV
ajlm-975	13	50	promote	promote	VERB
ajlm-975	13	51	cancer	cancer	NOUN
ajlm-975	13	52	invasiveness	invasiveness	NOUN
ajlm-975	13	53	and	and	CCONJ
ajlm-975	13	54	metastasis	metastasis	NOUN
ajlm-975	13	55	are	be	AUX
ajlm-975	13	56	yet	yet	ADV
ajlm-975	13	57	to	to	PART
ajlm-975	13	58	be	be	AUX
ajlm-975	13	59	fully	fully	ADV
ajlm-975	13	60	understood	understand	VERB
ajlm-975	13	61	.	.	PUNCT
ajlm-975	14	1	although	although	SCONJ
ajlm-975	14	2	controversies	controversy	NOUN
ajlm-975	14	3	still	still	ADV
ajlm-975	14	4	exist	exist	VERB
ajlm-975	14	5	concerning	concern	VERB
ajlm-975	14	6	the	the	DET
ajlm-975	14	7	role	role	NOUN
ajlm-975	14	8	of	of	ADP
ajlm-975	14	9	type	type	NOUN
ajlm-975	14	10	2	2	NUM
ajlm-975	14	11	herpes	herpe	NOUN
ajlm-975	14	12	simplex	simplex	NOUN
ajlm-975	14	13	virus	virus	NOUN
ajlm-975	14	14	(	(	PUNCT
ajlm-975	14	15	hsv-2	hsv-2	NOUN
ajlm-975	14	16	)	)	PUNCT
ajlm-975	14	17	in	in	ADP
ajlm-975	14	18	cervical	cervical	ADJ
ajlm-975	14	19	carcinogenesis	carcinogenesis	NOUN
ajlm-975	14	20	,	,	PUNCT
ajlm-975	14	21	mounting	mount	VERB
ajlm-975	14	22	evidence	evidence	NOUN
ajlm-975	14	23	suggests	suggest	VERB
ajlm-975	14	24	that	that	SCONJ
ajlm-975	14	25	the	the	DET
ajlm-975	14	26	persistence	persistence	NOUN
ajlm-975	14	27	and	and	CCONJ
ajlm-975	14	28	reactivation	reactivation	NOUN
ajlm-975	14	29	of	of	ADP
ajlm-975	14	30	hsv-2	hsv-2	PUNCT
ajlm-975	14	31	not	not	PART
ajlm-975	14	32	only	only	ADV
ajlm-975	14	33	facilitates	facilitate	VERB
ajlm-975	14	34	ebv	ebv	NOUN
ajlm-975	14	35	and	and	CCONJ
ajlm-975	14	36	hpv	hpv	NOUN
ajlm-975	14	37	infection	infection	NOUN
ajlm-975	14	38	entry	entry	NOUN
ajlm-975	14	39	but	but	CCONJ
ajlm-975	14	40	also	also	ADV
ajlm-975	14	41	increases	increase	VERB
ajlm-975	14	42	the	the	DET
ajlm-975	14	43	risk	risk	NOUN
ajlm-975	14	44	of	of	ADP
ajlm-975	14	45	cervical	cervical	ADJ
ajlm-975	14	46	squamous	squamous	ADJ
ajlm-975	14	47	cell	cell	NOUN
ajlm-975	14	48	carcinoma	carcinoma	NOUN
ajlm-975	14	49	by	by	ADP
ajlm-975	14	50	60	60	NUM
ajlm-975	14	51	times.3,4	times.3,4	NOUN
ajlm-975	14	52	this	this	DET
ajlm-975	14	53	viral	viral	ADJ
ajlm-975	14	54	co	co	NOUN
ajlm-975	14	55	-	-	NOUN
ajlm-975	14	56	infection	infection	NOUN
ajlm-975	14	57	may	may	AUX
ajlm-975	14	58	elicit	elicit	VERB
ajlm-975	14	59	diverse	diverse	ADJ
ajlm-975	14	60	,	,	PUNCT
ajlm-975	14	61	overwhelming	overwhelming	ADJ
ajlm-975	14	62	dysregulation	dysregulation	NOUN
ajlm-975	14	63	of	of	ADP
ajlm-975	14	64	the	the	DET
ajlm-975	14	65	host	host	NOUN
ajlm-975	14	66	’s	’s	PART
ajlm-975	14	67	oncomirs	oncomirs	NOUN
ajlm-975	14	68	-	-	PUNCT
ajlm-975	14	69	cancer	cancer	NOUN
ajlm-975	14	70	-	-	PUNCT
ajlm-975	14	71	associated	associate	VERB
ajlm-975	14	72	micro	micro	ADJ
ajlm-975	14	73	-	-	ADJ
ajlm-975	14	74	ribonucleic	ribonucleic	ADJ
ajlm-975	14	75	acids	acid	NOUN
ajlm-975	14	76	(	(	PUNCT
ajlm-975	14	77	mirnas	mirna	NOUN
ajlm-975	14	78	)	)	PUNCT
ajlm-975	14	79	or	or	CCONJ
ajlm-975	14	80	the	the	DET
ajlm-975	14	81	tumour	tumour	ADJ
ajlm-975	14	82	suppressor	suppressor	NOUN
ajlm-975	14	83	mirnas	mirna	NOUN
ajlm-975	14	84	.	.	PUNCT
ajlm-975	15	1	microrna	microrna	PROPN
ajlm-975	15	2	is	be	AUX
ajlm-975	15	3	a	a	DET
ajlm-975	15	4	short	short	ADJ
ajlm-975	15	5	unit	unit	NOUN
ajlm-975	15	6	of	of	ADP
ajlm-975	15	7	non	non	ADJ
ajlm-975	15	8	-	-	ADJ
ajlm-975	15	9	coding	coding	ADJ
ajlm-975	15	10	rna	rna	NOUN
ajlm-975	15	11	that	that	PRON
ajlm-975	15	12	post	post	ADJ
ajlm-975	15	13	-	-	ADJ
ajlm-975	15	14	transcriptionally	transcriptionally	ADV
ajlm-975	15	15	regulates	regulate	VERB
ajlm-975	15	16	gene	gene	NOUN
ajlm-975	15	17	expression.5	expression.5	PROPN
ajlm-975	15	18	viruses	virus	NOUN
ajlm-975	15	19	are	be	AUX
ajlm-975	15	20	known	know	VERB
ajlm-975	15	21	to	to	PART
ajlm-975	15	22	cause	cause	VERB
ajlm-975	15	23	overexpression	overexpression	NOUN
ajlm-975	15	24	or	or	CCONJ
ajlm-975	15	25	underexpression	underexpression	NOUN
ajlm-975	15	26	of	of	ADP
ajlm-975	15	27	certain	certain	ADJ
ajlm-975	15	28	mirna	mirna	NOUN
ajlm-975	15	29	,	,	PUNCT
ajlm-975	15	30	especially	especially	ADV
ajlm-975	15	31	in	in	ADP
ajlm-975	15	32	individuals	individual	NOUN
ajlm-975	15	33	with	with	ADP
ajlm-975	15	34	cancer.5	cancer.5	PROPN
ajlm-975	15	35	in	in	ADP
ajlm-975	15	36	this	this	DET
ajlm-975	15	37	study	study	NOUN
ajlm-975	15	38	,	,	PUNCT
ajlm-975	15	39	we	we	PRON
ajlm-975	15	40	ascertained	ascertain	VERB
ajlm-975	15	41	whether	whether	SCONJ
ajlm-975	15	42	the	the	DET
ajlm-975	15	43	extent	extent	NOUN
ajlm-975	15	44	of	of	ADP
ajlm-975	15	45	mirna	mirna	PROPN
ajlm-975	15	46	overexpression	overexpression	NOUN
ajlm-975	15	47	or	or	CCONJ
ajlm-975	15	48	underexpression	underexpression	NOUN
ajlm-975	15	49	is	be	AUX
ajlm-975	15	50	higher	high	ADJ
ajlm-975	15	51	or	or	CCONJ
ajlm-975	15	52	lower	low	ADJ
ajlm-975	15	53	in	in	ADP
ajlm-975	15	54	viral	viral	ADJ
ajlm-975	15	55	co	co	NOUN
ajlm-975	15	56	-	-	NOUN
ajlm-975	15	57	infection	infection	NOUN
ajlm-975	15	58	than	than	ADP
ajlm-975	15	59	in	in	ADP
ajlm-975	15	60	mono	mono	NOUN
ajlm-975	15	61	-	-	PUNCT
ajlm-975	15	62	infection	infection	NOUN
ajlm-975	15	63	,	,	PUNCT
ajlm-975	15	64	and	and	CCONJ
ajlm-975	15	65	which	which	DET
ajlm-975	15	66	type	type	NOUN
ajlm-975	15	67	of	of	ADP
ajlm-975	15	68	co	co	NOUN
ajlm-975	15	69	-	-	NOUN
ajlm-975	15	70	infection	infection	NOUN
ajlm-975	15	71	is	be	AUX
ajlm-975	15	72	associated	associate	VERB
ajlm-975	15	73	with	with	ADP
ajlm-975	15	74	the	the	DET
ajlm-975	15	75	highest	high	ADJ
ajlm-975	15	76	and	and	CCONJ
ajlm-975	15	77	lowest	low	ADJ
ajlm-975	15	78	expression	expression	NOUN
ajlm-975	15	79	of	of	ADP
ajlm-975	15	80	mirna	mirna	NOUN
ajlm-975	15	81	when	when	SCONJ
ajlm-975	15	82	compared	compare	VERB
ajlm-975	15	83	with	with	ADP
ajlm-975	15	84	uninfected	uninfected	ADJ
ajlm-975	15	85	individuals	individual	NOUN
ajlm-975	15	86	.	.	PUNCT
ajlm-975	16	1	hence	hence	ADV
ajlm-975	16	2	,	,	PUNCT
ajlm-975	16	3	this	this	DET
ajlm-975	16	4	study	study	NOUN
ajlm-975	16	5	evaluated	evaluate	VERB
ajlm-975	16	6	the	the	DET
ajlm-975	16	7	expression	expression	NOUN
ajlm-975	16	8	of	of	ADP
ajlm-975	16	9	normally	normally	ADV
ajlm-975	16	10	downregulated	downregulate	VERB
ajlm-975	16	11	biomarkers	biomarker	NOUN
ajlm-975	16	12	(	(	PUNCT
ajlm-975	16	13	mir-21	mir-21	PROPN
ajlm-975	16	14	,	,	PUNCT
ajlm-975	16	15	mir-155	mir-155	NOUN
ajlm-975	16	16	,	,	PUNCT
ajlm-975	16	17	mir-182	mir-182	PROPN
ajlm-975	16	18	,	,	PUNCT
ajlm-975	16	19	mir-200	mir-200	X
ajlm-975	16	20	,	,	PUNCT
ajlm-975	16	21	p53	p53	NOUN
ajlm-975	16	22	gene	gene	NOUN
ajlm-975	16	23	,	,	PUNCT
ajlm-975	16	24	ki67	ki67	PROPN
ajlm-975	16	25	,	,	PUNCT
ajlm-975	16	26	and	and	CCONJ
ajlm-975	16	27	squamous	squamous	ADJ
ajlm-975	16	28	cell	cell	NOUN
ajlm-975	16	29	carcinoma	carcinoma	NOUN
ajlm-975	16	30	antigen	antigen	ADP
ajlm-975	16	31	1	1	NUM
ajlm-975	17	1	[	[	X
ajlm-975	17	2	scca1	scca1	NOUN
ajlm-975	17	3	]	]	X
ajlm-975	17	4	)	)	PUNCT
ajlm-975	17	5	and	and	CCONJ
ajlm-975	17	6	normally	normally	ADV
ajlm-975	17	7	upregulated	upregulated	ADJ
ajlm-975	17	8	biomarkers	biomarker	NOUN
ajlm-975	17	9	(	(	PUNCT
ajlm-975	17	10	mir	mir	NOUN
ajlm-975	17	11	-	-	ADJ
ajlm-975	17	12	let-7b	let-7b	ADJ
ajlm-975	17	13	,	,	PUNCT
ajlm-975	17	14	mir-125b	mir-125b	NOUN
ajlm-975	17	15	,	,	PUNCT
ajlm-975	17	16	mir-143	mir-143	PROPN
ajlm-975	17	17	,	,	PUNCT
ajlm-975	17	18	mir-145	mir-145	NOUN
ajlm-975	17	19	,	,	PUNCT
ajlm-975	17	20	and	and	CCONJ
ajlm-975	17	21	cd4	cd4	PROPN
ajlm-975	17	22	+	+	PROPN
ajlm-975	17	23	t	t	PROPN
ajlm-975	17	24	-	-	PUNCT
ajlm-975	17	25	cells	cell	NOUN
ajlm-975	17	26	)	)	PUNCT
ajlm-975	17	27	in	in	ADP
ajlm-975	17	28	individuals	individual	NOUN
ajlm-975	17	29	with	with	ADP
ajlm-975	17	30	single	single	ADJ
ajlm-975	17	31	through	through	ADP
ajlm-975	17	32	ternary	ternary	ADJ
ajlm-975	17	33	viral	viral	ADJ
ajlm-975	17	34	infections	infection	NOUN
ajlm-975	17	35	and	and	CCONJ
ajlm-975	17	36	those	those	PRON
ajlm-975	17	37	without	without	ADP
ajlm-975	17	38	the	the	DET
ajlm-975	17	39	targeted	target	VERB
ajlm-975	17	40	viral	viral	ADJ
ajlm-975	17	41	infections	infection	NOUN
ajlm-975	17	42	(	(	PUNCT
ajlm-975	17	43	ebv	ebv	NOUN
ajlm-975	17	44	,	,	PUNCT
ajlm-975	17	45	hpv	hpv	NOUN
ajlm-975	17	46	and	and	CCONJ
ajlm-975	17	47	hsv-2	hsv-2	NUM
ajlm-975	17	48	)	)	PUNCT
ajlm-975	17	49	.	.	PUNCT
ajlm-975	18	1	overexpressed	overexpresse	VERB
ajlm-975	18	2	and	and	CCONJ
ajlm-975	18	3	underexpressed	underexpressed	ADJ
ajlm-975	18	4	mirnas	mirna	NOUN
ajlm-975	18	5	could	could	AUX
ajlm-975	18	6	serve	serve	VERB
ajlm-975	18	7	as	as	ADP
ajlm-975	18	8	biomarkers	biomarker	NOUN
ajlm-975	18	9	for	for	ADP
ajlm-975	18	10	identifying	identify	VERB
ajlm-975	18	11	and	and	CCONJ
ajlm-975	18	12	or	or	CCONJ
ajlm-975	18	13	monitoring	monitor	VERB
ajlm-975	18	14	individuals	individual	NOUN
ajlm-975	18	15	who	who	PRON
ajlm-975	18	16	are	be	AUX
ajlm-975	18	17	at	at	ADP
ajlm-975	18	18	risk	risk	NOUN
ajlm-975	18	19	of	of	ADP
ajlm-975	18	20	developing	develop	VERB
ajlm-975	18	21	cervical	cervical	ADJ
ajlm-975	18	22	lesions.6	lesions.6	NOUN
ajlm-975	18	23	methods	method	NOUN
ajlm-975	18	24	ethical	ethical	ADJ
ajlm-975	18	25	considerations	consideration	NOUN
ajlm-975	18	26	for	for	ADP
ajlm-975	18	27	this	this	DET
ajlm-975	18	28	study	study	NOUN
ajlm-975	18	29	,	,	PUNCT
ajlm-975	18	30	ethical	ethical	ADJ
ajlm-975	18	31	approvals	approval	NOUN
ajlm-975	18	32	were	be	AUX
ajlm-975	18	33	obtained	obtain	VERB
ajlm-975	18	34	from	from	ADP
ajlm-975	18	35	the	the	DET
ajlm-975	18	36	state	state	NOUN
ajlm-975	18	37	hospital	hospital	NOUN
ajlm-975	18	38	abeokuta	abeokuta	PROPN
ajlm-975	18	39	ethics	ethics	PROPN
ajlm-975	18	40	committee	committee	PROPN
ajlm-975	18	41	(	(	PUNCT
ajlm-975	18	42	sha	sha	PROPN
ajlm-975	18	43	/	/	SYM
ajlm-975	18	44	res	res	PROPN
ajlm-975	18	45	/	/	SYM
ajlm-975	18	46	vol.2/177	vol.2/177	PROPN
ajlm-975	18	47	)	)	PUNCT
ajlm-975	18	48	and	and	CCONJ
ajlm-975	18	49	babcock	babcock	PROPN
ajlm-975	18	50	university	university	PROPN
ajlm-975	18	51	health	health	PROPN
ajlm-975	18	52	research	research	PROPN
ajlm-975	18	53	committee	committee	PROPN
ajlm-975	18	54	(	(	PUNCT
ajlm-975	18	55	buhrec549/18	buhrec549/18	PROPN
ajlm-975	18	56	)	)	PUNCT
ajlm-975	18	57	.	.	PUNCT
ajlm-975	19	1	written	write	VERB
ajlm-975	19	2	consent	consent	NOUN
ajlm-975	19	3	was	be	AUX
ajlm-975	19	4	obtained	obtain	VERB
ajlm-975	19	5	from	from	ADP
ajlm-975	19	6	all	all	DET
ajlm-975	19	7	participants	participant	NOUN
ajlm-975	19	8	.	.	PUNCT
ajlm-975	20	1	the	the	DET
ajlm-975	20	2	questionnaires	questionnaire	NOUN
ajlm-975	20	3	filled	fill	VERB
ajlm-975	20	4	by	by	ADP
ajlm-975	20	5	the	the	DET
ajlm-975	20	6	participants	participant	NOUN
ajlm-975	20	7	and	and	CCONJ
ajlm-975	20	8	samples	sample	NOUN
ajlm-975	20	9	taken	take	VERB
ajlm-975	20	10	following	follow	VERB
ajlm-975	20	11	selection	selection	NOUN
ajlm-975	20	12	were	be	AUX
ajlm-975	20	13	given	give	VERB
ajlm-975	20	14	specific	specific	ADJ
ajlm-975	20	15	numbers	number	NOUN
ajlm-975	20	16	in	in	ADP
ajlm-975	20	17	place	place	NOUN
ajlm-975	20	18	of	of	ADP
ajlm-975	20	19	names	name	NOUN
ajlm-975	20	20	to	to	PART
ajlm-975	20	21	protect	protect	VERB
ajlm-975	20	22	the	the	DET
ajlm-975	20	23	privacy	privacy	NOUN
ajlm-975	20	24	of	of	ADP
ajlm-975	20	25	participants	participant	NOUN
ajlm-975	20	26	.	.	PUNCT
ajlm-975	21	1	personal	personal	ADJ
ajlm-975	21	2	information	information	NOUN
ajlm-975	21	3	and	and	CCONJ
ajlm-975	21	4	results	result	NOUN
ajlm-975	21	5	of	of	ADP
ajlm-975	21	6	the	the	DET
ajlm-975	21	7	participants	participant	NOUN
ajlm-975	21	8	remained	remain	VERB
ajlm-975	21	9	undisclosed	undisclosed	ADJ
ajlm-975	21	10	to	to	ADP
ajlm-975	21	11	other	other	ADJ
ajlm-975	21	12	personnel	personnel	NOUN
ajlm-975	21	13	,	,	PUNCT
ajlm-975	21	14	except	except	SCONJ
ajlm-975	21	15	the	the	DET
ajlm-975	21	16	investigators	investigator	NOUN
ajlm-975	21	17	and	and	CCONJ
ajlm-975	21	18	respective	respective	ADJ
ajlm-975	21	19	participants	participant	NOUN
ajlm-975	21	20	.	.	PUNCT
ajlm-975	22	1	study	study	NOUN
ajlm-975	22	2	area	area	NOUN
ajlm-975	22	3	and	and	CCONJ
ajlm-975	22	4	participants	participant	NOUN
ajlm-975	22	5	this	this	DET
ajlm-975	22	6	cross	cross	ADJ
ajlm-975	22	7	-	-	ADJ
ajlm-975	22	8	sectional	sectional	ADJ
ajlm-975	22	9	study	study	NOUN
ajlm-975	22	10	was	be	AUX
ajlm-975	22	11	carried	carry	VERB
ajlm-975	22	12	out	out	ADP
ajlm-975	22	13	between	between	ADP
ajlm-975	22	14	may	may	PROPN
ajlm-975	22	15	2017	2017	NUM
ajlm-975	22	16	and	and	CCONJ
ajlm-975	22	17	august	august	PROPN
ajlm-975	22	18	2018	2018	NUM
ajlm-975	22	19	during	during	ADP
ajlm-975	22	20	a	a	DET
ajlm-975	22	21	free	free	ADJ
ajlm-975	22	22	screening	screening	NOUN
ajlm-975	22	23	programme	programme	NOUN
ajlm-975	22	24	.	.	PUNCT
ajlm-975	23	1	using	use	VERB
ajlm-975	23	2	the	the	DET
ajlm-975	23	3	convenience	convenience	NOUN
ajlm-975	23	4	sampling	sample	VERB
ajlm-975	23	5	technique	technique	NOUN
ajlm-975	23	6	,	,	PUNCT
ajlm-975	23	7	this	this	DET
ajlm-975	23	8	study	study	NOUN
ajlm-975	23	9	included	include	VERB
ajlm-975	23	10	active	active	ADJ
ajlm-975	23	11	commercial	commercial	ADJ
ajlm-975	23	12	sex	sex	NOUN
ajlm-975	23	13	workers	worker	NOUN
ajlm-975	23	14	(	(	PUNCT
ajlm-975	23	15	n	n	NOUN
ajlm-975	23	16	=	=	SYM
ajlm-975	23	17	319	319	NUM
ajlm-975	23	18	;	;	PUNCT
ajlm-975	23	19	mean	mean	VERB
ajlm-975	23	20	age	age	NOUN
ajlm-975	23	21	=	=	SYM
ajlm-975	23	22	33.84	33.84	NUM
ajlm-975	23	23	±	±	NUM
ajlm-975	23	24	8.38	8.38	NUM
ajlm-975	23	25	years	year	NOUN
ajlm-975	23	26	)	)	PUNCT
ajlm-975	23	27	living	live	VERB
ajlm-975	23	28	in	in	ADP
ajlm-975	23	29	selected	select	VERB
ajlm-975	23	30	brothels	brothel	NOUN
ajlm-975	23	31	in	in	ADP
ajlm-975	23	32	abeokuta	abeokuta	PROPN
ajlm-975	23	33	and	and	CCONJ
ajlm-975	23	34	ilishan	ilishan	NOUN
ajlm-975	23	35	-	-	PUNCT
ajlm-975	23	36	remo	remo	NOUN
ajlm-975	23	37	communities	community	NOUN
ajlm-975	23	38	.	.	PUNCT
ajlm-975	24	1	interested	interested	ADJ
ajlm-975	24	2	participants	participant	NOUN
ajlm-975	24	3	visited	visit	VERB
ajlm-975	24	4	the	the	DET
ajlm-975	24	5	family	family	NOUN
ajlm-975	24	6	planning	planning	NOUN
ajlm-975	24	7	clinic	clinic	NOUN
ajlm-975	24	8	at	at	ADP
ajlm-975	24	9	their	their	PRON
ajlm-975	24	10	own	own	ADJ
ajlm-975	24	11	expense	expense	NOUN
ajlm-975	24	12	.	.	PUNCT
ajlm-975	25	1	sex	sex	NOUN
ajlm-975	25	2	workers	worker	NOUN
ajlm-975	25	3	who	who	PRON
ajlm-975	25	4	voluntarily	voluntarily	ADV
ajlm-975	25	5	visited	visit	VERB
ajlm-975	25	6	the	the	DET
ajlm-975	25	7	family	family	NOUN
ajlm-975	25	8	planning	planning	NOUN
ajlm-975	25	9	clinic	clinic	NOUN
ajlm-975	25	10	were	be	AUX
ajlm-975	25	11	selected	select	VERB
ajlm-975	25	12	by	by	ADP
ajlm-975	25	13	researchers	researcher	NOUN
ajlm-975	25	14	based	base	VERB
ajlm-975	25	15	on	on	ADP
ajlm-975	25	16	the	the	DET
ajlm-975	25	17	description	description	NOUN
ajlm-975	25	18	provided	provide	VERB
ajlm-975	25	19	by	by	ADP
ajlm-975	25	20	the	the	DET
ajlm-975	25	21	reports	report	NOUN
ajlm-975	25	22	of	of	ADP
ajlm-975	25	23	the	the	DET
ajlm-975	25	24	united	united	PROPN
ajlm-975	25	25	states	states	PROPN
ajlm-975	25	26	centers	center	NOUN
ajlm-975	25	27	for	for	ADP
ajlm-975	25	28	disease	disease	NOUN
ajlm-975	25	29	control	control	NOUN
ajlm-975	25	30	and	and	CCONJ
ajlm-975	25	31	prevention	prevention	NOUN
ajlm-975	25	32	,	,	PUNCT
ajlm-975	25	33	the	the	DET
ajlm-975	25	34	united	united	PROPN
ajlm-975	25	35	nations	nations	PROPN
ajlm-975	25	36	for	for	ADP
ajlm-975	25	37	aids	aids	PROPN
ajlm-975	25	38	and	and	CCONJ
ajlm-975	25	39	world	world	NOUN
ajlm-975	25	40	health	health	NOUN
ajlm-975	25	41	organization.7,8	organization.7,8	PROPN
ajlm-975	25	42	the	the	DET
ajlm-975	25	43	demographics	demographic	NOUN
ajlm-975	25	44	were	be	AUX
ajlm-975	25	45	collected	collect	VERB
ajlm-975	25	46	using	use	VERB
ajlm-975	25	47	an	an	DET
ajlm-975	25	48	interview	interview	NOUN
ajlm-975	25	49	-	-	PUNCT
ajlm-975	25	50	based	base	VERB
ajlm-975	25	51	questionnaire	questionnaire	NOUN
ajlm-975	25	52	.	.	PUNCT
ajlm-975	26	1	inclusion	inclusion	NOUN
ajlm-975	26	2	criteria	criterion	NOUN
ajlm-975	26	3	included	include	VERB
ajlm-975	26	4	being	be	AUX
ajlm-975	26	5	a	a	DET
ajlm-975	26	6	self	self	NOUN
ajlm-975	26	7	-	-	PUNCT
ajlm-975	26	8	proclaimed	proclaim	VERB
ajlm-975	26	9	direct	direct	ADJ
ajlm-975	26	10	(	(	PUNCT
ajlm-975	26	11	commercial	commercial	ADJ
ajlm-975	26	12	;	;	PUNCT
ajlm-975	26	13	receive	receive	VERB
ajlm-975	26	14	money	money	NOUN
ajlm-975	26	15	for	for	ADP
ajlm-975	26	16	sex	sex	NOUN
ajlm-975	26	17	)	)	PUNCT
ajlm-975	26	18	and	and	CCONJ
ajlm-975	26	19	sexually	sexually	ADV
ajlm-975	26	20	active	active	ADJ
ajlm-975	26	21	female	female	ADJ
ajlm-975	26	22	sex	sex	NOUN
ajlm-975	26	23	workers	worker	NOUN
ajlm-975	26	24	aged	age	VERB
ajlm-975	26	25	18–54	18–54	NUM
ajlm-975	26	26	years	year	NOUN
ajlm-975	26	27	.	.	PUNCT
ajlm-975	27	1	individuals	individual	NOUN
ajlm-975	27	2	with	with	ADP
ajlm-975	27	3	any	any	DET
ajlm-975	27	4	history	history	NOUN
ajlm-975	27	5	of	of	ADP
ajlm-975	27	6	cervical	cervical	ADJ
ajlm-975	27	7	,	,	PUNCT
ajlm-975	27	8	breast	breast	NOUN
ajlm-975	27	9	and	and	CCONJ
ajlm-975	27	10	oral	oral	ADJ
ajlm-975	27	11	cancers	cancer	NOUN
ajlm-975	27	12	or	or	CCONJ
ajlm-975	27	13	those	those	PRON
ajlm-975	27	14	that	that	PRON
ajlm-975	27	15	are	be	AUX
ajlm-975	27	16	transgender	transgender	NOUN
ajlm-975	27	17	or	or	CCONJ
ajlm-975	27	18	below	below	ADP
ajlm-975	27	19	18	18	NUM
ajlm-975	27	20	years	year	NOUN
ajlm-975	27	21	or	or	CCONJ
ajlm-975	27	22	above	above	ADP
ajlm-975	27	23	54	54	NUM
ajlm-975	27	24	years	year	NOUN
ajlm-975	27	25	were	be	AUX
ajlm-975	27	26	excluded	exclude	VERB
ajlm-975	27	27	.	.	PUNCT
ajlm-975	28	1	sample	sample	NOUN
ajlm-975	28	2	collection	collection	NOUN
ajlm-975	28	3	and	and	CCONJ
ajlm-975	28	4	handling	handle	VERB
ajlm-975	28	5	the	the	DET
ajlm-975	28	6	majority	majority	NOUN
ajlm-975	28	7	of	of	ADP
ajlm-975	28	8	samples	sample	NOUN
ajlm-975	28	9	were	be	AUX
ajlm-975	28	10	taken	take	VERB
ajlm-975	28	11	at	at	ADP
ajlm-975	28	12	the	the	DET
ajlm-975	28	13	family	family	NOUN
ajlm-975	28	14	planning	planning	NOUN
ajlm-975	28	15	unit	unit	NOUN
ajlm-975	28	16	,	,	PUNCT
ajlm-975	28	17	state	state	NOUN
ajlm-975	28	18	hospital	hospital	NOUN
ajlm-975	28	19	ijaiye	ijaiye	NOUN
ajlm-975	28	20	,	,	PUNCT
ajlm-975	28	21	abeokuta	abeokuta	PROPN
ajlm-975	28	22	and	and	CCONJ
ajlm-975	28	23	the	the	DET
ajlm-975	28	24	phlebotomy	phlebotomy	NOUN
ajlm-975	28	25	unit	unit	NOUN
ajlm-975	28	26	,	,	PUNCT
ajlm-975	28	27	babcock	babcock	PROPN
ajlm-975	28	28	university	university	PROPN
ajlm-975	28	29	teaching	teaching	NOUN
ajlm-975	28	30	hospital	hospital	NOUN
ajlm-975	28	31	,	,	PUNCT
ajlm-975	28	32	nigeria	nigeria	PROPN
ajlm-975	28	33	,	,	PUNCT
ajlm-975	28	34	by	by	ADP
ajlm-975	28	35	nurses	nurse	NOUN
ajlm-975	28	36	and	and	CCONJ
ajlm-975	28	37	researchers	researcher	NOUN
ajlm-975	28	38	.	.	PUNCT
ajlm-975	29	1	some	some	DET
ajlm-975	29	2	samples	sample	NOUN
ajlm-975	29	3	were	be	AUX
ajlm-975	29	4	collected	collect	VERB
ajlm-975	29	5	at	at	ADP
ajlm-975	29	6	the	the	DET
ajlm-975	29	7	brothels	brothel	NOUN
ajlm-975	29	8	only	only	ADV
ajlm-975	29	9	on	on	ADP
ajlm-975	29	10	the	the	DET
ajlm-975	29	11	insistence	insistence	NOUN
ajlm-975	29	12	of	of	ADP
ajlm-975	29	13	concerned	concerned	ADJ
ajlm-975	29	14	participants	participant	NOUN
ajlm-975	29	15	.	.	PUNCT
ajlm-975	30	1	all	all	DET
ajlm-975	30	2	samples	sample	NOUN
ajlm-975	30	3	(	(	PUNCT
ajlm-975	30	4	blood	blood	NOUN
ajlm-975	30	5	and	and	CCONJ
ajlm-975	30	6	pap	pap	NOUN
ajlm-975	30	7	smears	smear	NOUN
ajlm-975	30	8	)	)	PUNCT
ajlm-975	30	9	were	be	AUX
ajlm-975	30	10	collected	collect	VERB
ajlm-975	30	11	according	accord	VERB
ajlm-975	30	12	to	to	ADP
ajlm-975	30	13	the	the	DET
ajlm-975	30	14	standard	standard	ADJ
ajlm-975	30	15	operating	operate	VERB
ajlm-975	30	16	procedure	procedure	NOUN
ajlm-975	30	17	of	of	ADP
ajlm-975	30	18	the	the	DET
ajlm-975	30	19	hospitals	hospital	NOUN
ajlm-975	30	20	.	.	PUNCT
ajlm-975	31	1	participants	participant	NOUN
ajlm-975	31	2	were	be	AUX
ajlm-975	31	3	screened	screen	VERB
ajlm-975	31	4	for	for	ADP
ajlm-975	31	5	cervical	cervical	ADJ
ajlm-975	31	6	cancer	cancer	NOUN
ajlm-975	31	7	using	use	VERB
ajlm-975	31	8	liquid	liquid	ADJ
ajlm-975	31	9	base	base	NOUN
ajlm-975	31	10	preparation	preparation	NOUN
ajlm-975	31	11	and	and	CCONJ
ajlm-975	31	12	papanicolaou	papanicolaou	NOUN
ajlm-975	31	13	techniques	technique	NOUN
ajlm-975	31	14	.	.	PUNCT
ajlm-975	32	1	smears	smear	NOUN
ajlm-975	32	2	were	be	AUX
ajlm-975	32	3	taken	take	VERB
ajlm-975	32	4	by	by	ADP
ajlm-975	32	5	nurses	nurse	NOUN
ajlm-975	32	6	and	and	CCONJ
ajlm-975	32	7	clinicians	clinician	NOUN
ajlm-975	32	8	and	and	CCONJ
ajlm-975	32	9	evaluated	evaluate	VERB
ajlm-975	32	10	by	by	ADP
ajlm-975	32	11	two	two	NUM
ajlm-975	32	12	cytopathologists	cytopathologist	NOUN
ajlm-975	32	13	.	.	PUNCT
ajlm-975	33	1	five	five	NUM
ajlm-975	33	2	millilitres	millilitre	NOUN
ajlm-975	33	3	(	(	PUNCT
ajlm-975	33	4	ml	ml	NOUN
ajlm-975	33	5	)	)	PUNCT
ajlm-975	33	6	of	of	ADP
ajlm-975	33	7	peripheral	peripheral	ADJ
ajlm-975	33	8	blood	blood	NOUN
ajlm-975	33	9	was	be	AUX
ajlm-975	33	10	drawn	draw	VERB
ajlm-975	33	11	between	between	ADP
ajlm-975	33	12	the	the	DET
ajlm-975	33	13	hours	hour	NOUN
ajlm-975	33	14	of	of	ADP
ajlm-975	33	15	09:00	09:00	NUM
ajlm-975	33	16	and	and	CCONJ
ajlm-975	33	17	10:00	10:00	NUM
ajlm-975	33	18	,	,	PUNCT
ajlm-975	33	19	from	from	ADP
ajlm-975	33	20	each	each	DET
ajlm-975	33	21	participant	participant	NOUN
ajlm-975	33	22	,	,	PUNCT
ajlm-975	33	23	by	by	ADP
ajlm-975	33	24	medical	medical	ADJ
ajlm-975	33	25	laboratory	laboratory	NOUN
ajlm-975	33	26	scientists	scientist	NOUN
ajlm-975	33	27	;	;	PUNCT
ajlm-975	33	28	3	3	NUM
ajlm-975	33	29	ml	ml	NOUN
ajlm-975	33	30	was	be	AUX
ajlm-975	33	31	drawn	draw	VERB
ajlm-975	33	32	into	into	ADP
ajlm-975	33	33	an	an	DET
ajlm-975	33	34	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-975	33	35	acid	acid	NOUN
ajlm-975	33	36	vacutainer	vacutainer	ADJ
ajlm-975	33	37	tube	tube	NOUN
ajlm-975	33	38	for	for	ADP
ajlm-975	33	39	cd4	cd4	PROPN
ajlm-975	33	40	+	+	PROPN
ajlm-975	33	41	t	t	PROPN
ajlm-975	33	42	-	-	PUNCT
ajlm-975	33	43	cell	cell	NOUN
ajlm-975	33	44	counts	count	NOUN
ajlm-975	33	45	and	and	CCONJ
ajlm-975	33	46	2	2	NUM
ajlm-975	33	47	ml	ml	NOUN
ajlm-975	33	48	was	be	AUX
ajlm-975	33	49	drawn	draw	VERB
ajlm-975	33	50	into	into	ADP
ajlm-975	33	51	a	a	DET
ajlm-975	33	52	plain	plain	ADJ
ajlm-975	33	53	tube	tube	NOUN
ajlm-975	33	54	for	for	ADP
ajlm-975	33	55	enzyme	enzyme	NOUN
ajlm-975	33	56	-	-	PUNCT
ajlm-975	33	57	linked	link	VERB
ajlm-975	33	58	immunosorbent	immunosorbent	NOUN
ajlm-975	33	59	assay	assay	PROPN
ajlm-975	33	60	(	(	PUNCT
ajlm-975	33	61	elisa	elisa	NOUN
ajlm-975	33	62	)	)	PUNCT
ajlm-975	33	63	.	.	PUNCT
ajlm-975	34	1	samples	sample	NOUN
ajlm-975	34	2	taken	take	VERB
ajlm-975	34	3	at	at	ADP
ajlm-975	34	4	the	the	DET
ajlm-975	34	5	abeokuta	abeokuta	PROPN
ajlm-975	34	6	collection	collection	NOUN
ajlm-975	34	7	centre	centre	NOUN
ajlm-975	34	8	were	be	AUX
ajlm-975	34	9	transported	transport	VERB
ajlm-975	34	10	to	to	ADP
ajlm-975	34	11	the	the	DET
ajlm-975	34	12	chemical	chemical	ADJ
ajlm-975	34	13	pathology	pathology	NOUN
ajlm-975	34	14	unit	unit	NOUN
ajlm-975	34	15	,	,	PUNCT
ajlm-975	34	16	babcock	babcock	PROPN
ajlm-975	34	17	university	university	PROPN
ajlm-975	34	18	teaching	teaching	NOUN
ajlm-975	34	19	hospital	hospital	NOUN
ajlm-975	34	20	,	,	PUNCT
ajlm-975	34	21	in	in	ADP
ajlm-975	34	22	a	a	DET
ajlm-975	34	23	specimen	speciman	NOUN
ajlm-975	34	24	transport	transport	NOUN
ajlm-975	34	25	cooler	cooler	NOUN
ajlm-975	34	26	containing	contain	VERB
ajlm-975	34	27	some	some	DET
ajlm-975	34	28	ice	ice	NOUN
ajlm-975	34	29	packs	pack	NOUN
ajlm-975	34	30	.	.	PUNCT
ajlm-975	35	1	all	all	DET
ajlm-975	35	2	samples	sample	NOUN
ajlm-975	35	3	were	be	AUX
ajlm-975	35	4	analysed	analyse	VERB
ajlm-975	35	5	at	at	ADP
ajlm-975	35	6	the	the	DET
ajlm-975	35	7	chemical	chemical	ADJ
ajlm-975	35	8	pathology	pathology	NOUN
ajlm-975	35	9	unit	unit	NOUN
ajlm-975	35	10	,	,	PUNCT
ajlm-975	35	11	babcock	babcock	PROPN
ajlm-975	35	12	university	university	PROPN
ajlm-975	35	13	teaching	teaching	NOUN
ajlm-975	35	14	hospital	hospital	NOUN
ajlm-975	35	15	.	.	PUNCT
ajlm-975	36	1	after	after	ADP
ajlm-975	36	2	allowing	allow	VERB
ajlm-975	36	3	the	the	DET
ajlm-975	36	4	blood	blood	NOUN
ajlm-975	36	5	in	in	ADP
ajlm-975	36	6	the	the	DET
ajlm-975	36	7	plain	plain	ADJ
ajlm-975	36	8	tube	tube	NOUN
ajlm-975	36	9	(	(	PUNCT
ajlm-975	36	10	2	2	NUM
ajlm-975	36	11	ml	ml	NOUN
ajlm-975	36	12	)	)	PUNCT
ajlm-975	36	13	to	to	PART
ajlm-975	36	14	stand	stand	VERB
ajlm-975	36	15	for	for	ADP
ajlm-975	36	16	not	not	PART
ajlm-975	36	17	more	more	ADJ
ajlm-975	36	18	than	than	ADP
ajlm-975	36	19	2	2	NUM
ajlm-975	36	20	h	h	NOUN
ajlm-975	36	21	,	,	PUNCT
ajlm-975	36	22	clear	clear	ADJ
ajlm-975	36	23	serum	serum	NOUN
ajlm-975	36	24	was	be	AUX
ajlm-975	36	25	separated	separate	VERB
ajlm-975	36	26	into	into	ADP
ajlm-975	36	27	another	another	DET
ajlm-975	36	28	plain	plain	ADJ
ajlm-975	36	29	tube	tube	NOUN
ajlm-975	36	30	and	and	CCONJ
ajlm-975	36	31	stored	store	VERB
ajlm-975	36	32	at	at	ADP
ajlm-975	36	33	−20	−20	PROPN
ajlm-975	36	34	°	°	ADP
ajlm-975	36	35	c	c	NOUN
ajlm-975	36	36	until	until	SCONJ
ajlm-975	36	37	analysed	analyse	VERB
ajlm-975	36	38	.	.	PUNCT
ajlm-975	37	1	cd4	cd4	PROPN
ajlm-975	37	2	+	+	PROPN
ajlm-975	37	3	t	t	PROPN
ajlm-975	37	4	-	-	PUNCT
ajlm-975	37	5	cell	cell	NOUN
ajlm-975	37	6	counts	count	NOUN
ajlm-975	37	7	and	and	CCONJ
ajlm-975	37	8	pap	pap	NOUN
ajlm-975	37	9	smears	smear	NOUN
ajlm-975	37	10	were	be	AUX
ajlm-975	37	11	investigated	investigate	VERB
ajlm-975	37	12	daily	daily	ADV
ajlm-975	37	13	while	while	SCONJ
ajlm-975	37	14	other	other	ADJ
ajlm-975	37	15	test	test	NOUN
ajlm-975	37	16	were	be	AUX
ajlm-975	37	17	carried	carry	VERB
ajlm-975	37	18	out	out	ADP
ajlm-975	37	19	at	at	ADP
ajlm-975	37	20	intervals	interval	NOUN
ajlm-975	37	21	(	(	PUNCT
ajlm-975	37	22	≤	≤	ADV
ajlm-975	37	23	2	2	NUM
ajlm-975	37	24	months	month	NOUN
ajlm-975	37	25	)	)	PUNCT
ajlm-975	37	26	.	.	PUNCT
ajlm-975	38	1	sample	sample	NOUN
ajlm-975	38	2	assays	assay	VERB
ajlm-975	38	3	the	the	DET
ajlm-975	38	4	cd4	cd4	PROPN
ajlm-975	38	5	easy	easy	ADJ
ajlm-975	38	6	count	count	NOUN
ajlm-975	38	7	kit	kit	NOUN
ajlm-975	38	8	and	and	CCONJ
ajlm-975	38	9	cyflow	cyflow	NOUN
ajlm-975	38	10	counter	counter	NOUN
ajlm-975	38	11	(	(	PUNCT
ajlm-975	38	12	sysmex	sysmex	NOUN
ajlm-975	38	13	partec	partec	NOUN
ajlm-975	38	14	gmbh	gmbh	PROPN
ajlm-975	38	15	,	,	PUNCT
ajlm-975	38	16	gorlitz	gorlitz	PROPN
ajlm-975	38	17	,	,	PUNCT
ajlm-975	38	18	germany	germany	PROPN
ajlm-975	38	19	)	)	PUNCT
ajlm-975	38	20	were	be	AUX
ajlm-975	38	21	used	use	VERB
ajlm-975	38	22	for	for	ADP
ajlm-975	38	23	counting	count	VERB
ajlm-975	38	24	cd4	cd4	PROPN
ajlm-975	38	25	+	+	PROPN
ajlm-975	38	26	t	t	PROPN
ajlm-975	38	27	-	-	PUNCT
ajlm-975	38	28	cells	cell	NOUN
ajlm-975	38	29	in	in	ADP
ajlm-975	38	30	whole	whole	ADJ
ajlm-975	38	31	blood	blood	NOUN
ajlm-975	38	32	,	,	PUNCT
ajlm-975	38	33	not	not	PART
ajlm-975	38	34	more	more	ADJ
ajlm-975	38	35	than	than	ADP
ajlm-975	38	36	2	2	NUM
ajlm-975	38	37	h	h	NOUN
ajlm-975	38	38	after	after	ADP
ajlm-975	38	39	collection	collection	NOUN
ajlm-975	38	40	.	.	PUNCT
ajlm-975	39	1	to	to	PART
ajlm-975	39	2	maintain	maintain	VERB
ajlm-975	39	3	cd4	cd4	PROPN
ajlm-975	39	4	+	+	PROPN
ajlm-975	39	5	t	t	PROPN
ajlm-975	39	6	-	-	PUNCT
ajlm-975	39	7	cell	cell	NOUN
ajlm-975	39	8	day	day	NOUN
ajlm-975	39	9	-	-	PUNCT
ajlm-975	39	10	to	to	ADP
ajlm-975	39	11	-	-	PUNCT
ajlm-975	39	12	day	day	NOUN
ajlm-975	39	13	counts	count	NOUN
ajlm-975	39	14	,	,	PUNCT
ajlm-975	39	15	two	two	NUM
ajlm-975	39	16	internal	internal	ADJ
ajlm-975	39	17	quality	quality	NOUN
ajlm-975	39	18	controls	control	NOUN
ajlm-975	39	19	were	be	AUX
ajlm-975	39	20	employed	employ	VERB
ajlm-975	39	21	:	:	PUNCT
ajlm-975	39	22	previously	previously	ADV
ajlm-975	39	23	tested	test	VERB
ajlm-975	39	24	whole	whole	ADJ
ajlm-975	39	25	blood	blood	NOUN
ajlm-975	39	26	samples	sample	NOUN
ajlm-975	39	27	and	and	CCONJ
ajlm-975	39	28	stabilised	stabilise	VERB
ajlm-975	39	29	whole	whole	ADJ
ajlm-975	39	30	blood	blood	NOUN
ajlm-975	39	31	samples	sample	NOUN
ajlm-975	39	32	.	.	PUNCT
ajlm-975	40	1	the	the	DET
ajlm-975	40	2	separated	separate	VERB
ajlm-975	40	3	sera	sera	NOUN
ajlm-975	40	4	were	be	AUX
ajlm-975	40	5	tested	test	VERB
ajlm-975	40	6	for	for	ADP
ajlm-975	40	7	antibodies	antibody	NOUN
ajlm-975	40	8	against	against	ADP
ajlm-975	40	9	hiv-2	hiv-2	ADV
ajlm-975	40	10	,	,	PUNCT
ajlm-975	40	11	ebv	ebv	NOUN
ajlm-975	40	12	,	,	PUNCT
ajlm-975	40	13	hpv	hpv	NOUN
ajlm-975	40	14	,	,	PUNCT
ajlm-975	40	15	and	and	CCONJ
ajlm-975	40	16	hsv-2	hsv-2	PUNCT
ajlm-975	40	17	by	by	ADP
ajlm-975	40	18	elisa	elisa	PROPN
ajlm-975	40	19	(	(	PUNCT
ajlm-975	40	20	qingdao	qingdao	PROPN
ajlm-975	40	21	hightop	hightop	PROPN
ajlm-975	40	22	biotech	biotech	PROPN
ajlm-975	40	23	co.	co.	PROPN
ajlm-975	40	24	ltd	ltd	PROPN
ajlm-975	40	25	,	,	PUNCT
ajlm-975	40	26	qingdao	qingdao	PROPN
ajlm-975	40	27	,	,	PUNCT
ajlm-975	40	28	shandong	shandong	PROPN
ajlm-975	40	29	,	,	PUNCT
ajlm-975	40	30	china	china	PROPN
ajlm-975	40	31	,	,	PUNCT
ajlm-975	40	32	and	and	CCONJ
ajlm-975	40	33	calbiotech	calbiotech	PROPN
ajlm-975	40	34	inc	inc	PROPN
ajlm-975	40	35	.	.	PROPN
ajlm-975	40	36	,	,	PUNCT
ajlm-975	40	37	el	el	PROPN
ajlm-975	40	38	cajon	cajon	PROPN
ajlm-975	40	39	,	,	PUNCT
ajlm-975	40	40	california	california	PROPN
ajlm-975	40	41	,	,	PUNCT
ajlm-975	40	42	united	united	PROPN
ajlm-975	40	43	states	states	PROPN
ajlm-975	40	44	)	)	PUNCT
ajlm-975	40	45	according	accord	VERB
ajlm-975	40	46	to	to	ADP
ajlm-975	40	47	manufacturers	manufacturer	NOUN
ajlm-975	40	48	’	’	PART
ajlm-975	40	49	instructions	instruction	NOUN
ajlm-975	40	50	.	.	PUNCT
ajlm-975	41	1	according	accord	VERB
ajlm-975	41	2	to	to	ADP
ajlm-975	41	3	the	the	DET
ajlm-975	41	4	manufacturers	manufacturer	NOUN
ajlm-975	41	5	instructions	instruction	NOUN
ajlm-975	41	6	,	,	PUNCT
ajlm-975	41	7	a	a	DET
ajlm-975	41	8	96	96	NUM
ajlm-975	41	9	%	%	NOUN
ajlm-975	41	10	to	to	PART
ajlm-975	41	11	99	99	NUM
ajlm-975	41	12	%	%	NOUN
ajlm-975	41	13	agreement	agreement	NOUN
ajlm-975	41	14	(	(	PUNCT
ajlm-975	41	15	performance	performance	NOUN
ajlm-975	41	16	)	)	PUNCT
ajlm-975	41	17	was	be	AUX
ajlm-975	41	18	observed	observe	VERB
ajlm-975	41	19	between	between	ADP
ajlm-975	41	20	elisa	elisa	PROPN
ajlm-975	41	21	kits	kit	NOUN
ajlm-975	41	22	and	and	CCONJ
ajlm-975	41	23	the	the	DET
ajlm-975	41	24	reference	reference	NOUN
ajlm-975	41	25	elisa	elisa	NOUN
ajlm-975	41	26	method	method	NOUN
ajlm-975	41	27	.	.	PUNCT
ajlm-975	42	1	serum	serum	NOUN
ajlm-975	42	2	samples	sample	NOUN
ajlm-975	42	3	from	from	ADP
ajlm-975	42	4	participants	participant	NOUN
ajlm-975	42	5	whose	whose	DET
ajlm-975	42	6	cervical	cervical	ADJ
ajlm-975	42	7	cells	cell	NOUN
ajlm-975	42	8	had	have	VERB
ajlm-975	42	9	hpv	hpv	NOUN
ajlm-975	42	10	and	and	CCONJ
ajlm-975	42	11	hsv-2	hsv-2	PUNCT
ajlm-975	42	12	viral	viral	ADJ
ajlm-975	42	13	cytopathic	cytopathic	ADJ
ajlm-975	42	14	effects	effect	NOUN
ajlm-975	42	15	–	–	PUNCT
ajlm-975	42	16	koilocytes	koilocyte	NOUN
ajlm-975	42	17	and	and	CCONJ
ajlm-975	42	18	viral	viral	ADJ
ajlm-975	42	19	cytoplasmic	cytoplasmic	ADJ
ajlm-975	42	20	inclusions	inclusion	NOUN
ajlm-975	42	21	–	–	PUNCT
ajlm-975	42	22	were	be	AUX
ajlm-975	42	23	considered	consider	VERB
ajlm-975	42	24	as	as	ADP
ajlm-975	42	25	internal	internal	ADJ
ajlm-975	42	26	positive	positive	ADJ
ajlm-975	42	27	controls	control	NOUN
ajlm-975	42	28	.	.	PUNCT
ajlm-975	43	1	previously	previously	ADV
ajlm-975	43	2	tested	test	VERB
ajlm-975	43	3	samples	sample	NOUN
ajlm-975	43	4	from	from	ADP
ajlm-975	43	5	laboratory	laboratory	NOUN
ajlm-975	43	6	and	and	CCONJ
ajlm-975	43	7	clinically	clinically	ADV
ajlm-975	43	8	confirmed	confirm	VERB
ajlm-975	43	9	hiv	hiv	PROPN
ajlm-975	43	10	positive	positive	ADJ
ajlm-975	43	11	and	and	CCONJ
ajlm-975	43	12	negative	negative	ADJ
ajlm-975	43	13	cases	case	NOUN
ajlm-975	43	14	were	be	AUX
ajlm-975	43	15	used	use	VERB
ajlm-975	43	16	as	as	ADP
ajlm-975	43	17	internal	internal	ADJ
ajlm-975	43	18	positive	positive	ADJ
ajlm-975	43	19	and	and	CCONJ
ajlm-975	43	20	negative	negative	ADJ
ajlm-975	43	21	controls	control	NOUN
ajlm-975	43	22	for	for	ADP
ajlm-975	43	23	hiv	hiv	PROPN
ajlm-975	43	24	testing	testing	NOUN
ajlm-975	43	25	.	.	PUNCT
ajlm-975	44	1	p16	p16	PROPN
ajlm-975	44	2	regulates	regulate	VERB
ajlm-975	44	3	the	the	DET
ajlm-975	44	4	cell	cell	NOUN
ajlm-975	44	5	cycle	cycle	NOUN
ajlm-975	44	6	by	by	ADP
ajlm-975	44	7	acting	act	VERB
ajlm-975	44	8	as	as	ADP
ajlm-975	44	9	a	a	DET
ajlm-975	44	10	cyclin	cyclin	NOUN
ajlm-975	44	11	-	-	PUNCT
ajlm-975	44	12	dependent	dependent	ADJ
ajlm-975	44	13	kinase	kinase	NOUN
ajlm-975	44	14	inhibitor	inhibitor	NOUN
ajlm-975	44	15	and	and	CCONJ
ajlm-975	44	16	has	have	AUX
ajlm-975	44	17	been	be	AUX
ajlm-975	44	18	used	use	VERB
ajlm-975	44	19	as	as	ADP
ajlm-975	44	20	an	an	DET
ajlm-975	44	21	alternative	alternative	ADJ
ajlm-975	44	22	biomarker	biomarker	NOUN
ajlm-975	44	23	for	for	ADP
ajlm-975	44	24	hpv	hpv	PROPN
ajlm-975	44	25	testing.10,11	testing.10,11	NOUN
ajlm-975	44	26	thus	thus	ADV
ajlm-975	44	27	,	,	PUNCT
ajlm-975	44	28	serum	serum	NOUN
ajlm-975	44	29	samples	sample	NOUN
ajlm-975	44	30	that	that	PRON
ajlm-975	44	31	were	be	AUX
ajlm-975	44	32	positive	positive	ADJ
ajlm-975	44	33	and	and	CCONJ
ajlm-975	44	34	negative	negative	ADJ
ajlm-975	44	35	for	for	ADP
ajlm-975	44	36	p16	p16	NOUN
ajlm-975	44	37	(	(	PUNCT
ajlm-975	44	38	from	from	ADP
ajlm-975	44	39	previous	previous	ADJ
ajlm-975	44	40	a	a	DET
ajlm-975	44	41	study	study	NOUN
ajlm-975	44	42	)	)	PUNCT
ajlm-975	44	43	were	be	AUX
ajlm-975	44	44	also	also	ADV
ajlm-975	44	45	used	use	VERB
ajlm-975	44	46	as	as	ADP
ajlm-975	44	47	internal	internal	ADJ
ajlm-975	44	48	positive	positive	ADJ
ajlm-975	44	49	and	and	CCONJ
ajlm-975	44	50	negative	negative	ADJ
ajlm-975	44	51	controls	control	NOUN
ajlm-975	44	52	for	for	ADP
ajlm-975	44	53	hpv	hpv	NOUN
ajlm-975	44	54	testing	testing	NOUN
ajlm-975	44	55	.	.	PUNCT
ajlm-975	45	1	p16	p16	PROPN
ajlm-975	45	2	kit	kit	NOUN
ajlm-975	45	3	-	-	PUNCT
ajlm-975	45	4	included	include	VERB
ajlm-975	45	5	positive	positive	ADJ
ajlm-975	45	6	and	and	CCONJ
ajlm-975	45	7	negative	negative	ADJ
ajlm-975	45	8	controls	control	NOUN
ajlm-975	45	9	were	be	AUX
ajlm-975	45	10	considered	consider	VERB
ajlm-975	45	11	as	as	ADP
ajlm-975	45	12	external	external	ADJ
ajlm-975	45	13	controls	control	NOUN
ajlm-975	45	14	(	(	PUNCT
ajlm-975	45	15	bioassay	bioassay	NOUN
ajlm-975	45	16	technology	technology	PROPN
ajlm-975	45	17	laboratory	laboratory	PROPN
ajlm-975	45	18	,	,	PUNCT
ajlm-975	45	19	yangpu	yangpu	PROPN
ajlm-975	45	20	,	,	PUNCT
ajlm-975	45	21	shangai	shangai	PROPN
ajlm-975	45	22	,	,	PUNCT
ajlm-975	45	23	china	china	PROPN
ajlm-975	45	24	)	)	PUNCT
ajlm-975	45	25	.	.	PUNCT
ajlm-975	46	1	the	the	DET
ajlm-975	46	2	cut	cut	VERB
ajlm-975	46	3	-	-	PUNCT
ajlm-975	46	4	off	off	ADP
ajlm-975	46	5	values	value	NOUN
ajlm-975	46	6	for	for	ADP
ajlm-975	46	7	positive	positive	ADJ
ajlm-975	46	8	and	and	CCONJ
ajlm-975	46	9	negative	negative	ADJ
ajlm-975	46	10	controls	control	NOUN
ajlm-975	46	11	were	be	AUX
ajlm-975	46	12	≥	≥	NOUN
ajlm-975	46	13	8100	8100	NUM
ajlm-975	46	14	ng	ng	PROPN
ajlm-975	46	15	/	/	SYM
ajlm-975	46	16	l	l	PROPN
ajlm-975	46	17	and	and	CCONJ
ajlm-975	46	18	≥	≥	NUM
ajlm-975	46	19	8099	8099	NUM
ajlm-975	46	20	ng	ng	PROPN
ajlm-975	46	21	/	/	SYM
ajlm-975	46	22	l	l	PROPN
ajlm-975	46	23	,	,	PUNCT
ajlm-975	46	24	respectively	respectively	ADV
ajlm-975	46	25	.	.	PUNCT
ajlm-975	47	1	both	both	CCONJ
ajlm-975	47	2	internal	internal	ADJ
ajlm-975	47	3	and	and	CCONJ
ajlm-975	47	4	external	external	ADJ
ajlm-975	47	5	positive	positive	ADJ
ajlm-975	47	6	and	and	CCONJ
ajlm-975	47	7	negative	negative	ADJ
ajlm-975	47	8	controls	control	NOUN
ajlm-975	47	9	were	be	AUX
ajlm-975	47	10	used	use	VERB
ajlm-975	47	11	in	in	ADP
ajlm-975	47	12	the	the	DET
ajlm-975	47	13	calibration	calibration	NOUN
ajlm-975	47	14	and	and	CCONJ
ajlm-975	47	15	calculation	calculation	NOUN
ajlm-975	47	16	of	of	ADP
ajlm-975	47	17	cut	cut	NOUN
ajlm-975	47	18	-	-	PUNCT
ajlm-975	47	19	off	off	ADP
ajlm-975	47	20	values	value	NOUN
ajlm-975	47	21	for	for	ADP
ajlm-975	47	22	hpv	hpv	NOUN
ajlm-975	47	23	and	and	CCONJ
ajlm-975	47	24	hsv-2	hsv-2	X
ajlm-975	47	25	antibodies	antibody	NOUN
ajlm-975	47	26	.	.	PUNCT
ajlm-975	48	1	furthermore	furthermore	ADV
ajlm-975	48	2	,	,	PUNCT
ajlm-975	48	3	serum	serum	NOUN
ajlm-975	48	4	samples	sample	NOUN
ajlm-975	48	5	from	from	ADP
ajlm-975	48	6	cervical	cervical	ADJ
ajlm-975	48	7	cancer	cancer	NOUN
ajlm-975	48	8	patients	patient	NOUN
ajlm-975	48	9	whose	whose	DET
ajlm-975	48	10	cervical	cervical	ADJ
ajlm-975	48	11	tissues	tissue	NOUN
ajlm-975	48	12	or	or	CCONJ
ajlm-975	48	13	biopsies	biopsy	NOUN
ajlm-975	48	14	tested	test	VERB
ajlm-975	48	15	positive	positive	ADJ
ajlm-975	48	16	for	for	ADP
ajlm-975	48	17	ebv	ebv	NOUN
ajlm-975	48	18	(	(	PUNCT
ajlm-975	48	19	lmp-1	lmp-1	NOUN
ajlm-975	48	20	)	)	PUNCT
ajlm-975	48	21	,	,	PUNCT
ajlm-975	48	22	hpv	hpv	NOUN
ajlm-975	48	23	and	and	CCONJ
ajlm-975	48	24	hsv-2	hsv-2	PUNCT
ajlm-975	48	25	antigen	antigen	VERB
ajlm-975	48	26	by	by	ADP
ajlm-975	48	27	immunohistochemistry	immunohistochemistry	NOUN
ajlm-975	48	28	were	be	AUX
ajlm-975	48	29	used	use	VERB
ajlm-975	48	30	as	as	ADP
ajlm-975	48	31	internal	internal	ADJ
ajlm-975	48	32	positive	positive	ADJ
ajlm-975	48	33	controls	control	NOUN
ajlm-975	48	34	while	while	SCONJ
ajlm-975	48	35	those	those	PRON
ajlm-975	48	36	whose	whose	DET
ajlm-975	48	37	cervical	cervical	ADJ
ajlm-975	48	38	tissues	tissue	NOUN
ajlm-975	48	39	or	or	CCONJ
ajlm-975	48	40	biopsies	biopsy	NOUN
ajlm-975	48	41	tested	test	VERB
ajlm-975	48	42	negative	negative	ADJ
ajlm-975	48	43	for	for	ADP
ajlm-975	48	44	the	the	DET
ajlm-975	48	45	viral	viral	ADJ
ajlm-975	48	46	antigens	antigen	NOUN
ajlm-975	48	47	by	by	ADP
ajlm-975	48	48	immunohistochemistry	immunohistochemistry	NOUN
ajlm-975	48	49	were	be	AUX
ajlm-975	48	50	used	use	VERB
ajlm-975	48	51	as	as	ADP
ajlm-975	48	52	internal	internal	ADJ
ajlm-975	48	53	negative	negative	ADJ
ajlm-975	48	54	controls	control	NOUN
ajlm-975	48	55	(	(	PUNCT
ajlm-975	48	56	using	use	VERB
ajlm-975	48	57	a	a	DET
ajlm-975	48	58	commercial	commercial	ADJ
ajlm-975	48	59	kit	kit	NOUN
ajlm-975	48	60	from	from	ADP
ajlm-975	48	61	bio	bio	PROPN
ajlm-975	48	62	sb	sb	PROPN
ajlm-975	48	63	inc	inc	PROPN
ajlm-975	48	64	.	.	PROPN
ajlm-975	48	65	,	,	PUNCT
ajlm-975	48	66	santa	santa	PROPN
ajlm-975	48	67	barbara	barbara	PROPN
ajlm-975	48	68	,	,	PUNCT
ajlm-975	48	69	california	california	PROPN
ajlm-975	48	70	,	,	PUNCT
ajlm-975	48	71	united	united	PROPN
ajlm-975	48	72	states	states	PROPN
ajlm-975	48	73	)	)	PUNCT
ajlm-975	48	74	.	.	PUNCT
ajlm-975	49	1	in	in	ADP
ajlm-975	49	2	all	all	DET
ajlm-975	49	3	four	four	NUM
ajlm-975	49	4	positive	positive	ADJ
ajlm-975	49	5	and	and	CCONJ
ajlm-975	49	6	four	four	NUM
ajlm-975	49	7	negative	negative	ADJ
ajlm-975	49	8	controls	control	NOUN
ajlm-975	49	9	(	(	PUNCT
ajlm-975	49	10	based	base	VERB
ajlm-975	49	11	on	on	ADP
ajlm-975	49	12	koilocyte	koilocyte	PROPN
ajlm-975	49	13	presence	presence	NOUN
ajlm-975	49	14	,	,	PUNCT
ajlm-975	49	15	p16	p16	NOUN
ajlm-975	49	16	positivity	positivity	NOUN
ajlm-975	49	17	,	,	PUNCT
ajlm-975	49	18	hpv	hpv	NOUN
ajlm-975	49	19	immunohistochemistry	immunohistochemistry	NOUN
ajlm-975	49	20	status	status	NOUN
ajlm-975	49	21	and	and	CCONJ
ajlm-975	49	22	manufacturer	manufacturer	NOUN
ajlm-975	49	23	’s	’s	PART
ajlm-975	49	24	hpv	hpv	PROPN
ajlm-975	49	25	control	control	PROPN
ajlm-975	49	26	sample	sample	PROPN
ajlm-975	49	27	)	)	PUNCT
ajlm-975	49	28	were	be	AUX
ajlm-975	49	29	used	use	VERB
ajlm-975	49	30	for	for	ADP
ajlm-975	49	31	hpv	hpv	NOUN
ajlm-975	49	32	testing	testing	NOUN
ajlm-975	49	33	while	while	SCONJ
ajlm-975	49	34	three	three	NUM
ajlm-975	49	35	positive	positive	ADJ
ajlm-975	49	36	and	and	CCONJ
ajlm-975	49	37	three	three	NUM
ajlm-975	49	38	negative	negative	ADJ
ajlm-975	49	39	controls	control	NOUN
ajlm-975	49	40	(	(	PUNCT
ajlm-975	49	41	based	base	VERB
ajlm-975	49	42	on	on	ADP
ajlm-975	49	43	viral	viral	ADJ
ajlm-975	49	44	inclusion	inclusion	NOUN
ajlm-975	49	45	in	in	ADP
ajlm-975	49	46	cervical	cervical	ADJ
ajlm-975	49	47	cells	cell	NOUN
ajlm-975	49	48	,	,	PUNCT
ajlm-975	49	49	hsv-2	hsv-2	X
ajlm-975	49	50	immunohistochemistry	immunohistochemistry	NOUN
ajlm-975	49	51	status	status	NOUN
ajlm-975	49	52	,	,	PUNCT
ajlm-975	49	53	and	and	CCONJ
ajlm-975	49	54	manufacturer	manufacturer	NOUN
ajlm-975	49	55	’s	’s	PART
ajlm-975	49	56	hsv-2	hsv-2	PRON
ajlm-975	49	57	control	control	NOUN
ajlm-975	49	58	sample	sample	NOUN
ajlm-975	49	59	)	)	PUNCT
ajlm-975	49	60	were	be	AUX
ajlm-975	49	61	used	use	VERB
ajlm-975	49	62	for	for	ADP
ajlm-975	49	63	hsv-2	hsv-2	DET
ajlm-975	49	64	testing	testing	NOUN
ajlm-975	49	65	.	.	PUNCT
ajlm-975	50	1	more	more	ADV
ajlm-975	50	2	so	so	ADV
ajlm-975	50	3	,	,	PUNCT
ajlm-975	50	4	two	two	NUM
ajlm-975	50	5	positive	positive	ADJ
ajlm-975	50	6	and	and	CCONJ
ajlm-975	50	7	two	two	NUM
ajlm-975	50	8	negative	negative	ADJ
ajlm-975	50	9	controls	control	NOUN
ajlm-975	50	10	(	(	PUNCT
ajlm-975	50	11	based	base	VERB
ajlm-975	50	12	on	on	ADP
ajlm-975	50	13	ebv	ebv	NOUN
ajlm-975	50	14	immunohistochemistry	immunohistochemistry	NOUN
ajlm-975	50	15	status	status	NOUN
ajlm-975	50	16	and	and	CCONJ
ajlm-975	50	17	manufacturer	manufacturer	NOUN
ajlm-975	50	18	’s	’s	PART
ajlm-975	50	19	ebv	ebv	PROPN
ajlm-975	50	20	control	control	NOUN
ajlm-975	50	21	sample	sample	NOUN
ajlm-975	50	22	)	)	PUNCT
ajlm-975	50	23	were	be	AUX
ajlm-975	50	24	used	use	VERB
ajlm-975	50	25	for	for	ADP
ajlm-975	50	26	ebv	ebv	NOUN
ajlm-975	50	27	testing	testing	NOUN
ajlm-975	50	28	.	.	PUNCT
ajlm-975	51	1	the	the	DET
ajlm-975	51	2	controls	control	NOUN
ajlm-975	51	3	were	be	AUX
ajlm-975	51	4	included	include	VERB
ajlm-975	51	5	during	during	ADP
ajlm-975	51	6	assay	assay	PROPN
ajlm-975	51	7	(	(	PUNCT
ajlm-975	51	8	in	in	ADP
ajlm-975	51	9	order	order	NOUN
ajlm-975	51	10	to	to	PART
ajlm-975	51	11	eliminate	eliminate	VERB
ajlm-975	51	12	false	false	ADJ
ajlm-975	51	13	positives	positive	NOUN
ajlm-975	51	14	and	and	CCONJ
ajlm-975	51	15	forestall	forestall	VERB
ajlm-975	51	16	false	false	ADJ
ajlm-975	51	17	negatives	negative	NOUN
ajlm-975	51	18	)	)	PUNCT
ajlm-975	51	19	,	,	PUNCT
ajlm-975	51	20	prior	prior	ADV
ajlm-975	51	21	to	to	ADP
ajlm-975	51	22	calculation	calculation	NOUN
ajlm-975	51	23	of	of	ADP
ajlm-975	51	24	cut	cut	NOUN
ajlm-975	51	25	-	-	PUNCT
ajlm-975	51	26	offs	off	NOUN
ajlm-975	51	27	.	.	PUNCT
ajlm-975	52	1	the	the	DET
ajlm-975	52	2	sera	sera	NOUN
ajlm-975	52	3	were	be	AUX
ajlm-975	52	4	also	also	ADV
ajlm-975	52	5	tested	test	VERB
ajlm-975	52	6	by	by	ADP
ajlm-975	52	7	the	the	DET
ajlm-975	52	8	elisa	elisa	NOUN
ajlm-975	52	9	method	method	NOUN
ajlm-975	52	10	for	for	ADP
ajlm-975	52	11	human	human	ADJ
ajlm-975	52	12	proliferation	proliferation	NOUN
ajlm-975	52	13	-	-	PUNCT
ajlm-975	52	14	related	relate	VERB
ajlm-975	52	15	ki-67	ki-67	ADJ
ajlm-975	52	16	antigen	antigen	NOUN
ajlm-975	52	17	(	(	PUNCT
ajlm-975	52	18	ki67	ki67	PROPN
ajlm-975	52	19	;	;	PUNCT
ajlm-975	52	20	using	use	VERB
ajlm-975	52	21	kits	kit	NOUN
ajlm-975	52	22	from	from	ADP
ajlm-975	52	23	melsin	melsin	PROPN
ajlm-975	52	24	medical	medical	PROPN
ajlm-975	52	25	co.	co.	PROPN
ajlm-975	52	26	ltd	ltd	PROPN
ajlm-975	52	27	,	,	PUNCT
ajlm-975	52	28	changchun	changchun	PROPN
ajlm-975	52	29	,	,	PUNCT
ajlm-975	52	30	jilin	jilin	PROPN
ajlm-975	52	31	,	,	PUNCT
ajlm-975	52	32	china	china	PROPN
ajlm-975	52	33	)	)	PUNCT
ajlm-975	52	34	and	and	CCONJ
ajlm-975	52	35	squamous	squamous	ADJ
ajlm-975	52	36	cell	cell	NOUN
ajlm-975	52	37	carcinoma	carcinoma	NOUN
ajlm-975	52	38	antigen	antigen	ADP
ajlm-975	52	39	1	1	NUM
ajlm-975	52	40	(	(	PUNCT
ajlm-975	52	41	scca1	scca1	PROPN
ajlm-975	52	42	;	;	PUNCT
ajlm-975	52	43	using	use	VERB
ajlm-975	52	44	kits	kit	NOUN
ajlm-975	52	45	from	from	ADP
ajlm-975	52	46	elabscience	elabscience	PROPN
ajlm-975	52	47	biotechnology	biotechnology	PROPN
ajlm-975	52	48	co.	co.	PROPN
ajlm-975	52	49	ltd	ltd	PROPN
ajlm-975	52	50	,	,	PUNCT
ajlm-975	52	51	wuhan	wuhan	PROPN
ajlm-975	52	52	,	,	PUNCT
ajlm-975	52	53	hubei	hubei	PROPN
ajlm-975	52	54	,	,	PUNCT
ajlm-975	52	55	china	china	PROPN
ajlm-975	52	56	)	)	PUNCT
ajlm-975	52	57	.	.	PUNCT
ajlm-975	53	1	using	use	VERB
ajlm-975	53	2	the	the	DET
ajlm-975	53	3	internal	internal	ADJ
ajlm-975	53	4	and	and	CCONJ
ajlm-975	53	5	external	external	ADJ
ajlm-975	53	6	control	control	NOUN
ajlm-975	53	7	samples	sample	NOUN
ajlm-975	53	8	,	,	PUNCT
ajlm-975	53	9	tests	test	NOUN
ajlm-975	53	10	for	for	ADP
ajlm-975	53	11	viral	viral	ADJ
ajlm-975	53	12	antibodies	antibody	NOUN
ajlm-975	53	13	were	be	AUX
ajlm-975	53	14	considered	consider	VERB
ajlm-975	53	15	valid	valid	ADJ
ajlm-975	53	16	when	when	SCONJ
ajlm-975	53	17	the	the	DET
ajlm-975	53	18	mean	mean	ADJ
ajlm-975	53	19	negative	negative	ADJ
ajlm-975	53	20	control	control	NOUN
ajlm-975	53	21	optical	optical	ADJ
ajlm-975	53	22	density	density	NOUN
ajlm-975	53	23	was	be	AUX
ajlm-975	53	24	0.1	0.1	NUM
ajlm-975	53	25	or	or	CCONJ
ajlm-975	53	26	lower	low	ADJ
ajlm-975	53	27	and	and	CCONJ
ajlm-975	53	28	the	the	DET
ajlm-975	53	29	mean	mean	ADJ
ajlm-975	53	30	positive	positive	ADJ
ajlm-975	53	31	control	control	NOUN
ajlm-975	53	32	optical	optical	ADJ
ajlm-975	53	33	density	density	NOUN
ajlm-975	53	34	was	be	AUX
ajlm-975	53	35	0.8	0.8	NUM
ajlm-975	53	36	or	or	CCONJ
ajlm-975	53	37	higher	high	ADJ
ajlm-975	53	38	.	.	PUNCT
ajlm-975	54	1	based	base	VERB
ajlm-975	54	2	on	on	ADP
ajlm-975	54	3	the	the	DET
ajlm-975	54	4	formula	formula	NOUN
ajlm-975	54	5	provided	provide	VERB
ajlm-975	54	6	by	by	ADP
ajlm-975	54	7	the	the	DET
ajlm-975	54	8	manufacturers	manufacturer	NOUN
ajlm-975	54	9	of	of	ADP
ajlm-975	54	10	the	the	DET
ajlm-975	54	11	elisa	elisa	PROPN
ajlm-975	54	12	kits	kit	NOUN
ajlm-975	54	13	,	,	PUNCT
ajlm-975	54	14	test	test	NOUN
ajlm-975	54	15	samples	sample	NOUN
ajlm-975	54	16	were	be	AUX
ajlm-975	54	17	considered	consider	VERB
ajlm-975	54	18	positive	positive	ADJ
ajlm-975	54	19	when	when	SCONJ
ajlm-975	54	20	their	their	PRON
ajlm-975	54	21	viral	viral	ADJ
ajlm-975	54	22	antibody	antibody	NOUN
ajlm-975	54	23	estimates	estimate	NOUN
ajlm-975	54	24	were	be	AUX
ajlm-975	54	25	greater	great	ADJ
ajlm-975	54	26	than	than	ADP
ajlm-975	54	27	the	the	DET
ajlm-975	54	28	cut	cut	VERB
ajlm-975	54	29	-	-	PUNCT
ajlm-975	54	30	off	off	ADP
ajlm-975	54	31	values	value	NOUN
ajlm-975	54	32	.	.	PUNCT
ajlm-975	55	1	the	the	DET
ajlm-975	55	2	positive	positive	ADJ
ajlm-975	55	3	cut	cut	NOUN
ajlm-975	55	4	-	-	PUNCT
ajlm-975	55	5	off	off	ADP
ajlm-975	55	6	values	value	NOUN
ajlm-975	55	7	for	for	ADP
ajlm-975	55	8	hiv	hiv	PROPN
ajlm-975	55	9	,	,	PUNCT
ajlm-975	55	10	hpv	hpv	PROPN
ajlm-975	55	11	igg	igg	PROPN
ajlm-975	55	12	,	,	PUNCT
ajlm-975	55	13	hpv	hpv	PROPN
ajlm-975	55	14	igm	igm	PROPN
ajlm-975	55	15	,	,	PUNCT
ajlm-975	55	16	hsv-2	hsv-2	PART
ajlm-975	55	17	igg	igg	PROPN
ajlm-975	55	18	,	,	PUNCT
ajlm-975	55	19	hsv-2	hsv-2	PART
ajlm-975	55	20	igm	igm	PROPN
ajlm-975	55	21	,	,	PUNCT
ajlm-975	55	22	ebv	ebv	NOUN
ajlm-975	55	23	igg	igg	PROPN
ajlm-975	55	24	,	,	PUNCT
ajlm-975	55	25	and	and	CCONJ
ajlm-975	55	26	ebv	ebv	NOUN
ajlm-975	55	27	igm	igm	NOUN
ajlm-975	55	28	antibodies	antibody	NOUN
ajlm-975	55	29	were	be	AUX
ajlm-975	55	30	1.077	1.077	NUM
ajlm-975	55	31	,	,	PUNCT
ajlm-975	55	32	1.071	1.071	NUM
ajlm-975	55	33	,	,	PUNCT
ajlm-975	55	34	0.438	0.438	NUM
ajlm-975	55	35	,	,	PUNCT
ajlm-975	55	36	1.520	1.520	NUM
ajlm-975	55	37	,	,	PUNCT
ajlm-975	55	38	0.102	0.102	NUM
ajlm-975	55	39	,	,	PUNCT
ajlm-975	55	40	1.570	1.570	NUM
ajlm-975	55	41	and	and	CCONJ
ajlm-975	55	42	1.030	1.030	NUM
ajlm-975	55	43	or	or	CCONJ
ajlm-975	55	44	higher	high	ADJ
ajlm-975	55	45	,	,	PUNCT
ajlm-975	55	46	respectively	respectively	ADV
ajlm-975	55	47	,	,	PUNCT
ajlm-975	55	48	while	while	SCONJ
ajlm-975	55	49	the	the	DET
ajlm-975	55	50	negative	negative	ADJ
ajlm-975	55	51	cut	cut	NOUN
ajlm-975	55	52	-	-	PUNCT
ajlm-975	55	53	off	off	ADP
ajlm-975	55	54	values	value	NOUN
ajlm-975	55	55	for	for	ADP
ajlm-975	55	56	the	the	DET
ajlm-975	55	57	parameters	parameter	NOUN
ajlm-975	55	58	were	be	AUX
ajlm-975	55	59	1.076	1.076	NUM
ajlm-975	55	60	,	,	PUNCT
ajlm-975	55	61	1.070	1.070	NUM
ajlm-975	55	62	,	,	PUNCT
ajlm-975	55	63	0.438	0.438	NUM
ajlm-975	55	64	,	,	PUNCT
ajlm-975	55	65	1.519	1.519	NUM
ajlm-975	55	66	,	,	PUNCT
ajlm-975	55	67	0.101	0.101	NUM
ajlm-975	55	68	,	,	PUNCT
ajlm-975	55	69	1.569	1.569	NUM
ajlm-975	55	70	and	and	CCONJ
ajlm-975	55	71	1.029	1.029	NUM
ajlm-975	55	72	or	or	CCONJ
ajlm-975	55	73	lower	low	ADJ
ajlm-975	55	74	,	,	PUNCT
ajlm-975	55	75	respectively	respectively	ADV
ajlm-975	55	76	.	.	PUNCT
ajlm-975	56	1	the	the	DET
ajlm-975	56	2	positive	positive	ADJ
ajlm-975	56	3	cut	cut	NOUN
ajlm-975	56	4	-	-	PUNCT
ajlm-975	56	5	off	off	ADP
ajlm-975	56	6	values	value	NOUN
ajlm-975	56	7	for	for	ADP
ajlm-975	56	8	ki67	ki67	PROPN
ajlm-975	56	9	and	and	CCONJ
ajlm-975	56	10	scca1	scca1	NOUN
ajlm-975	56	11	were	be	AUX
ajlm-975	56	12	7849	7849	NUM
ajlm-975	56	13	ng	ng	PROPN
ajlm-975	56	14	/	/	SYM
ajlm-975	56	15	ml	ml	PROPN
ajlm-975	56	16	and	and	CCONJ
ajlm-975	56	17	1670	1670	NUM
ajlm-975	56	18	pg	pg	NOUN
ajlm-975	56	19	/	/	SYM
ajlm-975	56	20	ml	ml	NOUN
ajlm-975	56	21	or	or	CCONJ
ajlm-975	56	22	higher	high	ADJ
ajlm-975	56	23	while	while	SCONJ
ajlm-975	56	24	the	the	DET
ajlm-975	56	25	negative	negative	ADJ
ajlm-975	56	26	cut	cut	NOUN
ajlm-975	56	27	-	-	PUNCT
ajlm-975	56	28	off	off	ADP
ajlm-975	56	29	values	value	NOUN
ajlm-975	56	30	were	be	AUX
ajlm-975	56	31	7848	7848	NUM
ajlm-975	56	32	ng	ng	PROPN
ajlm-975	56	33	/	/	SYM
ajlm-975	56	34	ml	ml	PROPN
ajlm-975	56	35	and	and	CCONJ
ajlm-975	56	36	1669	1669	NUM
ajlm-975	56	37	pg	pg	NOUN
ajlm-975	56	38	/	/	SYM
ajlm-975	56	39	ml	ml	NOUN
ajlm-975	56	40	or	or	CCONJ
ajlm-975	56	41	lower	low	ADJ
ajlm-975	56	42	.	.	PUNCT
ajlm-975	57	1	gene	gene	NOUN
ajlm-975	57	2	expression	expression	NOUN
ajlm-975	57	3	profiling	profile	VERB
ajlm-975	57	4	rna	rna	NOUN
ajlm-975	57	5	isolation	isolation	NOUN
ajlm-975	57	6	and	and	CCONJ
ajlm-975	57	7	complementary	complementary	ADJ
ajlm-975	57	8	dna	dna	PROPN
ajlm-975	57	9	synthesis	synthesis	NOUN
ajlm-975	57	10	using	use	VERB
ajlm-975	57	11	the	the	DET
ajlm-975	57	12	optimised	optimise	VERB
ajlm-975	57	13	phenol	phenol	NOUN
ajlm-975	57	14	-	-	PUNCT
ajlm-975	57	15	chloroform	chloroform	NOUN
ajlm-975	57	16	rna	rna	NOUN
ajlm-975	57	17	extraction	extraction	NOUN
ajlm-975	57	18	method,12	method,12	VERB
ajlm-975	57	19	50	50	NUM
ajlm-975	57	20	µl	µl	NOUN
ajlm-975	57	21	of	of	ADP
ajlm-975	57	22	serum	serum	NOUN
ajlm-975	57	23	was	be	AUX
ajlm-975	57	24	added	add	VERB
ajlm-975	57	25	to	to	ADP
ajlm-975	57	26	eppendorf	eppendorf	PROPN
ajlm-975	57	27	tubes	tube	NOUN
ajlm-975	57	28	containing	contain	VERB
ajlm-975	57	29	50	50	NUM
ajlm-975	57	30	µl	µl	ADP
ajlm-975	57	31	trizol	trizol	ADJ
ajlm-975	57	32	reagent	reagent	ADJ
ajlm-975	57	33	and	and	CCONJ
ajlm-975	57	34	vortexed	vortexe	VERB
ajlm-975	57	35	at	at	ADP
ajlm-975	57	36	2500	2500	NUM
ajlm-975	57	37	revolutions	revolution	NOUN
ajlm-975	57	38	per	per	ADP
ajlm-975	57	39	minute	minute	NOUN
ajlm-975	57	40	for	for	ADP
ajlm-975	57	41	15	15	NUM
ajlm-975	57	42	min	min	NOUN
ajlm-975	57	43	.	.	PROPN
ajlm-975	57	44	chloroform	chloroform	NOUN
ajlm-975	57	45	(	(	PUNCT
ajlm-975	57	46	100	100	NUM
ajlm-975	57	47	µl	µl	NOUN
ajlm-975	57	48	)	)	PUNCT
ajlm-975	57	49	was	be	AUX
ajlm-975	57	50	added	add	VERB
ajlm-975	57	51	to	to	ADP
ajlm-975	57	52	the	the	DET
ajlm-975	57	53	mixture	mixture	NOUN
ajlm-975	57	54	which	which	PRON
ajlm-975	57	55	was	be	AUX
ajlm-975	57	56	subsequently	subsequently	ADV
ajlm-975	57	57	vortexed	vortexe	VERB
ajlm-975	57	58	and	and	CCONJ
ajlm-975	57	59	centrifuged	centrifuge	VERB
ajlm-975	57	60	for	for	ADP
ajlm-975	57	61	30	30	NUM
ajlm-975	57	62	min	min	NOUN
ajlm-975	57	63	at	at	ADP
ajlm-975	57	64	1500	1500	NUM
ajlm-975	57	65	revolutions	revolution	NOUN
ajlm-975	57	66	per	per	ADP
ajlm-975	57	67	minute	minute	NOUN
ajlm-975	57	68	.	.	PUNCT
ajlm-975	58	1	the	the	DET
ajlm-975	58	2	supernatants	supernatant	NOUN
ajlm-975	58	3	containing	contain	VERB
ajlm-975	58	4	the	the	DET
ajlm-975	58	5	rna	rna	NOUN
ajlm-975	58	6	were	be	AUX
ajlm-975	58	7	aspirated	aspirate	VERB
ajlm-975	58	8	into	into	ADP
ajlm-975	58	9	new	new	ADJ
ajlm-975	58	10	labelled	label	VERB
ajlm-975	58	11	tubes	tube	NOUN
ajlm-975	58	12	.	.	PUNCT
ajlm-975	59	1	iso	iso	NOUN
ajlm-975	59	2	-	-	PUNCT
ajlm-975	59	3	amyl	amyl	NOUN
ajlm-975	59	4	alcohol	alcohol	NOUN
ajlm-975	59	5	(	(	PUNCT
ajlm-975	59	6	100	100	NUM
ajlm-975	59	7	µl	µl	NOUN
ajlm-975	59	8	)	)	PUNCT
ajlm-975	59	9	was	be	AUX
ajlm-975	59	10	added	add	VERB
ajlm-975	59	11	to	to	ADP
ajlm-975	59	12	the	the	DET
ajlm-975	59	13	supernatant	supernatant	NOUN
ajlm-975	59	14	with	with	ADP
ajlm-975	59	15	subsequent	subsequent	ADJ
ajlm-975	59	16	centrifugation	centrifugation	NOUN
ajlm-975	59	17	for	for	ADP
ajlm-975	59	18	30	30	NUM
ajlm-975	59	19	min	min	NOUN
ajlm-975	59	20	at	at	ADP
ajlm-975	59	21	1500	1500	NUM
ajlm-975	59	22	revolutions	revolution	NOUN
ajlm-975	59	23	per	per	ADP
ajlm-975	59	24	minute	minute	NOUN
ajlm-975	59	25	.	.	PUNCT
ajlm-975	60	1	the	the	DET
ajlm-975	60	2	rna	rna	NOUN
ajlm-975	60	3	was	be	AUX
ajlm-975	60	4	recovered	recover	VERB
ajlm-975	60	5	in	in	ADP
ajlm-975	60	6	pellet	pellet	NOUN
ajlm-975	60	7	form	form	NOUN
ajlm-975	60	8	following	follow	VERB
ajlm-975	60	9	decantation	decantation	NOUN
ajlm-975	60	10	of	of	ADP
ajlm-975	60	11	the	the	DET
ajlm-975	60	12	supernatant	supernatant	NOUN
ajlm-975	60	13	.	.	PUNCT
ajlm-975	61	1	the	the	DET
ajlm-975	61	2	rna	rna	NOUN
ajlm-975	61	3	pellet	pellet	NOUN
ajlm-975	61	4	was	be	AUX
ajlm-975	61	5	washed	wash	VERB
ajlm-975	61	6	thrice	thrice	NOUN
ajlm-975	61	7	with	with	ADP
ajlm-975	61	8	70	70	NUM
ajlm-975	61	9	%	%	NOUN
ajlm-975	61	10	ethanol	ethanol	NOUN
ajlm-975	61	11	.	.	PUNCT
ajlm-975	62	1	fifty	fifty	NUM
ajlm-975	62	2	µl	µl	NOUN
ajlm-975	62	3	of	of	ADP
ajlm-975	62	4	70	70	NUM
ajlm-975	62	5	%	%	NOUN
ajlm-975	62	6	ethanol	ethanol	NOUN
ajlm-975	62	7	was	be	AUX
ajlm-975	62	8	added	add	VERB
ajlm-975	62	9	to	to	ADP
ajlm-975	62	10	the	the	DET
ajlm-975	62	11	tube	tube	NOUN
ajlm-975	62	12	and	and	CCONJ
ajlm-975	62	13	the	the	DET
ajlm-975	62	14	tube	tube	NOUN
ajlm-975	62	15	was	be	AUX
ajlm-975	62	16	centrifuged	centrifuge	VERB
ajlm-975	62	17	for	for	ADP
ajlm-975	62	18	5	5	NUM
ajlm-975	62	19	min	min	NOUN
ajlm-975	62	20	at	at	ADP
ajlm-975	62	21	1500	1500	NUM
ajlm-975	62	22	revolutions	revolution	NOUN
ajlm-975	62	23	per	per	ADP
ajlm-975	62	24	minute	minute	NOUN
ajlm-975	62	25	.	.	PUNCT
ajlm-975	63	1	after	after	ADP
ajlm-975	63	2	which	which	PRON
ajlm-975	63	3	,	,	PUNCT
ajlm-975	63	4	the	the	DET
ajlm-975	63	5	supernatant	supernatant	NOUN
ajlm-975	63	6	was	be	AUX
ajlm-975	63	7	decanted	decant	VERB
ajlm-975	63	8	.	.	PUNCT
ajlm-975	64	1	after	after	ADP
ajlm-975	64	2	washing	wash	VERB
ajlm-975	64	3	all	all	DET
ajlm-975	64	4	tubes	tube	NOUN
ajlm-975	64	5	were	be	AUX
ajlm-975	64	6	allowed	allow	VERB
ajlm-975	64	7	to	to	PART
ajlm-975	64	8	air	air	VERB
ajlm-975	64	9	dry	dry	VERB
ajlm-975	64	10	.	.	PUNCT
ajlm-975	65	1	fifty	fifty	NUM
ajlm-975	65	2	microlitre	microlitre	NOUN
ajlm-975	65	3	(	(	PUNCT
ajlm-975	65	4	µl	µl	NOUN
ajlm-975	65	5	)	)	PUNCT
ajlm-975	65	6	of	of	ADP
ajlm-975	65	7	nuclease	nuclease	NOUN
ajlm-975	65	8	-	-	PUNCT
ajlm-975	65	9	free	free	ADJ
ajlm-975	65	10	water	water	NOUN
ajlm-975	65	11	was	be	AUX
ajlm-975	65	12	added	add	VERB
ajlm-975	65	13	to	to	ADP
ajlm-975	65	14	the	the	DET
ajlm-975	65	15	total	total	ADJ
ajlm-975	65	16	rna	rna	NOUN
ajlm-975	65	17	to	to	PART
ajlm-975	65	18	form	form	VERB
ajlm-975	65	19	the	the	DET
ajlm-975	65	20	rna	rna	NOUN
ajlm-975	65	21	solution	solution	NOUN
ajlm-975	65	22	.	.	PUNCT
ajlm-975	66	1	the	the	DET
ajlm-975	66	2	total	total	ADJ
ajlm-975	66	3	rna	rna	NOUN
ajlm-975	66	4	concentration	concentration	NOUN
ajlm-975	66	5	(	(	PUNCT
ajlm-975	66	6	48	48	NUM
ajlm-975	66	7	µl	µl	NOUN
ajlm-975	66	8	of	of	ADP
ajlm-975	66	9	deionised	deionise	VERB
ajlm-975	66	10	distilled	distil	VERB
ajlm-975	66	11	water	water	NOUN
ajlm-975	66	12	+	+	CCONJ
ajlm-975	66	13	2	2	NUM
ajlm-975	66	14	µl	µl	NOUN
ajlm-975	66	15	of	of	ADP
ajlm-975	66	16	rna	rna	NOUN
ajlm-975	66	17	solution	solution	NOUN
ajlm-975	66	18	)	)	PUNCT
ajlm-975	66	19	was	be	AUX
ajlm-975	66	20	quantified	quantify	VERB
ajlm-975	66	21	spectrophotometrically	spectrophotometrically	ADV
ajlm-975	66	22	at	at	ADP
ajlm-975	66	23	260	260	NUM
ajlm-975	66	24	nanometre	nanometre	NOUN
ajlm-975	66	25	.	.	PUNCT
ajlm-975	67	1	the	the	DET
ajlm-975	67	2	rna	rna	NOUN
ajlm-975	67	3	limit	limit	NOUN
ajlm-975	67	4	of	of	ADP
ajlm-975	67	5	importance	importance	NOUN
ajlm-975	67	6	was	be	AUX
ajlm-975	67	7	set	set	VERB
ajlm-975	67	8	at	at	ADP
ajlm-975	67	9	0.05–1.00	0.05–1.00	NUM
ajlm-975	67	10	.	.	PUNCT
ajlm-975	68	1	the	the	DET
ajlm-975	68	2	complementary	complementary	ADJ
ajlm-975	68	3	dna	dna	PROPN
ajlm-975	68	4	synthesis	synthesis	NOUN
ajlm-975	68	5	was	be	AUX
ajlm-975	68	6	carried	carry	VERB
ajlm-975	68	7	out	out	ADP
ajlm-975	68	8	by	by	ADP
ajlm-975	68	9	adding	add	VERB
ajlm-975	68	10	mirna	mirna	NOUN
ajlm-975	68	11	-	-	PUNCT
ajlm-975	68	12	universal	universal	ADJ
ajlm-975	68	13	stem	stem	NOUN
ajlm-975	68	14	-	-	PUNCT
ajlm-975	68	15	loop	loop	NOUN
ajlm-975	68	16	primer	primer	NOUN
ajlm-975	68	17	cocktail	cocktail	NOUN
ajlm-975	68	18	(	(	PUNCT
ajlm-975	68	19	containing	contain	VERB
ajlm-975	68	20	nuclease	nuclease	NOUN
ajlm-975	68	21	-	-	PUNCT
ajlm-975	68	22	free	free	ADJ
ajlm-975	68	23	water	water	NOUN
ajlm-975	68	24	,	,	PUNCT
ajlm-975	68	25	the	the	DET
ajlm-975	68	26	reverse	reverse	ADJ
ajlm-975	68	27	transcriptase	transcriptase	NOUN
ajlm-975	68	28	buffer	buffer	NOUN
ajlm-975	68	29	,	,	PUNCT
ajlm-975	68	30	the	the	DET
ajlm-975	68	31	reverse	reverse	NOUN
ajlm-975	68	32	transcriptase	transcriptase	NOUN
ajlm-975	68	33	,	,	PUNCT
ajlm-975	68	34	mirnauniversal	mirnauniversal	ADJ
ajlm-975	68	35	stem	stem	NOUN
ajlm-975	68	36	-	-	PUNCT
ajlm-975	68	37	loop	loop	NOUN
ajlm-975	68	38	primer	primer	NOUN
ajlm-975	68	39	specific	specific	ADJ
ajlm-975	68	40	oligos	oligo	NOUN
ajlm-975	68	41	,	,	PUNCT
ajlm-975	68	42	and	and	CCONJ
ajlm-975	68	43	oligo	oligo	ADJ
ajlm-975	68	44	deoxyribonucleotide	deoxyribonucleotide	NOUN
ajlm-975	68	45	triphosphate	triphosphate	NOUN
ajlm-975	68	46	)	)	PUNCT
ajlm-975	68	47	to	to	ADP
ajlm-975	68	48	20	20	NUM
ajlm-975	68	49	µl	µl	NOUN
ajlm-975	68	50	of	of	ADP
ajlm-975	68	51	total	total	ADJ
ajlm-975	68	52	rna	rna	NOUN
ajlm-975	68	53	of	of	ADP
ajlm-975	68	54	each	each	DET
ajlm-975	68	55	sample	sample	NOUN
ajlm-975	68	56	.	.	PUNCT
ajlm-975	69	1	the	the	DET
ajlm-975	69	2	samples	sample	NOUN
ajlm-975	69	3	were	be	AUX
ajlm-975	69	4	then	then	ADV
ajlm-975	69	5	incubated	incubate	VERB
ajlm-975	69	6	at	at	ADP
ajlm-975	69	7	room	room	NOUN
ajlm-975	69	8	temperature	temperature	NOUN
ajlm-975	69	9	overnight	overnight	ADV
ajlm-975	69	10	.	.	PUNCT
ajlm-975	70	1	the	the	DET
ajlm-975	70	2	concentration	concentration	NOUN
ajlm-975	70	3	of	of	ADP
ajlm-975	70	4	complementary	complementary	ADJ
ajlm-975	70	5	dna	dna	PROPN
ajlm-975	70	6	was	be	AUX
ajlm-975	70	7	determined	determine	VERB
ajlm-975	70	8	spectrophotometrically	spectrophotometrically	ADV
ajlm-975	70	9	at	at	ADP
ajlm-975	70	10	260	260	NUM
ajlm-975	70	11	nanometre	nanometre	NOUN
ajlm-975	70	12	and	and	CCONJ
ajlm-975	70	13	homogeneity	homogeneity	NOUN
ajlm-975	70	14	was	be	AUX
ajlm-975	70	15	carried	carry	VERB
ajlm-975	70	16	out	out	ADP
ajlm-975	70	17	on	on	ADP
ajlm-975	70	18	every	every	DET
ajlm-975	70	19	sample	sample	NOUN
ajlm-975	70	20	.	.	PUNCT
ajlm-975	71	1	reverse	reverse	ADJ
ajlm-975	71	2	transcriptase	transcriptase	NOUN
ajlm-975	71	3	polymerase	polymerase	NOUN
ajlm-975	71	4	chain	chain	NOUN
ajlm-975	71	5	reaction	reaction	NOUN
ajlm-975	71	6	the	the	DET
ajlm-975	71	7	amplification	amplification	NOUN
ajlm-975	71	8	was	be	AUX
ajlm-975	71	9	performed	perform	VERB
ajlm-975	71	10	using	use	VERB
ajlm-975	71	11	optimisation	optimisation	NOUN
ajlm-975	71	12	and	and	CCONJ
ajlm-975	71	13	the	the	DET
ajlm-975	71	14	universal	universal	ADJ
ajlm-975	71	15	stem	stem	NOUN
ajlm-975	71	16	-	-	PUNCT
ajlm-975	71	17	loop	loop	NOUN
ajlm-975	71	18	primer	primer	NOUN
ajlm-975	71	19	method.13	method.13	NOUN
ajlm-975	71	20	in	in	ADP
ajlm-975	71	21	order	order	NOUN
ajlm-975	71	22	to	to	PART
ajlm-975	71	23	validate	validate	VERB
ajlm-975	71	24	our	our	PRON
ajlm-975	71	25	primers	primer	NOUN
ajlm-975	71	26	for	for	ADP
ajlm-975	71	27	mirna	mirna	NOUN
ajlm-975	71	28	quantification	quantification	NOUN
ajlm-975	71	29	listed	list	VERB
ajlm-975	71	30	in	in	ADP
ajlm-975	71	31	table	table	NOUN
ajlm-975	71	32	1	1	NUM
ajlm-975	72	1	,	,	PUNCT
ajlm-975	72	2	we	we	PRON
ajlm-975	72	3	test	test	VERB
ajlm-975	72	4	ran	run	VERB
ajlm-975	72	5	the	the	DET
ajlm-975	72	6	primers	primer	NOUN
ajlm-975	72	7	against	against	ADP
ajlm-975	72	8	samples	sample	NOUN
ajlm-975	72	9	from	from	ADP
ajlm-975	72	10	known	know	VERB
ajlm-975	72	11	cervical	cervical	ADJ
ajlm-975	72	12	cancer	cancer	NOUN
ajlm-975	72	13	patients	patient	NOUN
ajlm-975	72	14	(	(	PUNCT
ajlm-975	72	15	as	as	ADP
ajlm-975	72	16	a	a	DET
ajlm-975	72	17	positive	positive	ADJ
ajlm-975	72	18	control	control	NOUN
ajlm-975	72	19	;	;	PUNCT
ajlm-975	72	20	n	n	NOUN
ajlm-975	72	21	=	=	SYM
ajlm-975	72	22	10	10	NUM
ajlm-975	72	23	)	)	PUNCT
ajlm-975	72	24	and	and	CCONJ
ajlm-975	72	25	patients	patient	NOUN
ajlm-975	72	26	with	with	ADP
ajlm-975	72	27	normal	normal	ADJ
ajlm-975	72	28	cervix	cervix	NOUN
ajlm-975	72	29	(	(	PUNCT
ajlm-975	72	30	negative	negative	ADJ
ajlm-975	72	31	control	control	NOUN
ajlm-975	72	32	;	;	PUNCT
ajlm-975	72	33	n	n	NOUN
ajlm-975	72	34	=	=	SYM
ajlm-975	72	35	10	10	NUM
ajlm-975	72	36	)	)	PUNCT
ajlm-975	72	37	.	.	PUNCT
ajlm-975	73	1	the	the	DET
ajlm-975	73	2	expression	expression	NOUN
ajlm-975	73	3	of	of	ADP
ajlm-975	73	4	oncomirs	oncomir	NOUN
ajlm-975	73	5	were	be	AUX
ajlm-975	73	6	at	at	ADP
ajlm-975	73	7	least	least	ADJ
ajlm-975	73	8	fourfold	fourfold	VERB
ajlm-975	73	9	higher	higher	ADV
ajlm-975	73	10	in	in	ADP
ajlm-975	73	11	cancer	cancer	NOUN
ajlm-975	73	12	patients	patient	NOUN
ajlm-975	73	13	than	than	ADP
ajlm-975	73	14	in	in	ADP
ajlm-975	73	15	healthy	healthy	ADJ
ajlm-975	73	16	individuals	individual	NOUN
ajlm-975	73	17	while	while	SCONJ
ajlm-975	73	18	the	the	DET
ajlm-975	73	19	expression	expression	NOUN
ajlm-975	73	20	of	of	ADP
ajlm-975	73	21	tumour	tumour	NOUN
ajlm-975	73	22	suppressors	suppressor	NOUN
ajlm-975	73	23	were	be	AUX
ajlm-975	73	24	at	at	ADP
ajlm-975	73	25	least	least	ADJ
ajlm-975	73	26	threefold	threefold	ADV
ajlm-975	73	27	higher	higher	ADV
ajlm-975	73	28	in	in	ADP
ajlm-975	73	29	healthy	healthy	ADJ
ajlm-975	73	30	individuals	individual	NOUN
ajlm-975	73	31	than	than	ADP
ajlm-975	73	32	in	in	ADP
ajlm-975	73	33	cancer	cancer	NOUN
ajlm-975	73	34	patients	patient	NOUN
ajlm-975	73	35	.	.	PUNCT
ajlm-975	74	1	template	template	NOUN
ajlm-975	74	2	(	(	PUNCT
ajlm-975	74	3	complementary	complementary	ADJ
ajlm-975	74	4	dna	dna	NOUN
ajlm-975	74	5	,	,	PUNCT
ajlm-975	74	6	2	2	NUM
ajlm-975	74	7	µl	µl	NOUN
ajlm-975	74	8	)	)	PUNCT
ajlm-975	74	9	,	,	PUNCT
ajlm-975	74	10	nuclease	nuclease	NOUN
ajlm-975	74	11	-	-	PUNCT
ajlm-975	74	12	free	free	ADJ
ajlm-975	74	13	water	water	NOUN
ajlm-975	74	14	(	(	PUNCT
ajlm-975	74	15	3	3	NUM
ajlm-975	74	16	µl	µl	NOUN
ajlm-975	74	17	)	)	PUNCT
ajlm-975	74	18	,	,	PUNCT
ajlm-975	74	19	forward	forward	ADJ
ajlm-975	74	20	primer	primer	NOUN
ajlm-975	74	21	(	(	PUNCT
ajlm-975	74	22	0.5	0.5	NUM
ajlm-975	74	23	µl	µl	NOUN
ajlm-975	74	24	)	)	PUNCT
ajlm-975	74	25	and	and	CCONJ
ajlm-975	74	26	reverse	reverse	ADJ
ajlm-975	74	27	primer	primer	NOUN
ajlm-975	74	28	(	(	PUNCT
ajlm-975	74	29	0.5	0.5	NUM
ajlm-975	74	30	µl	µl	NOUN
ajlm-975	74	31	;	;	PUNCT
ajlm-975	74	32	inqaba	inqaba	PROPN
ajlm-975	74	33	biotechnical	biotechnical	PROPN
ajlm-975	74	34	industries	industries	PROPN
ajlm-975	74	35	ltd	ltd	PROPN
ajlm-975	74	36	,	,	PUNCT
ajlm-975	74	37	hatfield	hatfield	PROPN
ajlm-975	74	38	,	,	PUNCT
ajlm-975	74	39	pretoria	pretoria	PROPN
ajlm-975	74	40	,	,	PUNCT
ajlm-975	74	41	south	south	PROPN
ajlm-975	74	42	africa	africa	PROPN
ajlm-975	74	43	)	)	PUNCT
ajlm-975	74	44	and	and	CCONJ
ajlm-975	74	45	master	master	NOUN
ajlm-975	74	46	mix	mix	NOUN
ajlm-975	74	47	(	(	PUNCT
ajlm-975	74	48	4	4	NUM
ajlm-975	74	49	µl	µl	NOUN
ajlm-975	74	50	;	;	PUNCT
ajlm-975	74	51	new	new	PROPN
ajlm-975	74	52	england	england	PROPN
ajlm-975	74	53	biolabs	biolabs	PROPN
ajlm-975	74	54	gmbh	gmbh	PROPN
ajlm-975	74	55	,	,	PUNCT
ajlm-975	74	56	frankfurt	frankfurt	PROPN
ajlm-975	74	57	,	,	PUNCT
ajlm-975	74	58	germany	germany	PROPN
ajlm-975	74	59	)	)	PUNCT
ajlm-975	74	60	were	be	AUX
ajlm-975	74	61	added	add	VERB
ajlm-975	74	62	to	to	ADP
ajlm-975	74	63	each	each	DET
ajlm-975	74	64	sample	sample	NOUN
ajlm-975	74	65	in	in	ADP
ajlm-975	74	66	no	no	DET
ajlm-975	74	67	specific	specific	ADJ
ajlm-975	74	68	order	order	NOUN
ajlm-975	74	69	.	.	PUNCT
ajlm-975	75	1	all	all	DET
ajlm-975	75	2	reactions	reaction	NOUN
ajlm-975	75	3	were	be	AUX
ajlm-975	75	4	done	do	VERB
ajlm-975	75	5	as	as	ADP
ajlm-975	75	6	singleplexes	singleplexe	NOUN
ajlm-975	75	7	for	for	ADP
ajlm-975	75	8	each	each	DET
ajlm-975	75	9	biomarker	biomarker	NOUN
ajlm-975	75	10	.	.	PUNCT
ajlm-975	76	1	amplification	amplification	NOUN
ajlm-975	76	2	conditions	condition	NOUN
ajlm-975	76	3	were	be	AUX
ajlm-975	76	4	:	:	PUNCT
ajlm-975	76	5	94	94	NUM
ajlm-975	76	6	°	°	NUM
ajlm-975	76	7	c	c	PART
ajlm-975	76	8	pre	pre	NOUN
ajlm-975	76	9	-	-	NOUN
ajlm-975	76	10	denaturation	denaturation	ADJ
ajlm-975	76	11	for	for	ADP
ajlm-975	76	12	5	5	NUM
ajlm-975	76	13	min	min	NOUN
ajlm-975	76	14	,	,	PUNCT
ajlm-975	76	15	94	94	NUM
ajlm-975	76	16	°	°	NUM
ajlm-975	76	17	c	c	NOUN
ajlm-975	76	18	for	for	ADP
ajlm-975	76	19	30	30	NUM
ajlm-975	76	20	s	s	NOUN
ajlm-975	76	21	,	,	PUNCT
ajlm-975	76	22	annealing	anneal	VERB
ajlm-975	76	23	55	55	NUM
ajlm-975	76	24	°	°	NOUN
ajlm-975	76	25	c	c	NOUN
ajlm-975	76	26	for	for	ADP
ajlm-975	76	27	30	30	NUM
ajlm-975	76	28	s	s	NOUN
ajlm-975	76	29	and	and	CCONJ
ajlm-975	76	30	extension	extension	NOUN
ajlm-975	76	31	72	72	NUM
ajlm-975	76	32	°	°	ADP
ajlm-975	76	33	c	c	NOUN
ajlm-975	76	34	for	for	ADP
ajlm-975	76	35	30	30	NUM
ajlm-975	76	36	s	s	PART
ajlm-975	76	37	and	and	CCONJ
ajlm-975	76	38	then	then	ADV
ajlm-975	76	39	5	5	NUM
ajlm-975	76	40	min	min	NOUN
ajlm-975	76	41	at	at	ADP
ajlm-975	76	42	72	72	NUM
ajlm-975	76	43	°	°	NOUN
ajlm-975	76	44	c	c	NOUN
ajlm-975	76	45	by	by	ADP
ajlm-975	76	46	45	45	NUM
ajlm-975	76	47	cycles	cycle	NOUN
ajlm-975	76	48	.	.	PUNCT
ajlm-975	77	1	table	table	NOUN
ajlm-975	77	2	1	1	NUM
ajlm-975	77	3	:	:	PUNCT
ajlm-975	77	4	 	 	SPACE
ajlm-975	77	5	list	list	NOUN
ajlm-975	77	6	of	of	ADP
ajlm-975	77	7	primer	primer	NOUN
ajlm-975	77	8	sequences	sequence	NOUN
ajlm-975	77	9	.	.	PUNCT
ajlm-975	78	1	gel	gel	NOUN
ajlm-975	78	2	electrophoresis	electrophoresis	NOUN
ajlm-975	78	3	products	product	NOUN
ajlm-975	78	4	from	from	ADP
ajlm-975	78	5	polymerase	polymerase	NOUN
ajlm-975	78	6	chain	chain	NOUN
ajlm-975	78	7	reaction	reaction	NOUN
ajlm-975	78	8	(	(	PUNCT
ajlm-975	78	9	pcr	pcr	PROPN
ajlm-975	78	10	)	)	PUNCT
ajlm-975	78	11	were	be	AUX
ajlm-975	78	12	electrophoresed	electrophorese	VERB
ajlm-975	78	13	in	in	ADP
ajlm-975	78	14	0.5	0.5	NUM
ajlm-975	78	15	%	%	NOUN
ajlm-975	78	16	of	of	ADP
ajlm-975	78	17	agarose	agarose	NOUN
ajlm-975	78	18	gel	gel	NOUN
ajlm-975	78	19	using	use	VERB
ajlm-975	78	20	0.5×	0.5×	ADJ
ajlm-975	78	21	tris	tris	ADJ
ajlm-975	78	22	-	-	PUNCT
ajlm-975	78	23	borate	borate	NOUN
ajlm-975	78	24	-	-	PUNCT
ajlm-975	78	25	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-975	78	26	acid	acid	NOUN
ajlm-975	78	27	buffer	buffer	NOUN
ajlm-975	78	28	of	of	ADP
ajlm-975	78	29	ph	ph	ADJ
ajlm-975	78	30	8.3	8.3	NUM
ajlm-975	78	31	(	(	PUNCT
ajlm-975	78	32	2.6	2.6	NUM
ajlm-975	78	33	g	g	NOUN
ajlm-975	78	34	of	of	ADP
ajlm-975	78	35	tris	tris	ADJ
ajlm-975	78	36	base	base	NOUN
ajlm-975	78	37	,	,	PUNCT
ajlm-975	78	38	5.0	5.0	NUM
ajlm-975	78	39	g	g	NOUN
ajlm-975	78	40	of	of	ADP
ajlm-975	78	41	tris	tris	ADJ
ajlm-975	78	42	boric	boric	ADJ
ajlm-975	78	43	acid	acid	NOUN
ajlm-975	78	44	and	and	CCONJ
ajlm-975	78	45	2	2	NUM
ajlm-975	78	46	ml	ml	NOUN
ajlm-975	78	47	of	of	ADP
ajlm-975	78	48	0.5	0.5	NUM
ajlm-975	78	49	m	m	NOUN
ajlm-975	78	50	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-975	78	51	acid	acid	NOUN
ajlm-975	78	52	;	;	PUNCT
ajlm-975	78	53	thermo	thermo	PROPN
ajlm-975	78	54	fisher	fisher	PROPN
ajlm-975	78	55	scientific	scientific	PROPN
ajlm-975	78	56	johannesburg	johannesburg	PROPN
ajlm-975	78	57	pty	pty	PROPN
ajlm-975	78	58	,	,	PUNCT
ajlm-975	78	59	germiston	germiston	NOUN
ajlm-975	78	60	,	,	PUNCT
ajlm-975	78	61	south	south	PROPN
ajlm-975	78	62	africa	africa	PROPN
ajlm-975	78	63	)	)	PUNCT
ajlm-975	78	64	with	with	ADP
ajlm-975	78	65	0.2	0.2	NUM
ajlm-975	78	66	µl	µl	ADP
ajlm-975	78	67	ethidium	ethidium	NOUN
ajlm-975	78	68	as	as	ADP
ajlm-975	78	69	a	a	DET
ajlm-975	78	70	fluorescent	fluorescent	ADJ
ajlm-975	78	71	tag	tag	NOUN
ajlm-975	78	72	.	.	PUNCT
ajlm-975	79	1	the	the	DET
ajlm-975	79	2	expression	expression	NOUN
ajlm-975	79	3	products	product	NOUN
ajlm-975	79	4	were	be	AUX
ajlm-975	79	5	visualised	visualise	VERB
ajlm-975	79	6	as	as	ADP
ajlm-975	79	7	bands	band	NOUN
ajlm-975	79	8	(	(	PUNCT
ajlm-975	79	9	amplicons	amplicon	NOUN
ajlm-975	79	10	)	)	PUNCT
ajlm-975	79	11	using	use	VERB
ajlm-975	79	12	an	an	DET
ajlm-975	79	13	ultraviolet	ultraviolet	NOUN
ajlm-975	79	14	-	-	PUNCT
ajlm-975	79	15	transilluminator	transilluminator	NOUN
ajlm-975	79	16	.	.	PUNCT
ajlm-975	80	1	to	to	PART
ajlm-975	80	2	minimise	minimise	VERB
ajlm-975	80	3	image	image	NOUN
ajlm-975	80	4	variations	variation	NOUN
ajlm-975	80	5	,	,	PUNCT
ajlm-975	80	6	the	the	DET
ajlm-975	80	7	camera	camera	NOUN
ajlm-975	80	8	of	of	ADP
ajlm-975	80	9	an	an	DET
ajlm-975	80	10	iphone	iphone	NOUN
ajlm-975	80	11	(	(	PUNCT
ajlm-975	80	12	set	set	VERB
ajlm-975	80	13	at	at	ADP
ajlm-975	80	14	10	10	NUM
ajlm-975	80	15	cm	cm	NOUN
ajlm-975	80	16	above	above	ADP
ajlm-975	80	17	the	the	DET
ajlm-975	80	18	surface	surface	NOUN
ajlm-975	80	19	of	of	ADP
ajlm-975	80	20	the	the	DET
ajlm-975	80	21	transilluminator	transilluminator	NOUN
ajlm-975	80	22	and	and	CCONJ
ajlm-975	80	23	without	without	ADP
ajlm-975	80	24	flash	flash	NOUN
ajlm-975	80	25	or	or	CCONJ
ajlm-975	80	26	zoom	zoom	NUM
ajlm-975	80	27	;	;	PUNCT
ajlm-975	80	28	326	326	NUM
ajlm-975	80	29	pixels	pixel	NOUN
ajlm-975	80	30	per	per	ADP
ajlm-975	80	31	inch	inch	NOUN
ajlm-975	80	32	)	)	PUNCT
ajlm-975	80	33	was	be	AUX
ajlm-975	80	34	used	use	VERB
ajlm-975	80	35	in	in	ADP
ajlm-975	80	36	acquiring	acquire	VERB
ajlm-975	80	37	snapshots	snapshot	NOUN
ajlm-975	80	38	of	of	ADP
ajlm-975	80	39	the	the	DET
ajlm-975	80	40	amplicons	amplicon	NOUN
ajlm-975	80	41	(	(	PUNCT
ajlm-975	80	42	figures	figure	NOUN
ajlm-975	80	43	1e	1e	NOUN
ajlm-975	80	44	,	,	PUNCT
ajlm-975	80	45	2e	2e	NOUN
ajlm-975	80	46	and	and	CCONJ
ajlm-975	80	47	3e	3e	NUM
ajlm-975	80	48	)	)	PUNCT
ajlm-975	80	49	.	.	PUNCT
ajlm-975	81	1	densitometrical	densitometrical	ADJ
ajlm-975	81	2	analysis	analysis	NOUN
ajlm-975	81	3	of	of	ADP
ajlm-975	81	4	the	the	DET
ajlm-975	81	5	snapshots	snapshot	NOUN
ajlm-975	81	6	was	be	AUX
ajlm-975	81	7	carried	carry	VERB
ajlm-975	81	8	out	out	ADP
ajlm-975	81	9	using	use	VERB
ajlm-975	81	10	imagej	imagej	ADJ
ajlm-975	81	11	software	software	NOUN
ajlm-975	81	12	(	(	PUNCT
ajlm-975	81	13	version	version	NOUN
ajlm-975	81	14	1.49	1.49	NUM
ajlm-975	81	15	;	;	PUNCT
ajlm-975	81	16	national	national	PROPN
ajlm-975	81	17	institute	institute	PROPN
ajlm-975	81	18	of	of	ADP
ajlm-975	81	19	mental	mental	PROPN
ajlm-975	81	20	health	health	NOUN
ajlm-975	81	21	,	,	PUNCT
ajlm-975	81	22	bethesda	bethesda	NOUN
ajlm-975	81	23	,	,	PUNCT
ajlm-975	81	24	maryland	maryland	PROPN
ajlm-975	81	25	,	,	PUNCT
ajlm-975	81	26	united	united	PROPN
ajlm-975	81	27	states	states	PROPN
ajlm-975	81	28	)	)	PUNCT
ajlm-975	81	29	.	.	PUNCT
ajlm-975	82	1	using	use	VERB
ajlm-975	82	2	the	the	DET
ajlm-975	82	3	imagej	imagej	ADJ
ajlm-975	82	4	software	software	NOUN
ajlm-975	82	5	adjustment	adjustment	NOUN
ajlm-975	82	6	tool	tool	NOUN
ajlm-975	82	7	,	,	PUNCT
ajlm-975	82	8	the	the	DET
ajlm-975	82	9	snapshots	snapshot	NOUN
ajlm-975	82	10	were	be	AUX
ajlm-975	82	11	scanned	scan	VERB
ajlm-975	82	12	and	and	CCONJ
ajlm-975	82	13	background	background	NOUN
ajlm-975	82	14	impurities	impurity	NOUN
ajlm-975	82	15	(	(	PUNCT
ajlm-975	82	16	including	include	VERB
ajlm-975	82	17	non	non	ADJ
ajlm-975	82	18	-	-	ADJ
ajlm-975	82	19	ethidium	ethidium	ADJ
ajlm-975	82	20	bromide	bromide	NOUN
ajlm-975	82	21	luminescence	luminescence	NOUN
ajlm-975	82	22	and	and	CCONJ
ajlm-975	82	23	other	other	ADJ
ajlm-975	82	24	reflections	reflection	NOUN
ajlm-975	82	25	from	from	ADP
ajlm-975	82	26	gel	gel	NOUN
ajlm-975	82	27	particles	particle	NOUN
ajlm-975	82	28	)	)	PUNCT
ajlm-975	82	29	were	be	AUX
ajlm-975	82	30	eliminated	eliminate	VERB
ajlm-975	82	31	.	.	PUNCT
ajlm-975	83	1	only	only	ADV
ajlm-975	83	2	the	the	DET
ajlm-975	83	3	full	full	ADJ
ajlm-975	83	4	area	area	NOUN
ajlm-975	83	5	of	of	ADP
ajlm-975	83	6	the	the	DET
ajlm-975	83	7	bands	band	NOUN
ajlm-975	83	8	(	(	PUNCT
ajlm-975	83	9	specific	specific	ADJ
ajlm-975	83	10	ethidium	ethidium	NOUN
ajlm-975	83	11	bromide	bromide	NOUN
ajlm-975	83	12	luminescence	luminescence	NOUN
ajlm-975	83	13	)	)	PUNCT
ajlm-975	83	14	was	be	AUX
ajlm-975	83	15	selected	select	VERB
ajlm-975	83	16	and	and	CCONJ
ajlm-975	83	17	quantified	quantify	VERB
ajlm-975	83	18	by	by	ADP
ajlm-975	83	19	the	the	DET
ajlm-975	83	20	software	software	NOUN
ajlm-975	83	21	.	.	PUNCT
ajlm-975	84	1	results	result	NOUN
ajlm-975	84	2	were	be	AUX
ajlm-975	84	3	expressed	express	VERB
ajlm-975	84	4	in	in	ADP
ajlm-975	84	5	figures	figure	NOUN
ajlm-975	84	6	;	;	PUNCT
ajlm-975	84	7	three	three	NUM
ajlm-975	84	8	decimal	decimal	ADJ
ajlm-975	84	9	places	place	NOUN
ajlm-975	84	10	.	.	PUNCT
ajlm-975	85	1	relative	relative	ADJ
ajlm-975	85	2	expression	expression	NOUN
ajlm-975	85	3	of	of	ADP
ajlm-975	85	4	mirnas	mirna	NOUN
ajlm-975	85	5	and	and	CCONJ
ajlm-975	85	6	the	the	DET
ajlm-975	85	7	p53	p53	NOUN
ajlm-975	85	8	gene	gene	NOUN
ajlm-975	85	9	were	be	AUX
ajlm-975	85	10	calculated	calculate	VERB
ajlm-975	85	11	following	follow	VERB
ajlm-975	85	12	endogenous	endogenous	ADJ
ajlm-975	85	13	normalisation	normalisation	NOUN
ajlm-975	85	14	using	use	VERB
ajlm-975	85	15	mir-16	mir-16	PROPN
ajlm-975	85	16	for	for	ADP
ajlm-975	85	17	mirnas	mirna	NOUN
ajlm-975	85	18	and	and	CCONJ
ajlm-975	85	19	β	β	NOUN
ajlm-975	85	20	-	-	NOUN
ajlm-975	85	21	actin	actin	NOUN
ajlm-975	85	22	for	for	ADP
ajlm-975	85	23	the	the	DET
ajlm-975	85	24	p53	p53	NOUN
ajlm-975	85	25	gene.16	gene.16	PROPN
ajlm-975	85	26	figure	figure	NOUN
ajlm-975	85	27	1	1	NUM
ajlm-975	85	28	:	:	PUNCT
ajlm-975	85	29	relative	relative	ADJ
ajlm-975	85	30	expression	expression	NOUN
ajlm-975	85	31	of	of	ADP
ajlm-975	85	32	oncogenic	oncogenic	ADJ
ajlm-975	85	33	mirnas	mirna	NOUN
ajlm-975	85	34	among	among	ADP
ajlm-975	85	35	individuals	individual	NOUN
ajlm-975	85	36	with	with	ADP
ajlm-975	85	37	and	and	CCONJ
ajlm-975	85	38	without	without	ADP
ajlm-975	85	39	viral	viral	ADJ
ajlm-975	85	40	infection	infection	NOUN
ajlm-975	85	41	,	,	PUNCT
ajlm-975	85	42	ogun	ogun	PROPN
ajlm-975	85	43	state	state	PROPN
ajlm-975	85	44	,	,	PUNCT
ajlm-975	85	45	nigeria	nigeria	PROPN
ajlm-975	85	46	,	,	PUNCT
ajlm-975	85	47	2018	2018	NUM
ajlm-975	85	48	.	.	PUNCT
ajlm-975	86	1	(	(	PUNCT
ajlm-975	86	2	a	a	X
ajlm-975	86	3	)	)	PUNCT
ajlm-975	86	4	mir-21	mir-21	NOUN
ajlm-975	86	5	expression	expression	NOUN
ajlm-975	86	6	was	be	AUX
ajlm-975	86	7	higher	high	ADJ
ajlm-975	86	8	among	among	ADP
ajlm-975	86	9	participants	participant	NOUN
ajlm-975	86	10	with	with	ADP
ajlm-975	86	11	hpv	hpv	ADJ
ajlm-975	86	12	mono	mono	NOUN
ajlm-975	86	13	-	-	PUNCT
ajlm-975	86	14	infection	infection	NOUN
ajlm-975	86	15	;	;	PUNCT
ajlm-975	86	16	(	(	PUNCT
ajlm-975	86	17	b	b	X
ajlm-975	86	18	)	)	PUNCT
ajlm-975	86	19	mir-182	mir-182	NOUN
ajlm-975	86	20	expression	expression	NOUN
ajlm-975	86	21	was	be	AUX
ajlm-975	86	22	higher	high	ADJ
ajlm-975	86	23	among	among	ADP
ajlm-975	86	24	participants	participant	NOUN
ajlm-975	86	25	with	with	ADP
ajlm-975	86	26	ebv	ebv	NOUN
ajlm-975	86	27	and	and	CCONJ
ajlm-975	86	28	hsv-2	hsv-2	PUNCT
ajlm-975	86	29	bi	bi	NOUN
ajlm-975	86	30	-	-	NOUN
ajlm-975	86	31	infection	infection	NOUN
ajlm-975	86	32	;	;	PUNCT
ajlm-975	86	33	(	(	PUNCT
ajlm-975	86	34	c	c	X
ajlm-975	86	35	)	)	PUNCT
ajlm-975	86	36	mir-155	mir-155	NOUN
ajlm-975	86	37	expression	expression	NOUN
ajlm-975	86	38	was	be	AUX
ajlm-975	86	39	higher	high	ADJ
ajlm-975	86	40	among	among	ADP
ajlm-975	86	41	participants	participant	NOUN
ajlm-975	86	42	with	with	ADP
ajlm-975	86	43	ebv	ebv	NOUN
ajlm-975	86	44	mono	mono	NOUN
ajlm-975	86	45	-	-	PUNCT
ajlm-975	86	46	infection	infection	NOUN
ajlm-975	86	47	;	;	PUNCT
ajlm-975	86	48	(	(	PUNCT
ajlm-975	86	49	d	d	X
ajlm-975	86	50	)	)	PUNCT
ajlm-975	86	51	mir-200c	mir-200c	NOUN
ajlm-975	86	52	expression	expression	NOUN
ajlm-975	86	53	was	be	AUX
ajlm-975	86	54	higher	high	ADJ
ajlm-975	86	55	among	among	ADP
ajlm-975	86	56	participants	participant	NOUN
ajlm-975	86	57	with	with	ADP
ajlm-975	86	58	hpv	hpv	ADJ
ajlm-975	86	59	mono	mono	NOUN
ajlm-975	86	60	-	-	PUNCT
ajlm-975	86	61	infection	infection	NOUN
ajlm-975	86	62	;	;	PUNCT
ajlm-975	86	63	(	(	PUNCT
ajlm-975	86	64	e	e	NOUN
ajlm-975	86	65	)	)	PUNCT
ajlm-975	86	66	snapshots	snapshot	NOUN
ajlm-975	86	67	of	of	ADP
ajlm-975	86	68	gel	gel	NOUN
ajlm-975	86	69	amplicons	amplicon	NOUN
ajlm-975	86	70	of	of	ADP
ajlm-975	86	71	oncomirs	oncomir	NOUN
ajlm-975	86	72	and	and	CCONJ
ajlm-975	86	73	normalising	normalise	VERB
ajlm-975	86	74	gene	gene	NOUN
ajlm-975	86	75	(	(	PUNCT
ajlm-975	86	76	mir-16	mir-16	NOUN
ajlm-975	86	77	)	)	PUNCT
ajlm-975	86	78	based	base	VERB
ajlm-975	86	79	on	on	ADP
ajlm-975	86	80	viral	viral	ADJ
ajlm-975	86	81	status	status	NOUN
ajlm-975	86	82	(	(	PUNCT
ajlm-975	86	83	plotted	plot	VERB
ajlm-975	86	84	as	as	ADP
ajlm-975	86	85	a	a	DET
ajlm-975	86	86	–	–	PUNCT
ajlm-975	86	87	d	d	NOUN
ajlm-975	86	88	)	)	PUNCT
ajlm-975	86	89	.	.	PUNCT
ajlm-975	87	1	figure	figure	VERB
ajlm-975	87	2	2	2	NUM
ajlm-975	87	3	:	:	PUNCT
ajlm-975	88	1	relative	relative	ADJ
ajlm-975	88	2	expression	expression	NOUN
ajlm-975	88	3	of	of	ADP
ajlm-975	88	4	tumour	tumour	ADJ
ajlm-975	88	5	suppressor	suppressor	NOUN
ajlm-975	88	6	mirnas	mirna	NOUN
ajlm-975	88	7	in	in	ADP
ajlm-975	88	8	individuals	individual	NOUN
ajlm-975	88	9	with	with	ADP
ajlm-975	88	10	and	and	CCONJ
ajlm-975	88	11	without	without	ADP
ajlm-975	88	12	viral	viral	ADJ
ajlm-975	88	13	infection	infection	NOUN
ajlm-975	88	14	,	,	PUNCT
ajlm-975	88	15	ogun	ogun	PROPN
ajlm-975	88	16	state	state	PROPN
ajlm-975	88	17	,	,	PUNCT
ajlm-975	88	18	nigeria	nigeria	PROPN
ajlm-975	88	19	,	,	PUNCT
ajlm-975	88	20	2018	2018	NUM
ajlm-975	88	21	.	.	PUNCT
ajlm-975	89	1	(	(	PUNCT
ajlm-975	89	2	a	a	X
ajlm-975	89	3	)	)	PUNCT
ajlm-975	89	4	mir	mir	ADJ
ajlm-975	89	5	-	-	PUNCT
ajlm-975	89	6	let-7b	let-7b	ADJ
ajlm-975	89	7	expression	expression	NOUN
ajlm-975	89	8	was	be	AUX
ajlm-975	89	9	higher	high	ADJ
ajlm-975	89	10	among	among	ADP
ajlm-975	89	11	participants	participant	NOUN
ajlm-975	89	12	with	with	ADP
ajlm-975	89	13	ebv	ebv	NOUN
ajlm-975	89	14	and	and	CCONJ
ajlm-975	89	15	hpv	hpv	ADJ
ajlm-975	89	16	bi	bi	NOUN
ajlm-975	89	17	-	-	NOUN
ajlm-975	89	18	infection	infection	NOUN
ajlm-975	89	19	and	and	CCONJ
ajlm-975	89	20	lower	low	ADJ
ajlm-975	89	21	among	among	ADP
ajlm-975	89	22	participants	participant	NOUN
ajlm-975	89	23	with	with	ADP
ajlm-975	89	24	ebv	ebv	NOUN
ajlm-975	89	25	mono	mono	NOUN
ajlm-975	89	26	-	-	PUNCT
ajlm-975	89	27	infection	infection	NOUN
ajlm-975	89	28	;	;	PUNCT
ajlm-975	89	29	(	(	PUNCT
ajlm-975	89	30	b	b	X
ajlm-975	89	31	)	)	PUNCT
ajlm-975	89	32	mir-143	mir-143	NOUN
ajlm-975	89	33	expression	expression	NOUN
ajlm-975	89	34	was	be	AUX
ajlm-975	89	35	higher	high	ADJ
ajlm-975	89	36	among	among	ADP
ajlm-975	89	37	participants	participant	NOUN
ajlm-975	89	38	with	with	ADP
ajlm-975	89	39	ebv	ebv	NOUN
ajlm-975	89	40	,	,	PUNCT
ajlm-975	89	41	hpv	hpv	NOUN
ajlm-975	89	42	and	and	CCONJ
ajlm-975	89	43	hsv-2	hsv-2	PUNCT
ajlm-975	89	44	tri	tri	ADJ
ajlm-975	89	45	-	-	NOUN
ajlm-975	89	46	infection	infection	NOUN
ajlm-975	89	47	and	and	CCONJ
ajlm-975	89	48	lower	low	ADJ
ajlm-975	89	49	among	among	ADP
ajlm-975	89	50	participants	participant	NOUN
ajlm-975	89	51	with	with	ADP
ajlm-975	89	52	hpv	hpv	ADJ
ajlm-975	89	53	mono	mono	NOUN
ajlm-975	89	54	-	-	PUNCT
ajlm-975	89	55	infection	infection	NOUN
ajlm-975	89	56	;	;	PUNCT
ajlm-975	89	57	(	(	PUNCT
ajlm-975	89	58	c	c	X
ajlm-975	89	59	)	)	PUNCT
ajlm-975	89	60	mir-125b	mir-125b	NOUN
ajlm-975	89	61	expression	expression	NOUN
ajlm-975	89	62	was	be	AUX
ajlm-975	89	63	higher	high	ADJ
ajlm-975	89	64	among	among	ADP
ajlm-975	89	65	participants	participant	NOUN
ajlm-975	89	66	with	with	ADP
ajlm-975	89	67	ebv	ebv	NOUN
ajlm-975	89	68	mono	mono	NOUN
ajlm-975	89	69	-	-	PUNCT
ajlm-975	89	70	infection	infection	NOUN
ajlm-975	89	71	and	and	CCONJ
ajlm-975	89	72	lower	low	ADJ
ajlm-975	89	73	among	among	ADP
ajlm-975	89	74	participants	participant	NOUN
ajlm-975	89	75	with	with	ADP
ajlm-975	89	76	ebv	ebv	NOUN
ajlm-975	89	77	,	,	PUNCT
ajlm-975	89	78	hpv	hpv	NOUN
ajlm-975	89	79	and	and	CCONJ
ajlm-975	89	80	hsv-2	hsv-2	PUNCT
ajlm-975	89	81	tri	tri	ADJ
ajlm-975	89	82	-	-	NOUN
ajlm-975	89	83	infection	infection	NOUN
ajlm-975	89	84	;	;	PUNCT
ajlm-975	89	85	(	(	PUNCT
ajlm-975	89	86	d	d	X
ajlm-975	89	87	)	)	PUNCT
ajlm-975	89	88	mir-145	mir-145	NOUN
ajlm-975	89	89	expression	expression	NOUN
ajlm-975	89	90	was	be	AUX
ajlm-975	89	91	higher	high	ADJ
ajlm-975	89	92	among	among	ADP
ajlm-975	89	93	participants	participant	NOUN
ajlm-975	89	94	with	with	ADP
ajlm-975	89	95	hsv-2	hsv-2	PUNCT
ajlm-975	89	96	mono	mono	NOUN
ajlm-975	89	97	-	-	PUNCT
ajlm-975	89	98	infection	infection	NOUN
ajlm-975	89	99	and	and	CCONJ
ajlm-975	89	100	lower	low	ADJ
ajlm-975	89	101	among	among	ADP
ajlm-975	89	102	participants	participant	NOUN
ajlm-975	89	103	with	with	ADP
ajlm-975	89	104	ebv	ebv	NOUN
ajlm-975	89	105	and	and	CCONJ
ajlm-975	89	106	hpv	hpv	ADJ
ajlm-975	89	107	bi	bi	NOUN
ajlm-975	89	108	-	-	NOUN
ajlm-975	89	109	infection	infection	NOUN
ajlm-975	89	110	(	(	PUNCT
ajlm-975	89	111	d	d	NOUN
ajlm-975	89	112	)	)	PUNCT
ajlm-975	89	113	;	;	PUNCT
ajlm-975	89	114	(	(	PUNCT
ajlm-975	89	115	e	e	X
ajlm-975	89	116	)	)	PUNCT
ajlm-975	89	117	snapshots	snapshot	NOUN
ajlm-975	89	118	of	of	ADP
ajlm-975	89	119	gel	gel	NOUN
ajlm-975	89	120	amplicons	amplicon	NOUN
ajlm-975	89	121	of	of	ADP
ajlm-975	89	122	tumour	tumour	NOUN
ajlm-975	89	123	suppressors	suppressor	NOUN
ajlm-975	89	124	and	and	CCONJ
ajlm-975	89	125	normalising	normalise	VERB
ajlm-975	89	126	gene	gene	NOUN
ajlm-975	89	127	(	(	PUNCT
ajlm-975	89	128	mir-16	mir-16	NOUN
ajlm-975	89	129	)	)	PUNCT
ajlm-975	89	130	based	base	VERB
ajlm-975	89	131	on	on	ADP
ajlm-975	89	132	viral	viral	ADJ
ajlm-975	89	133	status	status	NOUN
ajlm-975	89	134	(	(	PUNCT
ajlm-975	89	135	plotted	plot	VERB
ajlm-975	89	136	as	as	ADP
ajlm-975	89	137	a	a	DET
ajlm-975	89	138	–	–	PUNCT
ajlm-975	89	139	d	d	NOUN
ajlm-975	89	140	)	)	PUNCT
ajlm-975	89	141	.	.	PUNCT
ajlm-975	90	1	figure	figure	VERB
ajlm-975	90	2	3	3	NUM
ajlm-975	90	3	:	:	PUNCT
ajlm-975	90	4	biomarker	biomarker	NOUN
ajlm-975	90	5	levels	level	NOUN
ajlm-975	90	6	and	and	CCONJ
ajlm-975	90	7	cd4	cd4	PROPN
ajlm-975	90	8	+	+	PROPN
ajlm-975	90	9	t	t	PROPN
ajlm-975	90	10	-	-	PUNCT
ajlm-975	90	11	cell	cell	NOUN
ajlm-975	90	12	counts	count	NOUN
ajlm-975	90	13	among	among	ADP
ajlm-975	90	14	individuals	individual	NOUN
ajlm-975	90	15	with	with	ADP
ajlm-975	90	16	and	and	CCONJ
ajlm-975	90	17	without	without	ADP
ajlm-975	90	18	viral	viral	ADJ
ajlm-975	90	19	infection	infection	NOUN
ajlm-975	90	20	,	,	PUNCT
ajlm-975	90	21	ogun	ogun	PROPN
ajlm-975	90	22	state	state	PROPN
ajlm-975	90	23	,	,	PUNCT
ajlm-975	90	24	nigeria	nigeria	PROPN
ajlm-975	90	25	,	,	PUNCT
ajlm-975	90	26	2018	2018	NUM
ajlm-975	90	27	.	.	PUNCT
ajlm-975	91	1	(	(	PUNCT
ajlm-975	91	2	a	a	X
ajlm-975	91	3	)	)	PUNCT
ajlm-975	91	4	p53	p53	NOUN
ajlm-975	91	5	gene	gene	NOUN
ajlm-975	91	6	expression	expression	NOUN
ajlm-975	91	7	was	be	AUX
ajlm-975	91	8	higher	high	ADJ
ajlm-975	91	9	among	among	ADP
ajlm-975	91	10	participants	participant	NOUN
ajlm-975	91	11	with	with	ADP
ajlm-975	91	12	hpv	hpv	ADJ
ajlm-975	91	13	mono	mono	NOUN
ajlm-975	91	14	-	-	PUNCT
ajlm-975	91	15	infection	infection	NOUN
ajlm-975	91	16	and	and	CCONJ
ajlm-975	91	17	lowest	low	ADJ
ajlm-975	91	18	in	in	ADP
ajlm-975	91	19	control	control	NOUN
ajlm-975	91	20	group	group	NOUN
ajlm-975	91	21	,	,	PUNCT
ajlm-975	91	22	participants	participant	NOUN
ajlm-975	91	23	who	who	PRON
ajlm-975	91	24	had	have	VERB
ajlm-975	91	25	no	no	DET
ajlm-975	91	26	viral	viral	ADJ
ajlm-975	91	27	infections	infection	NOUN
ajlm-975	91	28	(	(	PUNCT
ajlm-975	91	29	none	none	NOUN
ajlm-975	91	30	)	)	PUNCT
ajlm-975	91	31	;	;	PUNCT
ajlm-975	91	32	(	(	PUNCT
ajlm-975	91	33	b	b	X
ajlm-975	91	34	)	)	PUNCT
ajlm-975	91	35	cd4	cd4	PROPN
ajlm-975	91	36	+	+	PROPN
ajlm-975	91	37	t	t	PROPN
ajlm-975	91	38	-	-	PUNCT
ajlm-975	91	39	cell	cell	NOUN
ajlm-975	91	40	counts	count	NOUN
ajlm-975	91	41	were	be	AUX
ajlm-975	91	42	higher	high	ADJ
ajlm-975	91	43	among	among	ADP
ajlm-975	91	44	the	the	DET
ajlm-975	91	45	control	control	NOUN
ajlm-975	91	46	group	group	NOUN
ajlm-975	91	47	(	(	PUNCT
ajlm-975	91	48	none	none	NOUN
ajlm-975	91	49	)	)	PUNCT
ajlm-975	91	50	and	and	CCONJ
ajlm-975	91	51	lower	low	ADJ
ajlm-975	91	52	among	among	ADP
ajlm-975	91	53	those	those	PRON
ajlm-975	91	54	with	with	ADP
ajlm-975	91	55	ebv	ebv	NOUN
ajlm-975	91	56	and	and	CCONJ
ajlm-975	91	57	hsv-2	hsv-2	PUNCT
ajlm-975	91	58	co	co	NOUN
ajlm-975	91	59	-	-	NOUN
ajlm-975	91	60	infection	infection	NOUN
ajlm-975	91	61	;	;	PUNCT
ajlm-975	91	62	(	(	PUNCT
ajlm-975	91	63	c	c	X
ajlm-975	91	64	)	)	PUNCT
ajlm-975	91	65	ki67	ki67	PROPN
ajlm-975	91	66	expression	expression	NOUN
ajlm-975	91	67	was	be	AUX
ajlm-975	91	68	higher	high	ADJ
ajlm-975	91	69	among	among	ADP
ajlm-975	91	70	participants	participant	NOUN
ajlm-975	91	71	with	with	ADP
ajlm-975	91	72	hpv	hpv	ADJ
ajlm-975	91	73	infection	infection	NOUN
ajlm-975	91	74	and	and	CCONJ
ajlm-975	91	75	lower	low	ADJ
ajlm-975	91	76	in	in	ADP
ajlm-975	91	77	the	the	DET
ajlm-975	91	78	control	control	NOUN
ajlm-975	91	79	(	(	PUNCT
ajlm-975	91	80	none	none	NOUN
ajlm-975	91	81	)	)	PUNCT
ajlm-975	91	82	;	;	PUNCT
ajlm-975	91	83	(	(	PUNCT
ajlm-975	91	84	d	d	X
ajlm-975	91	85	)	)	PUNCT
ajlm-975	91	86	scca1	scca1	NOUN
ajlm-975	91	87	expression	expression	NOUN
ajlm-975	91	88	was	be	AUX
ajlm-975	91	89	higher	high	ADJ
ajlm-975	91	90	among	among	ADP
ajlm-975	91	91	participants	participant	NOUN
ajlm-975	91	92	with	with	ADP
ajlm-975	91	93	hpv	hpv	ADJ
ajlm-975	91	94	mono	mono	NOUN
ajlm-975	91	95	-	-	PUNCT
ajlm-975	91	96	infection	infection	NOUN
ajlm-975	91	97	and	and	CCONJ
ajlm-975	91	98	lower	low	ADJ
ajlm-975	91	99	in	in	ADP
ajlm-975	91	100	those	those	PRON
ajlm-975	91	101	with	with	ADP
ajlm-975	91	102	ebv	ebv	NOUN
ajlm-975	91	103	mono	mono	NOUN
ajlm-975	91	104	-	-	PUNCT
ajlm-975	91	105	infection	infection	NOUN
ajlm-975	91	106	;	;	PUNCT
ajlm-975	91	107	(	(	PUNCT
ajlm-975	91	108	e	e	NOUN
ajlm-975	91	109	)	)	PUNCT
ajlm-975	91	110	snapshots	snapshot	NOUN
ajlm-975	91	111	of	of	ADP
ajlm-975	91	112	gel	gel	NOUN
ajlm-975	91	113	amplicons	amplicon	NOUN
ajlm-975	91	114	of	of	ADP
ajlm-975	91	115	p53	p53	NOUN
ajlm-975	91	116	gene	gene	NOUN
ajlm-975	91	117	and	and	CCONJ
ajlm-975	91	118	normalising	normalise	VERB
ajlm-975	91	119	gene	gene	NOUN
ajlm-975	91	120	(	(	PUNCT
ajlm-975	91	121	β	β	NOUN
ajlm-975	91	122	-	-	NOUN
ajlm-975	91	123	actin	actin	NOUN
ajlm-975	91	124	)	)	PUNCT
ajlm-975	91	125	based	base	VERB
ajlm-975	91	126	on	on	ADP
ajlm-975	91	127	viral	viral	ADJ
ajlm-975	91	128	status	status	NOUN
ajlm-975	91	129	(	(	PUNCT
ajlm-975	91	130	plotted	plot	VERB
ajlm-975	91	131	as	as	ADP
ajlm-975	91	132	a	a	PRON
ajlm-975	91	133	)	)	PUNCT
ajlm-975	91	134	.	.	PUNCT
ajlm-975	92	1	statistical	statistical	ADJ
ajlm-975	92	2	analyses	analysis	NOUN
ajlm-975	92	3	descriptive	descriptive	ADJ
ajlm-975	92	4	statistics	statistic	NOUN
ajlm-975	92	5	were	be	AUX
ajlm-975	92	6	carried	carry	VERB
ajlm-975	92	7	out	out	ADP
ajlm-975	92	8	to	to	PART
ajlm-975	92	9	categorise	categorise	VERB
ajlm-975	92	10	participants	participant	NOUN
ajlm-975	92	11	into	into	ADP
ajlm-975	92	12	the	the	DET
ajlm-975	92	13	eight	eight	NUM
ajlm-975	92	14	groups	group	NOUN
ajlm-975	92	15	:	:	PUNCT
ajlm-975	92	16	group	group	NOUN
ajlm-975	92	17	1	1	NUM
ajlm-975	92	18	(	(	PUNCT
ajlm-975	92	19	none	none	NOUN
ajlm-975	92	20	):	):	PUNCT
ajlm-975	92	21	ebv	ebv	NOUN
ajlm-975	92	22	,	,	PUNCT
ajlm-975	92	23	hpv	hpv	NOUN
ajlm-975	92	24	and	and	CCONJ
ajlm-975	92	25	hsv-2	hsv-2	CCONJ
ajlm-975	92	26	seronegative	seronegative	ADJ
ajlm-975	92	27	participants	participant	NOUN
ajlm-975	92	28	;	;	PUNCT
ajlm-975	92	29	group	group	NOUN
ajlm-975	92	30	2	2	NUM
ajlm-975	92	31	:	:	PUNCT
ajlm-975	92	32	ebv	ebv	NOUN
ajlm-975	92	33	mono	mono	NOUN
ajlm-975	92	34	-	-	PUNCT
ajlm-975	92	35	infection	infection	NOUN
ajlm-975	92	36	;	;	PUNCT
ajlm-975	92	37	group	group	NOUN
ajlm-975	92	38	3	3	NUM
ajlm-975	92	39	:	:	PUNCT
ajlm-975	92	40	hpv	hpv	ADJ
ajlm-975	92	41	mono	mono	NOUN
ajlm-975	92	42	-	-	PUNCT
ajlm-975	92	43	infection	infection	NOUN
ajlm-975	92	44	;	;	PUNCT
ajlm-975	92	45	group	group	NOUN
ajlm-975	92	46	4	4	NUM
ajlm-975	92	47	:	:	PUNCT
ajlm-975	92	48	hsv-2	hsv-2	PUNCT
ajlm-975	92	49	mono	mono	NOUN
ajlm-975	92	50	-	-	PUNCT
ajlm-975	92	51	infection	infection	NOUN
ajlm-975	92	52	;	;	PUNCT
ajlm-975	92	53	group	group	NOUN
ajlm-975	92	54	5	5	NUM
ajlm-975	92	55	:	:	PUNCT
ajlm-975	92	56	ebv	ebv	NOUN
ajlm-975	92	57	/	/	SYM
ajlm-975	92	58	hpv	hpv	ADJ
ajlm-975	92	59	bi	bi	NOUN
ajlm-975	92	60	-	-	NOUN
ajlm-975	92	61	infection	infection	NOUN
ajlm-975	92	62	;	;	PUNCT
ajlm-975	92	63	group	group	NOUN
ajlm-975	92	64	6	6	NUM
ajlm-975	92	65	:	:	PUNCT
ajlm-975	92	66	ebv	ebv	NOUN
ajlm-975	92	67	/	/	SYM
ajlm-975	92	68	hsv-2	hsv-2	PUNCT
ajlm-975	92	69	bi	bi	NOUN
ajlm-975	92	70	-	-	NOUN
ajlm-975	92	71	infection	infection	NOUN
ajlm-975	92	72	;	;	PUNCT
ajlm-975	92	73	group	group	NOUN
ajlm-975	92	74	7	7	NUM
ajlm-975	92	75	:	:	PUNCT
ajlm-975	92	76	hpv+hsv-2	hpv+hsv-2	ADJ
ajlm-975	92	77	bi	bi	NOUN
ajlm-975	92	78	-	-	NOUN
ajlm-975	92	79	infection	infection	NOUN
ajlm-975	92	80	;	;	PUNCT
ajlm-975	92	81	and	and	CCONJ
ajlm-975	92	82	group	group	NOUN
ajlm-975	92	83	8	8	NUM
ajlm-975	92	84	:	:	PUNCT
ajlm-975	92	85	ebv	ebv	NOUN
ajlm-975	92	86	/	/	SYM
ajlm-975	92	87	hpv	hpv	NOUN
ajlm-975	92	88	/	/	SYM
ajlm-975	92	89	hsv-2	hsv-2	PART
ajlm-975	92	90	tri	tri	ADJ
ajlm-975	92	91	-	-	NOUN
ajlm-975	92	92	infection	infection	NOUN
ajlm-975	92	93	.	.	PUNCT
ajlm-975	93	1	the	the	DET
ajlm-975	93	2	relative	relative	ADJ
ajlm-975	93	3	expression	expression	NOUN
ajlm-975	93	4	of	of	ADP
ajlm-975	93	5	mirnas	mirna	NOUN
ajlm-975	93	6	and	and	CCONJ
ajlm-975	93	7	the	the	DET
ajlm-975	93	8	p53	p53	NOUN
ajlm-975	93	9	gene	gene	NOUN
ajlm-975	93	10	in	in	ADP
ajlm-975	93	11	the	the	DET
ajlm-975	93	12	healthy	healthy	ADJ
ajlm-975	93	13	control	control	NOUN
ajlm-975	93	14	group	group	NOUN
ajlm-975	93	15	(	(	PUNCT
ajlm-975	93	16	uninfected	uninfected	ADJ
ajlm-975	93	17	commercial	commercial	ADJ
ajlm-975	93	18	sex	sex	NOUN
ajlm-975	93	19	workers	worker	NOUN
ajlm-975	93	20	)	)	PUNCT
ajlm-975	93	21	and	and	CCONJ
ajlm-975	93	22	in	in	ADP
ajlm-975	93	23	the	the	DET
ajlm-975	93	24	different	different	ADJ
ajlm-975	93	25	viral	viral	ADJ
ajlm-975	93	26	status	status	NOUN
ajlm-975	93	27	groups	group	NOUN
ajlm-975	93	28	were	be	AUX
ajlm-975	93	29	compared	compare	VERB
ajlm-975	93	30	using	use	VERB
ajlm-975	93	31	analysis	analysis	NOUN
ajlm-975	93	32	of	of	ADP
ajlm-975	93	33	variance	variance	NOUN
ajlm-975	93	34	,	,	PUNCT
ajlm-975	93	35	partial	partial	ADJ
ajlm-975	93	36	correlation	correlation	NOUN
ajlm-975	93	37	and	and	CCONJ
ajlm-975	93	38	pearson	pearson	PROPN
ajlm-975	93	39	’s	’s	PART
ajlm-975	93	40	(	(	PUNCT
ajlm-975	93	41	bivariate	bivariate	ADJ
ajlm-975	93	42	)	)	PUNCT
ajlm-975	93	43	correlation	correlation	NOUN
ajlm-975	93	44	in	in	ADP
ajlm-975	93	45	statistical	statistical	ADJ
ajlm-975	93	46	package	package	NOUN
ajlm-975	93	47	for	for	ADP
ajlm-975	93	48	social	social	ADJ
ajlm-975	93	49	sciences	science	NOUN
ajlm-975	93	50	(	(	PUNCT
ajlm-975	93	51	version	version	NOUN
ajlm-975	93	52	21	21	NUM
ajlm-975	93	53	;	;	PUNCT
ajlm-975	93	54	ibm	ibm	PROPN
ajlm-975	93	55	corporation	corporation	PROPN
ajlm-975	93	56	,	,	PUNCT
ajlm-975	93	57	armonk	armonk	PROPN
ajlm-975	93	58	,	,	PUNCT
ajlm-975	93	59	new	new	PROPN
ajlm-975	93	60	york	york	PROPN
ajlm-975	93	61	,	,	PUNCT
ajlm-975	93	62	united	united	PROPN
ajlm-975	93	63	states	states	PROPN
ajlm-975	93	64	)	)	PUNCT
ajlm-975	93	65	.	.	PUNCT
ajlm-975	94	1	in	in	ADP
ajlm-975	94	2	terms	term	NOUN
ajlm-975	94	3	of	of	ADP
ajlm-975	94	4	viral	viral	ADJ
ajlm-975	94	5	status	status	NOUN
ajlm-975	94	6	(	(	PUNCT
ajlm-975	94	7	coded	code	VERB
ajlm-975	94	8	as	as	ADP
ajlm-975	94	9	‘	'	PUNCT
ajlm-975	94	10	0	0	NUM
ajlm-975	94	11	’	'	PUNCT
ajlm-975	94	12	for	for	ADP
ajlm-975	94	13	no	no	DET
ajlm-975	94	14	infection	infection	NOUN
ajlm-975	94	15	,	,	PUNCT
ajlm-975	94	16	‘	'	PUNCT
ajlm-975	94	17	1	1	NUM
ajlm-975	94	18	’	'	PUNCT
ajlm-975	94	19	for	for	ADP
ajlm-975	94	20	ebv	ebv	NOUN
ajlm-975	94	21	mono	mono	NOUN
ajlm-975	94	22	-	-	PUNCT
ajlm-975	94	23	infection	infection	NOUN
ajlm-975	94	24	,	,	PUNCT
ajlm-975	94	25	‘	'	PUNCT
ajlm-975	94	26	2	2	NUM
ajlm-975	94	27	’	'	PUNCT
ajlm-975	94	28	for	for	ADP
ajlm-975	94	29	hpv	hpv	ADJ
ajlm-975	94	30	mono	mono	NOUN
ajlm-975	94	31	-	-	PUNCT
ajlm-975	94	32	infection	infection	NOUN
ajlm-975	94	33	and	and	CCONJ
ajlm-975	94	34	‘	'	PUNCT
ajlm-975	94	35	3	3	NUM
ajlm-975	94	36	’	'	PUNCT
ajlm-975	94	37	for	for	ADP
ajlm-975	94	38	hsv-2	hsv-2	PUNCT
ajlm-975	94	39	mono	mono	NOUN
ajlm-975	94	40	-	-	PUNCT
ajlm-975	94	41	infection	infection	NOUN
ajlm-975	94	42	,	,	PUNCT
ajlm-975	94	43	‘	'	PUNCT
ajlm-975	94	44	4	4	NUM
ajlm-975	94	45	’	'	PUNCT
ajlm-975	94	46	for	for	ADP
ajlm-975	94	47	ebv	ebv	NOUN
ajlm-975	94	48	and	and	CCONJ
ajlm-975	94	49	hpv	hpv	ADJ
ajlm-975	94	50	bi	bi	NOUN
ajlm-975	94	51	-	-	NOUN
ajlm-975	94	52	infection	infection	NOUN
ajlm-975	94	53	,	,	PUNCT
ajlm-975	94	54	‘	'	PUNCT
ajlm-975	94	55	5	5	NUM
ajlm-975	94	56	’	'	PUNCT
ajlm-975	94	57	for	for	ADP
ajlm-975	94	58	ebv	ebv	NOUN
ajlm-975	94	59	and	and	CCONJ
ajlm-975	94	60	hsv-2	hsv-2	PUNCT
ajlm-975	94	61	bi	bi	NOUN
ajlm-975	94	62	-	-	NOUN
ajlm-975	94	63	infection	infection	NOUN
ajlm-975	94	64	,	,	PUNCT
ajlm-975	94	65	‘	'	PUNCT
ajlm-975	94	66	6	6	NUM
ajlm-975	94	67	’	'	PUNCT
ajlm-975	94	68	for	for	ADP
ajlm-975	94	69	hpv	hpv	NOUN
ajlm-975	94	70	and	and	CCONJ
ajlm-975	94	71	hsv-2	hsv-2	PUNCT
ajlm-975	94	72	bi	bi	NOUN
ajlm-975	94	73	-	-	NOUN
ajlm-975	94	74	infection	infection	NOUN
ajlm-975	94	75	and	and	CCONJ
ajlm-975	94	76	‘	'	PUNCT
ajlm-975	94	77	7	7	NUM
ajlm-975	94	78	’	'	PUNCT
ajlm-975	94	79	for	for	ADP
ajlm-975	94	80	ebv	ebv	NOUN
ajlm-975	94	81	,	,	PUNCT
ajlm-975	94	82	hpv	hpv	NOUN
ajlm-975	94	83	and	and	CCONJ
ajlm-975	94	84	hsv-2	hsv-2	PUNCT
ajlm-975	94	85	tri	tri	ADJ
ajlm-975	94	86	-	-	NOUN
ajlm-975	94	87	infection	infection	NOUN
ajlm-975	94	88	)	)	PUNCT
ajlm-975	94	89	,	,	PUNCT
ajlm-975	94	90	partial	partial	ADJ
ajlm-975	94	91	correlation	correlation	NOUN
ajlm-975	94	92	was	be	AUX
ajlm-975	94	93	carried	carry	VERB
ajlm-975	94	94	out	out	ADP
ajlm-975	94	95	to	to	PART
ajlm-975	94	96	determine	determine	VERB
ajlm-975	94	97	the	the	DET
ajlm-975	94	98	relationship	relationship	NOUN
ajlm-975	94	99	between	between	ADP
ajlm-975	94	100	the	the	DET
ajlm-975	94	101	expression	expression	NOUN
ajlm-975	94	102	of	of	ADP
ajlm-975	94	103	the	the	DET
ajlm-975	94	104	biomarkers	biomarker	NOUN
ajlm-975	94	105	in	in	ADP
ajlm-975	94	106	all	all	DET
ajlm-975	94	107	participants	participant	NOUN
ajlm-975	94	108	.	.	PUNCT
ajlm-975	95	1	results	result	NOUN
ajlm-975	95	2	were	be	AUX
ajlm-975	95	3	presented	present	VERB
ajlm-975	95	4	as	as	ADP
ajlm-975	95	5	mean	mean	NOUN
ajlm-975	95	6	±	±	NUM
ajlm-975	95	7	standard	standard	ADJ
ajlm-975	95	8	error	error	NOUN
ajlm-975	95	9	of	of	ADP
ajlm-975	95	10	the	the	DET
ajlm-975	95	11	mean	mean	NOUN
ajlm-975	95	12	.	.	PUNCT
ajlm-975	96	1	statistical	statistical	ADJ
ajlm-975	96	2	significance	significance	NOUN
ajlm-975	96	3	was	be	AUX
ajlm-975	96	4	set	set	VERB
ajlm-975	96	5	at	at	ADP
ajlm-975	96	6	p	p	NOUN
ajlm-975	96	7	-	-	PUNCT
ajlm-975	96	8	values	value	NOUN
ajlm-975	96	9	less	less	ADJ
ajlm-975	96	10	than	than	ADP
ajlm-975	96	11	0.05	0.05	NUM
ajlm-975	96	12	.	.	PUNCT
ajlm-975	97	1	results	result	VERB
ajlm-975	97	2	the	the	DET
ajlm-975	97	3	number	number	NOUN
ajlm-975	97	4	(	(	PUNCT
ajlm-975	97	5	%	%	NOUN
ajlm-975	97	6	)	)	PUNCT
ajlm-975	97	7	of	of	ADP
ajlm-975	97	8	participants	participant	NOUN
ajlm-975	97	9	(	(	PUNCT
ajlm-975	97	10	n	n	NOUN
ajlm-975	97	11	=	=	SYM
ajlm-975	97	12	319	319	NUM
ajlm-975	97	13	)	)	PUNCT
ajlm-975	97	14	in	in	ADP
ajlm-975	97	15	the	the	DET
ajlm-975	97	16	eight	eight	NUM
ajlm-975	97	17	groups	group	NOUN
ajlm-975	97	18	were	be	AUX
ajlm-975	97	19	:	:	PUNCT
ajlm-975	97	20	group	group	NOUN
ajlm-975	97	21	1	1	NUM
ajlm-975	97	22	(	(	PUNCT
ajlm-975	97	23	control	control	NOUN
ajlm-975	97	24	group	group	NOUN
ajlm-975	97	25	/	/	PUNCT
ajlm-975	97	26	none	none	NOUN
ajlm-975	97	27	;	;	PUNCT
ajlm-975	97	28	virus	virus	NOUN
ajlm-975	97	29	negative	negative	ADJ
ajlm-975	97	30	group	group	NOUN
ajlm-975	97	31	)	)	PUNCT
ajlm-975	98	1	=	=	SYM
ajlm-975	98	2	81	81	NUM
ajlm-975	98	3	(	(	PUNCT
ajlm-975	98	4	25.4	25.4	NUM
ajlm-975	98	5	%	%	NOUN
ajlm-975	98	6	)	)	PUNCT
ajlm-975	98	7	,	,	PUNCT
ajlm-975	98	8	group	group	NOUN
ajlm-975	98	9	2	2	NUM
ajlm-975	98	10	(	(	PUNCT
ajlm-975	98	11	ebv	ebv	NOUN
ajlm-975	98	12	mono	mono	NOUN
ajlm-975	98	13	-	-	PUNCT
ajlm-975	98	14	infection	infection	NOUN
ajlm-975	98	15	)	)	PUNCT
ajlm-975	99	1	=	=	SYM
ajlm-975	99	2	15	15	NUM
ajlm-975	99	3	(	(	PUNCT
ajlm-975	99	4	4.7	4.7	NUM
ajlm-975	99	5	%	%	NOUN
ajlm-975	99	6	)	)	PUNCT
ajlm-975	99	7	,	,	PUNCT
ajlm-975	99	8	group	group	NOUN
ajlm-975	99	9	3	3	NUM
ajlm-975	99	10	(	(	PUNCT
ajlm-975	99	11	hpv	hpv	NOUN
ajlm-975	99	12	mono	mono	NOUN
ajlm-975	99	13	-	-	PUNCT
ajlm-975	99	14	infection	infection	NOUN
ajlm-975	99	15	)	)	PUNCT
ajlm-975	99	16	=	=	SYM
ajlm-975	100	1	30	30	NUM
ajlm-975	100	2	(	(	PUNCT
ajlm-975	100	3	9.4	9.4	NUM
ajlm-975	100	4	%	%	NOUN
ajlm-975	100	5	)	)	PUNCT
ajlm-975	100	6	,	,	PUNCT
ajlm-975	100	7	group	group	NOUN
ajlm-975	100	8	4	4	NUM
ajlm-975	100	9	(	(	PUNCT
ajlm-975	100	10	hsv-2	hsv-2	ADP
ajlm-975	100	11	mono	mono	NOUN
ajlm-975	100	12	-	-	PUNCT
ajlm-975	100	13	infection	infection	NOUN
ajlm-975	100	14	)	)	PUNCT
ajlm-975	100	15	=	=	SYM
ajlm-975	101	1	67	67	NUM
ajlm-975	101	2	(	(	PUNCT
ajlm-975	101	3	21.0	21.0	NUM
ajlm-975	101	4	%	%	NOUN
ajlm-975	101	5	)	)	PUNCT
ajlm-975	101	6	,	,	PUNCT
ajlm-975	101	7	group	group	NOUN
ajlm-975	101	8	5	5	NUM
ajlm-975	101	9	(	(	PUNCT
ajlm-975	101	10	ebv	ebv	NOUN
ajlm-975	101	11	and	and	CCONJ
ajlm-975	101	12	hpv	hpv	ADJ
ajlm-975	101	13	bi	bi	NOUN
ajlm-975	101	14	-	-	NOUN
ajlm-975	101	15	infection	infection	NOUN
ajlm-975	101	16	)	)	PUNCT
ajlm-975	101	17	=	=	SYM
ajlm-975	101	18	5	5	NUM
ajlm-975	101	19	(	(	PUNCT
ajlm-975	101	20	1.6	1.6	NUM
ajlm-975	101	21	%	%	NOUN
ajlm-975	101	22	)	)	PUNCT
ajlm-975	101	23	,	,	PUNCT
ajlm-975	101	24	group	group	NOUN
ajlm-975	101	25	6	6	NUM
ajlm-975	101	26	(	(	PUNCT
ajlm-975	101	27	ebv	ebv	NOUN
ajlm-975	101	28	and	and	CCONJ
ajlm-975	101	29	hsv-2	hsv-2	PUNCT
ajlm-975	101	30	bi	bi	NOUN
ajlm-975	101	31	-	-	NOUN
ajlm-975	101	32	infection	infection	NOUN
ajlm-975	101	33	)	)	PUNCT
ajlm-975	102	1	=	=	SYM
ajlm-975	102	2	46	46	NUM
ajlm-975	102	3	(	(	PUNCT
ajlm-975	102	4	14.4	14.4	NUM
ajlm-975	102	5	%	%	NOUN
ajlm-975	102	6	)	)	PUNCT
ajlm-975	102	7	,	,	PUNCT
ajlm-975	102	8	group	group	NOUN
ajlm-975	102	9	7	7	NUM
ajlm-975	102	10	(	(	PUNCT
ajlm-975	102	11	hpv	hpv	NOUN
ajlm-975	102	12	and	and	CCONJ
ajlm-975	102	13	hsv-2	hsv-2	PUNCT
ajlm-975	102	14	bi	bi	NOUN
ajlm-975	102	15	-	-	NOUN
ajlm-975	102	16	infection	infection	NOUN
ajlm-975	102	17	)	)	PUNCT
ajlm-975	103	1	=	=	SYM
ajlm-975	103	2	22	22	NUM
ajlm-975	103	3	(	(	PUNCT
ajlm-975	103	4	6.9	6.9	NUM
ajlm-975	103	5	%	%	NOUN
ajlm-975	103	6	)	)	PUNCT
ajlm-975	103	7	and	and	CCONJ
ajlm-975	103	8	group	group	NOUN
ajlm-975	103	9	8	8	NUM
ajlm-975	103	10	(	(	PUNCT
ajlm-975	103	11	ebv	ebv	NOUN
ajlm-975	103	12	,	,	PUNCT
ajlm-975	103	13	hpv	hpv	NOUN
ajlm-975	103	14	and	and	CCONJ
ajlm-975	103	15	hsv-2	hsv-2	PUNCT
ajlm-975	103	16	tri	tri	ADJ
ajlm-975	103	17	-	-	NOUN
ajlm-975	103	18	infection	infection	NOUN
ajlm-975	103	19	)	)	PUNCT
ajlm-975	104	1	=	=	SYM
ajlm-975	104	2	53	53	NUM
ajlm-975	104	3	(	(	PUNCT
ajlm-975	104	4	16.6	16.6	NUM
ajlm-975	104	5	%	%	NOUN
ajlm-975	104	6	)	)	PUNCT
ajlm-975	104	7	.	.	PUNCT
ajlm-975	105	1	expression	expression	NOUN
ajlm-975	105	2	of	of	ADP
ajlm-975	105	3	oncomirs	oncomir	NOUN
ajlm-975	105	4	in	in	ADP
ajlm-975	105	5	viral	viral	ADJ
ajlm-975	105	6	infection	infection	NOUN
ajlm-975	105	7	mir-21	mir-21	PROPN
ajlm-975	105	8	was	be	AUX
ajlm-975	105	9	significantly	significantly	ADV
ajlm-975	105	10	overexpressed	overexpresse	VERB
ajlm-975	105	11	among	among	ADP
ajlm-975	105	12	participants	participant	NOUN
ajlm-975	105	13	with	with	ADP
ajlm-975	105	14	ebv	ebv	NOUN
ajlm-975	105	15	mono	mono	NOUN
ajlm-975	105	16	-	-	PUNCT
ajlm-975	105	17	infection	infection	NOUN
ajlm-975	105	18	(	(	PUNCT
ajlm-975	105	19	p	p	X
ajlm-975	105	20	=	=	NOUN
ajlm-975	105	21	0.047	0.047	NUM
ajlm-975	105	22	)	)	PUNCT
ajlm-975	105	23	,	,	PUNCT
ajlm-975	105	24	hpv	hpv	PROPN
ajlm-975	105	25	mono	mono	NOUN
ajlm-975	105	26	-	-	PUNCT
ajlm-975	105	27	infection	infection	NOUN
ajlm-975	105	28	(	(	PUNCT
ajlm-975	105	29	p	p	X
ajlm-975	105	30	<	<	X
ajlm-975	105	31	0.001	0.001	NUM
ajlm-975	105	32	)	)	PUNCT
ajlm-975	105	33	,	,	PUNCT
ajlm-975	105	34	and	and	CCONJ
ajlm-975	105	35	ebv	ebv	NOUN
ajlm-975	105	36	-	-	PUNCT
ajlm-975	105	37	hpv	hpv	ADJ
ajlm-975	105	38	bi	bi	NOUN
ajlm-975	105	39	-	-	NOUN
ajlm-975	105	40	infection	infection	NOUN
ajlm-975	105	41	(	(	PUNCT
ajlm-975	105	42	p	p	X
ajlm-975	105	43	=	=	NOUN
ajlm-975	105	44	0.015	0.015	NUM
ajlm-975	105	45	)	)	PUNCT
ajlm-975	105	46	when	when	SCONJ
ajlm-975	105	47	compared	compare	VERB
ajlm-975	105	48	with	with	ADP
ajlm-975	105	49	the	the	DET
ajlm-975	105	50	control	control	NOUN
ajlm-975	105	51	group	group	NOUN
ajlm-975	105	52	(	(	PUNCT
ajlm-975	105	53	figure	figure	NOUN
ajlm-975	105	54	1a	1a	NOUN
ajlm-975	105	55	)	)	PUNCT
ajlm-975	105	56	.	.	PUNCT
ajlm-975	106	1	a	a	DET
ajlm-975	106	2	statistically	statistically	ADV
ajlm-975	106	3	significant	significant	ADJ
ajlm-975	106	4	overexpression	overexpression	NOUN
ajlm-975	106	5	of	of	ADP
ajlm-975	106	6	mir-182	mir-182	NOUN
ajlm-975	106	7	among	among	ADP
ajlm-975	106	8	participants	participant	NOUN
ajlm-975	106	9	with	with	ADP
ajlm-975	106	10	hsv-2	hsv-2	PUNCT
ajlm-975	106	11	mono	mono	NOUN
ajlm-975	106	12	-	-	PUNCT
ajlm-975	106	13	infection	infection	NOUN
ajlm-975	106	14	(	(	PUNCT
ajlm-975	106	15	p	p	X
ajlm-975	106	16	=	=	NOUN
ajlm-975	106	17	0.043	0.043	NUM
ajlm-975	106	18	)	)	PUNCT
ajlm-975	106	19	,	,	PUNCT
ajlm-975	106	20	ebv	ebv	NOUN
ajlm-975	106	21	-	-	PUNCT
ajlm-975	106	22	hsv-2	hsv-2	ADJ
ajlm-975	106	23	bi	bi	NOUN
ajlm-975	106	24	-	-	NOUN
ajlm-975	106	25	infection	infection	NOUN
ajlm-975	106	26	(	(	PUNCT
ajlm-975	106	27	p	p	NOUN
ajlm-975	106	28	=	=	NOUN
ajlm-975	106	29	0.002	0.002	NUM
ajlm-975	106	30	)	)	PUNCT
ajlm-975	106	31	,	,	PUNCT
ajlm-975	106	32	hpv	hpv	PROPN
ajlm-975	106	33	-	-	PUNCT
ajlm-975	106	34	hsv-2	hsv-2	ADJ
ajlm-975	106	35	bi	bi	NOUN
ajlm-975	106	36	-	-	NOUN
ajlm-975	106	37	infection	infection	NOUN
ajlm-975	106	38	(	(	PUNCT
ajlm-975	106	39	p	p	X
ajlm-975	106	40	=	=	NOUN
ajlm-975	106	41	0.011	0.011	NUM
ajlm-975	106	42	)	)	PUNCT
ajlm-975	106	43	,	,	PUNCT
ajlm-975	106	44	and	and	CCONJ
ajlm-975	106	45	ebv	ebv	NOUN
ajlm-975	106	46	-	-	PUNCT
ajlm-975	106	47	hpv	hpv	NOUN
ajlm-975	106	48	-	-	PUNCT
ajlm-975	106	49	hsv-2	hsv-2	PRON
ajlm-975	106	50	tri	tri	ADJ
ajlm-975	106	51	-	-	NOUN
ajlm-975	106	52	infection	infection	NOUN
ajlm-975	106	53	(	(	PUNCT
ajlm-975	106	54	p	p	NOUN
ajlm-975	106	55	=	=	NOUN
ajlm-975	106	56	0.018	0.018	NUM
ajlm-975	106	57	)	)	PUNCT
ajlm-975	106	58	was	be	AUX
ajlm-975	106	59	observed	observe	VERB
ajlm-975	106	60	when	when	SCONJ
ajlm-975	106	61	compared	compare	VERB
ajlm-975	106	62	with	with	ADP
ajlm-975	106	63	the	the	DET
ajlm-975	106	64	control	control	NOUN
ajlm-975	106	65	group	group	NOUN
ajlm-975	106	66	(	(	PUNCT
ajlm-975	106	67	figure	figure	NOUN
ajlm-975	106	68	1b	1b	NUM
ajlm-975	106	69	)	)	PUNCT
ajlm-975	106	70	.	.	PUNCT
ajlm-975	107	1	a	a	DET
ajlm-975	107	2	significant	significant	ADJ
ajlm-975	107	3	mir-155	mir-155	NOUN
ajlm-975	107	4	overexpression	overexpression	NOUN
ajlm-975	107	5	among	among	ADP
ajlm-975	107	6	participants	participant	NOUN
ajlm-975	107	7	with	with	ADP
ajlm-975	107	8	ebv	ebv	NOUN
ajlm-975	107	9	mono	mono	NOUN
ajlm-975	107	10	-	-	PUNCT
ajlm-975	107	11	infection	infection	NOUN
ajlm-975	107	12	was	be	AUX
ajlm-975	107	13	observed	observe	VERB
ajlm-975	107	14	when	when	SCONJ
ajlm-975	107	15	compared	compare	VERB
ajlm-975	107	16	with	with	ADP
ajlm-975	107	17	the	the	DET
ajlm-975	107	18	control	control	NOUN
ajlm-975	107	19	group	group	NOUN
ajlm-975	107	20	(	(	PUNCT
ajlm-975	107	21	p	p	X
ajlm-975	107	22	<	<	X
ajlm-975	107	23	0.001	0.001	NUM
ajlm-975	107	24	;	;	PUNCT
ajlm-975	107	25	figure	figure	NOUN
ajlm-975	107	26	1c	1c	NOUN
ajlm-975	107	27	)	)	PUNCT
ajlm-975	107	28	.	.	PUNCT
ajlm-975	108	1	mir-200c	mir-200c	NOUN
ajlm-975	108	2	overexpression	overexpression	NOUN
ajlm-975	108	3	in	in	ADP
ajlm-975	108	4	ebv	ebv	NOUN
ajlm-975	108	5	mono	mono	NOUN
ajlm-975	108	6	-	-	PUNCT
ajlm-975	108	7	infection	infection	NOUN
ajlm-975	108	8	(	(	PUNCT
ajlm-975	108	9	p	p	NOUN
ajlm-975	108	10	=	=	NOUN
ajlm-975	108	11	0.025	0.025	NUM
ajlm-975	108	12	)	)	PUNCT
ajlm-975	108	13	and	and	CCONJ
ajlm-975	108	14	hpv	hpv	ADJ
ajlm-975	108	15	mono	mono	NOUN
ajlm-975	108	16	-	-	PUNCT
ajlm-975	108	17	infection	infection	NOUN
ajlm-975	108	18	(	(	PUNCT
ajlm-975	108	19	p	p	X
ajlm-975	108	20	=	=	NOUN
ajlm-975	108	21	0.003	0.003	NUM
ajlm-975	108	22	)	)	PUNCT
ajlm-975	108	23	when	when	SCONJ
ajlm-975	108	24	compared	compare	VERB
ajlm-975	108	25	with	with	ADP
ajlm-975	108	26	the	the	DET
ajlm-975	108	27	control	control	NOUN
ajlm-975	108	28	group	group	NOUN
ajlm-975	108	29	was	be	AUX
ajlm-975	108	30	statistically	statistically	ADV
ajlm-975	108	31	significant	significant	ADJ
ajlm-975	108	32	(	(	PUNCT
ajlm-975	108	33	figure	figure	NOUN
ajlm-975	108	34	1d	1d	NUM
ajlm-975	108	35	)	)	PUNCT
ajlm-975	108	36	.	.	PUNCT
ajlm-975	109	1	expression	expression	NOUN
ajlm-975	109	2	of	of	ADP
ajlm-975	109	3	both	both	DET
ajlm-975	109	4	mir-21	mir-21	PROPN
ajlm-975	109	5	(	(	PUNCT
ajlm-975	109	6	figure	figure	NOUN
ajlm-975	109	7	1a	1a	NOUN
ajlm-975	109	8	)	)	PUNCT
ajlm-975	109	9	and	and	CCONJ
ajlm-975	109	10	mir-200c	mir-200c	PROPN
ajlm-975	109	11	(	(	PUNCT
ajlm-975	109	12	figure	figure	NOUN
ajlm-975	109	13	1d	1d	NUM
ajlm-975	109	14	)	)	PUNCT
ajlm-975	109	15	were	be	AUX
ajlm-975	109	16	higher	high	ADJ
ajlm-975	109	17	among	among	ADP
ajlm-975	109	18	participants	participant	NOUN
ajlm-975	109	19	with	with	ADP
ajlm-975	109	20	hpv	hpv	ADJ
ajlm-975	109	21	mono	mono	NOUN
ajlm-975	109	22	-	-	PUNCT
ajlm-975	109	23	infection	infection	NOUN
ajlm-975	109	24	than	than	ADP
ajlm-975	109	25	participants	participant	NOUN
ajlm-975	109	26	with	with	ADP
ajlm-975	109	27	other	other	ADJ
ajlm-975	109	28	viral	viral	ADJ
ajlm-975	109	29	status	status	NOUN
ajlm-975	109	30	(	(	PUNCT
ajlm-975	109	31	test	test	NOUN
ajlm-975	109	32	groups	group	NOUN
ajlm-975	109	33	)	)	PUNCT
ajlm-975	109	34	at	at	ADP
ajlm-975	109	35	p	p	NOUN
ajlm-975	109	36	=	=	PROPN
ajlm-975	109	37	0.009	0.009	NUM
ajlm-975	109	38	and	and	CCONJ
ajlm-975	109	39	p	p	NOUN
ajlm-975	109	40	=	=	PROPN
ajlm-975	109	41	0.073	0.073	NUM
ajlm-975	109	42	,	,	PUNCT
ajlm-975	109	43	respectively	respectively	ADV
ajlm-975	109	44	.	.	PUNCT
ajlm-975	110	1	in	in	ADP
ajlm-975	110	2	terms	term	NOUN
ajlm-975	110	3	of	of	ADP
ajlm-975	110	4	expression	expression	NOUN
ajlm-975	110	5	level	level	NOUN
ajlm-975	110	6	,	,	PUNCT
ajlm-975	110	7	irrespective	irrespective	ADV
ajlm-975	110	8	of	of	ADP
ajlm-975	110	9	viral	viral	ADJ
ajlm-975	110	10	status	status	NOUN
ajlm-975	110	11	,	,	PUNCT
ajlm-975	110	12	results	result	NOUN
ajlm-975	110	13	showed	show	VERB
ajlm-975	110	14	significant	significant	ADJ
ajlm-975	110	15	direct	direct	ADJ
ajlm-975	110	16	relationships	relationship	NOUN
ajlm-975	110	17	between	between	ADP
ajlm-975	110	18	mir-21	mir-21	PROPN
ajlm-975	110	19	and	and	CCONJ
ajlm-975	110	20	mir-200c	mir-200c	NOUN
ajlm-975	110	21	(	(	PUNCT
ajlm-975	110	22	p	p	X
ajlm-975	110	23	<	<	X
ajlm-975	110	24	0.001	0.001	NUM
ajlm-975	110	25	)	)	PUNCT
ajlm-975	110	26	,	,	PUNCT
ajlm-975	110	27	between	between	ADP
ajlm-975	110	28	mir-182	mir-182	NOUN
ajlm-975	110	29	and	and	CCONJ
ajlm-975	110	30	scca1	scca1	PROPN
ajlm-975	111	1	(	(	PUNCT
ajlm-975	111	2	p	p	X
ajlm-975	111	3	=	=	PROPN
ajlm-975	111	4	0.051	0.051	NUM
ajlm-975	111	5	)	)	PUNCT
ajlm-975	111	6	and	and	CCONJ
ajlm-975	111	7	between	between	ADP
ajlm-975	111	8	the	the	DET
ajlm-975	111	9	p53	p53	NOUN
ajlm-975	111	10	gene	gene	NOUN
ajlm-975	111	11	and	and	CCONJ
ajlm-975	111	12	some	some	DET
ajlm-975	111	13	mirnas	mirna	NOUN
ajlm-975	111	14	(	(	PUNCT
ajlm-975	111	15	mir-21	mir-21	PROPN
ajlm-975	111	16	,	,	PUNCT
ajlm-975	111	17	p	p	X
ajlm-975	111	18	<	<	X
ajlm-975	111	19	0.001	0.001	NUM
ajlm-975	111	20	;	;	PUNCT
ajlm-975	111	21	mir-155	mir-155	NOUN
ajlm-975	111	22	,	,	PUNCT
ajlm-975	111	23	p	p	X
ajlm-975	111	24	<	<	X
ajlm-975	111	25	0.001	0.001	NUM
ajlm-975	111	26	;	;	PUNCT
ajlm-975	111	27	mir-200c	mir-200c	NOUN
ajlm-975	111	28	,	,	PUNCT
ajlm-975	111	29	p	p	NOUN
ajlm-975	111	30	=	=	NOUN
ajlm-975	111	31	0.001	0.001	NUM
ajlm-975	111	32	)	)	PUNCT
ajlm-975	111	33	.	.	PUNCT
ajlm-975	112	1	statistically	statistically	ADV
ajlm-975	112	2	significant	significant	ADJ
ajlm-975	112	3	inverse	inverse	NOUN
ajlm-975	112	4	relationships	relationship	NOUN
ajlm-975	112	5	were	be	AUX
ajlm-975	112	6	observed	observe	VERB
ajlm-975	112	7	between	between	ADP
ajlm-975	112	8	mir-143	mir-143	NOUN
ajlm-975	112	9	and	and	CCONJ
ajlm-975	112	10	mir-200c	mir-200c	PROPN
ajlm-975	112	11	(	(	PUNCT
ajlm-975	112	12	p	p	X
ajlm-975	112	13	=	=	NOUN
ajlm-975	112	14	0.025	0.025	NUM
ajlm-975	112	15	)	)	PUNCT
ajlm-975	112	16	and	and	CCONJ
ajlm-975	112	17	between	between	ADP
ajlm-975	112	18	mir-200c	mir-200c	NOUN
ajlm-975	112	19	and	and	CCONJ
ajlm-975	112	20	cd4	cd4	PROPN
ajlm-975	112	21	+	+	PROPN
ajlm-975	112	22	t	t	PROPN
ajlm-975	112	23	-	-	PUNCT
ajlm-975	112	24	cell	cell	NOUN
ajlm-975	112	25	counts	count	NOUN
ajlm-975	112	26	(	(	PUNCT
ajlm-975	112	27	p	p	X
ajlm-975	112	28	=	=	NOUN
ajlm-975	112	29	0.048	0.048	NUM
ajlm-975	112	30	;	;	PUNCT
ajlm-975	112	31	figures	figure	NOUN
ajlm-975	112	32	1d	1d	NUM
ajlm-975	112	33	and	and	CCONJ
ajlm-975	112	34	3b	3b	NUM
ajlm-975	112	35	)	)	PUNCT
ajlm-975	112	36	.	.	PUNCT
ajlm-975	113	1	in	in	ADP
ajlm-975	113	2	terms	term	NOUN
ajlm-975	113	3	of	of	ADP
ajlm-975	113	4	virus	virus	NOUN
ajlm-975	113	5	status	status	NOUN
ajlm-975	113	6	,	,	PUNCT
ajlm-975	113	7	(	(	PUNCT
ajlm-975	113	8	infected	infected	ADJ
ajlm-975	113	9	groups	group	NOUN
ajlm-975	113	10	)	)	PUNCT
ajlm-975	113	11	,	,	PUNCT
ajlm-975	113	12	significant	significant	ADJ
ajlm-975	113	13	direct	direct	ADJ
ajlm-975	113	14	relationships	relationship	NOUN
ajlm-975	113	15	were	be	AUX
ajlm-975	113	16	observed	observe	VERB
ajlm-975	113	17	between	between	ADP
ajlm-975	113	18	mir-21	mir-21	PROPN
ajlm-975	113	19	and	and	CCONJ
ajlm-975	113	20	mir-200c	mir-200c	NOUN
ajlm-975	113	21	(	(	PUNCT
ajlm-975	113	22	p	p	X
ajlm-975	113	23	=	=	NOUN
ajlm-975	113	24	0.053	0.053	NUM
ajlm-975	113	25	)	)	PUNCT
ajlm-975	113	26	,	,	PUNCT
ajlm-975	113	27	mir-21	mir-21	PROPN
ajlm-975	113	28	and	and	CCONJ
ajlm-975	113	29	ki67	ki67	PROPN
ajlm-975	113	30	(	(	PUNCT
ajlm-975	113	31	p	p	NOUN
ajlm-975	113	32	=	=	NOUN
ajlm-975	113	33	0.045	0.045	NUM
ajlm-975	113	34	)	)	PUNCT
ajlm-975	113	35	,	,	PUNCT
ajlm-975	113	36	mir-125b	mir-125b	PROPN
ajlm-975	113	37	and	and	CCONJ
ajlm-975	113	38	mir-143	mir-143	NOUN
ajlm-975	113	39	(	(	PUNCT
ajlm-975	113	40	p	p	X
ajlm-975	113	41	<	<	X
ajlm-975	113	42	0.001	0.001	NUM
ajlm-975	113	43	)	)	PUNCT
ajlm-975	113	44	,	,	PUNCT
ajlm-975	113	45	and	and	CCONJ
ajlm-975	113	46	p53	p53	NOUN
ajlm-975	113	47	gene	gene	NOUN
ajlm-975	113	48	and	and	CCONJ
ajlm-975	113	49	mir-155	mir-155	NOUN
ajlm-975	113	50	(	(	PUNCT
ajlm-975	113	51	p	p	NOUN
ajlm-975	113	52	=	=	NOUN
ajlm-975	113	53	0.039	0.039	NUM
ajlm-975	113	54	)	)	PUNCT
ajlm-975	113	55	.	.	PUNCT
ajlm-975	114	1	significant	significant	ADJ
ajlm-975	114	2	inverse	inverse	NOUN
ajlm-975	114	3	relationships	relationship	NOUN
ajlm-975	114	4	were	be	AUX
ajlm-975	114	5	also	also	ADV
ajlm-975	114	6	observed	observe	VERB
ajlm-975	114	7	between	between	ADP
ajlm-975	114	8	mir-200c	mir-200c	NOUN
ajlm-975	114	9	and	and	CCONJ
ajlm-975	114	10	mir-143	mir-143	NOUN
ajlm-975	114	11	(	(	PUNCT
ajlm-975	114	12	p	p	NOUN
ajlm-975	114	13	=	=	NOUN
ajlm-975	114	14	0.016	0.016	NUM
ajlm-975	114	15	)	)	PUNCT
ajlm-975	114	16	,	,	PUNCT
ajlm-975	114	17	and	and	CCONJ
ajlm-975	114	18	mir-145	mir-145	NOUN
ajlm-975	114	19	and	and	CCONJ
ajlm-975	114	20	ki67	ki67	PROPN
ajlm-975	114	21	(	(	PUNCT
ajlm-975	114	22	p	p	NOUN
ajlm-975	114	23	=	=	NOUN
ajlm-975	114	24	0.001	0.001	NUM
ajlm-975	114	25	)	)	PUNCT
ajlm-975	114	26	.	.	PUNCT
ajlm-975	115	1	insignificant	insignificant	ADJ
ajlm-975	115	2	direct	direct	ADJ
ajlm-975	115	3	relationships	relationship	NOUN
ajlm-975	115	4	were	be	AUX
ajlm-975	115	5	also	also	ADV
ajlm-975	115	6	observed	observe	VERB
ajlm-975	115	7	between	between	ADP
ajlm-975	115	8	mir-21	mir-21	PROPN
ajlm-975	115	9	and	and	CCONJ
ajlm-975	115	10	p53	p53	NOUN
ajlm-975	115	11	(	(	PUNCT
ajlm-975	115	12	p	p	NOUN
ajlm-975	115	13	=	=	NOUN
ajlm-975	115	14	0.075	0.075	NUM
ajlm-975	115	15	)	)	PUNCT
ajlm-975	115	16	and	and	CCONJ
ajlm-975	115	17	mir-200c	mir-200c	NOUN
ajlm-975	115	18	and	and	CCONJ
ajlm-975	115	19	p53	p53	NOUN
ajlm-975	115	20	(	(	PUNCT
ajlm-975	115	21	p	p	NOUN
ajlm-975	115	22	=	=	NOUN
ajlm-975	115	23	0.330	0.330	NUM
ajlm-975	115	24	)	)	PUNCT
ajlm-975	115	25	,	,	PUNCT
ajlm-975	115	26	while	while	SCONJ
ajlm-975	115	27	an	an	DET
ajlm-975	115	28	insignificant	insignificant	ADJ
ajlm-975	115	29	inverse	inverse	NOUN
ajlm-975	115	30	relationship	relationship	NOUN
ajlm-975	115	31	was	be	AUX
ajlm-975	115	32	observed	observe	VERB
ajlm-975	115	33	between	between	ADP
ajlm-975	115	34	the	the	DET
ajlm-975	115	35	mir-182	mir-182	NOUN
ajlm-975	115	36	and	and	CCONJ
ajlm-975	115	37	p53	p53	NOUN
ajlm-975	115	38	gene	gene	NOUN
ajlm-975	115	39	(	(	PUNCT
ajlm-975	115	40	p	p	NOUN
ajlm-975	115	41	=	=	NOUN
ajlm-975	115	42	0.826	0.826	NUM
ajlm-975	115	43	)	)	PUNCT
ajlm-975	115	44	.	.	PUNCT
ajlm-975	116	1	expression	expression	NOUN
ajlm-975	116	2	of	of	ADP
ajlm-975	116	3	tumour	tumour	NOUN
ajlm-975	116	4	suppressors	suppressor	NOUN
ajlm-975	116	5	in	in	ADP
ajlm-975	116	6	viral	viral	ADJ
ajlm-975	116	7	infection	infection	NOUN
ajlm-975	116	8	higher	high	ADJ
ajlm-975	116	9	expression	expression	NOUN
ajlm-975	116	10	was	be	AUX
ajlm-975	116	11	observed	observe	VERB
ajlm-975	116	12	for	for	ADP
ajlm-975	116	13	mir	mir	NOUN
ajlm-975	116	14	-	-	ADJ
ajlm-975	116	15	let-7b	let-7b	NOUN
ajlm-975	116	16	in	in	ADP
ajlm-975	116	17	ebv	ebv	NOUN
ajlm-975	116	18	and	and	CCONJ
ajlm-975	116	19	hpv	hpv	ADJ
ajlm-975	116	20	bi	bi	NOUN
ajlm-975	116	21	-	-	NOUN
ajlm-975	116	22	infection	infection	NOUN
ajlm-975	116	23	(	(	PUNCT
ajlm-975	116	24	p	p	X
ajlm-975	116	25	=	=	NOUN
ajlm-975	116	26	0.315	0.315	NUM
ajlm-975	116	27	)	)	PUNCT
ajlm-975	116	28	,	,	PUNCT
ajlm-975	116	29	mir-143	mir-143	NOUN
ajlm-975	116	30	in	in	ADP
ajlm-975	116	31	ebv	ebv	PROPN
ajlm-975	116	32	-	-	PUNCT
ajlm-975	116	33	hpv	hpv	NOUN
ajlm-975	116	34	-	-	PUNCT
ajlm-975	116	35	hsv-2	hsv-2	PRON
ajlm-975	116	36	tri	tri	ADJ
ajlm-975	116	37	-	-	NOUN
ajlm-975	116	38	infection	infection	NOUN
ajlm-975	116	39	(	(	PUNCT
ajlm-975	116	40	p	p	X
ajlm-975	116	41	=	=	NOUN
ajlm-975	116	42	0.668	0.668	NUM
ajlm-975	116	43	)	)	PUNCT
ajlm-975	116	44	,	,	PUNCT
ajlm-975	116	45	mir-125b	mir-125b	NOUN
ajlm-975	116	46	in	in	ADP
ajlm-975	116	47	ebv	ebv	NOUN
ajlm-975	116	48	mono	mono	NOUN
ajlm-975	116	49	-	-	PUNCT
ajlm-975	116	50	infection	infection	NOUN
ajlm-975	116	51	(	(	PUNCT
ajlm-975	117	1	p	p	X
ajlm-975	117	2	=	=	NOUN
ajlm-975	117	3	0.450	0.450	NUM
ajlm-975	117	4	)	)	PUNCT
ajlm-975	117	5	and	and	CCONJ
ajlm-975	117	6	mir-145	mir-145	VERB
ajlm-975	117	7	in	in	ADP
ajlm-975	117	8	hsv-2	hsv-2	PUNCT
ajlm-975	117	9	mono	mono	NOUN
ajlm-975	117	10	-	-	PUNCT
ajlm-975	117	11	infection	infection	NOUN
ajlm-975	117	12	(	(	PUNCT
ajlm-975	117	13	p	p	NOUN
ajlm-975	117	14	=	=	NOUN
ajlm-975	117	15	0.002	0.002	NUM
ajlm-975	117	16	)	)	PUNCT
ajlm-975	117	17	.	.	PUNCT
ajlm-975	118	1	lower	low	ADJ
ajlm-975	118	2	expression	expression	NOUN
ajlm-975	118	3	was	be	AUX
ajlm-975	118	4	observed	observe	VERB
ajlm-975	118	5	for	for	ADP
ajlm-975	118	6	mir	mir	NOUN
ajlm-975	118	7	-	-	ADJ
ajlm-975	118	8	let-7b	let-7b	NOUN
ajlm-975	118	9	in	in	ADP
ajlm-975	118	10	ebv	ebv	NOUN
ajlm-975	118	11	mono	mono	NOUN
ajlm-975	118	12	-	-	PUNCT
ajlm-975	118	13	infection	infection	NOUN
ajlm-975	118	14	,	,	PUNCT
ajlm-975	118	15	mir-143	mir-143	NOUN
ajlm-975	118	16	in	in	ADP
ajlm-975	118	17	hpv	hpv	NOUN
ajlm-975	118	18	mono	mono	NOUN
ajlm-975	118	19	-	-	PUNCT
ajlm-975	118	20	infection	infection	NOUN
ajlm-975	118	21	and	and	CCONJ
ajlm-975	118	22	mir-125b	mir-125b	NOUN
ajlm-975	118	23	in	in	ADP
ajlm-975	118	24	hsv-2	hsv-2	PUNCT
ajlm-975	118	25	mono	mono	NOUN
ajlm-975	118	26	-	-	PUNCT
ajlm-975	118	27	infection	infection	NOUN
ajlm-975	118	28	(	(	PUNCT
ajlm-975	118	29	figure	figure	NOUN
ajlm-975	118	30	2a	2a	NUM
ajlm-975	118	31	–	–	PUNCT
ajlm-975	118	32	c	c	NOUN
ajlm-975	118	33	)	)	PUNCT
ajlm-975	118	34	,	,	PUNCT
ajlm-975	118	35	when	when	SCONJ
ajlm-975	118	36	compared	compare	VERB
ajlm-975	118	37	with	with	ADP
ajlm-975	118	38	other	other	ADJ
ajlm-975	118	39	viral	viral	ADJ
ajlm-975	118	40	mono	mono	NOUN
ajlm-975	118	41	-	-	PUNCT
ajlm-975	118	42	infections	infection	NOUN
ajlm-975	118	43	.	.	PUNCT
ajlm-975	119	1	in	in	ADP
ajlm-975	119	2	terms	term	NOUN
ajlm-975	119	3	of	of	ADP
ajlm-975	119	4	expression	expression	NOUN
ajlm-975	119	5	level	level	NOUN
ajlm-975	119	6	,	,	PUNCT
ajlm-975	119	7	significant	significant	ADJ
ajlm-975	119	8	direct	direct	ADJ
ajlm-975	119	9	correlations	correlation	NOUN
ajlm-975	119	10	were	be	AUX
ajlm-975	119	11	observed	observe	VERB
ajlm-975	119	12	between	between	ADP
ajlm-975	119	13	the	the	DET
ajlm-975	119	14	following	follow	VERB
ajlm-975	119	15	biomarkers	biomarker	NOUN
ajlm-975	119	16	:	:	PUNCT
ajlm-975	119	17	mir143	mir143	NOUN
ajlm-975	119	18	and	and	CCONJ
ajlm-975	119	19	mir-145	mir-145	NOUN
ajlm-975	119	20	(	(	PUNCT
ajlm-975	119	21	p	p	X
ajlm-975	119	22	=	=	NOUN
ajlm-975	119	23	0.041	0.041	NUM
ajlm-975	119	24	)	)	PUNCT
ajlm-975	119	25	,	,	PUNCT
ajlm-975	119	26	mir-143	mir-143	NOUN
ajlm-975	119	27	and	and	CCONJ
ajlm-975	119	28	scca1	scca1	PROPN
ajlm-975	120	1	(	(	PUNCT
ajlm-975	120	2	p	p	X
ajlm-975	120	3	=	=	NOUN
ajlm-975	120	4	0.009	0.009	NUM
ajlm-975	120	5	)	)	PUNCT
ajlm-975	120	6	,	,	PUNCT
ajlm-975	120	7	and	and	CCONJ
ajlm-975	120	8	mir-143	mir-143	NOUN
ajlm-975	120	9	and	and	CCONJ
ajlm-975	120	10	mir-125b	mir-125b	PROPN
ajlm-975	120	11	(	(	PUNCT
ajlm-975	120	12	p	p	X
ajlm-975	120	13	=	=	NOUN
ajlm-975	120	14	0.052	0.052	NUM
ajlm-975	120	15	)	)	PUNCT
ajlm-975	120	16	,	,	PUNCT
ajlm-975	120	17	irrespective	irrespective	ADV
ajlm-975	120	18	of	of	ADP
ajlm-975	120	19	viral	viral	ADJ
ajlm-975	120	20	status	status	NOUN
ajlm-975	120	21	(	(	PUNCT
ajlm-975	120	22	figure	figure	NOUN
ajlm-975	120	23	2	2	NUM
ajlm-975	120	24	)	)	PUNCT
ajlm-975	120	25	.	.	PUNCT
ajlm-975	121	1	higher	high	ADJ
ajlm-975	121	2	expression	expression	NOUN
ajlm-975	121	3	of	of	ADP
ajlm-975	121	4	p53	p53	NOUN
ajlm-975	121	5	was	be	AUX
ajlm-975	121	6	observed	observe	VERB
ajlm-975	121	7	among	among	ADP
ajlm-975	121	8	participants	participant	NOUN
ajlm-975	121	9	who	who	PRON
ajlm-975	121	10	were	be	AUX
ajlm-975	121	11	seropositive	seropositive	ADJ
ajlm-975	121	12	for	for	ADP
ajlm-975	121	13	ebv	ebv	NOUN
ajlm-975	121	14	and	and	CCONJ
ajlm-975	121	15	hpv	hpv	ADJ
ajlm-975	121	16	mono	mono	NOUN
ajlm-975	121	17	-	-	PUNCT
ajlm-975	121	18	infections	infection	NOUN
ajlm-975	121	19	(	(	PUNCT
ajlm-975	121	20	p	p	X
ajlm-975	121	21	=	=	NOUN
ajlm-975	121	22	0.014	0.014	NUM
ajlm-975	121	23	)	)	PUNCT
ajlm-975	121	24	but	but	CCONJ
ajlm-975	121	25	lower	low	ADJ
ajlm-975	121	26	among	among	ADP
ajlm-975	121	27	those	those	DET
ajlm-975	121	28	seropositive	seropositive	ADJ
ajlm-975	121	29	for	for	ADP
ajlm-975	121	30	ebv	ebv	NOUN
ajlm-975	121	31	-	-	PUNCT
ajlm-975	121	32	hpv	hpv	NOUN
ajlm-975	121	33	-	-	PUNCT
ajlm-975	121	34	hsv-2	hsv-2	ADJ
ajlm-975	121	35	tri	tri	NOUN
ajlm-975	121	36	-	-	NOUN
ajlm-975	121	37	infection	infection	NOUN
ajlm-975	121	38	when	when	SCONJ
ajlm-975	121	39	compared	compare	VERB
ajlm-975	121	40	with	with	ADP
ajlm-975	121	41	those	those	PRON
ajlm-975	121	42	who	who	PRON
ajlm-975	121	43	were	be	AUX
ajlm-975	121	44	seronegative	seronegative	ADJ
ajlm-975	121	45	for	for	ADP
ajlm-975	121	46	the	the	DET
ajlm-975	121	47	three	three	NUM
ajlm-975	121	48	viruses	virus	NOUN
ajlm-975	121	49	(	(	PUNCT
ajlm-975	121	50	figure	figure	NOUN
ajlm-975	121	51	3a	3a	NUM
ajlm-975	121	52	)	)	PUNCT
ajlm-975	121	53	.	.	PUNCT
ajlm-975	122	1	the	the	DET
ajlm-975	122	2	result	result	NOUN
ajlm-975	122	3	showed	show	VERB
ajlm-975	122	4	that	that	SCONJ
ajlm-975	122	5	hsv-2	hsv-2	ADJ
ajlm-975	122	6	-	-	PUNCT
ajlm-975	122	7	related	relate	VERB
ajlm-975	122	8	infections	infection	NOUN
ajlm-975	122	9	had	have	VERB
ajlm-975	122	10	lower	low	ADJ
ajlm-975	122	11	cd4	cd4	PROPN
ajlm-975	122	12	+	+	PROPN
ajlm-975	122	13	t	t	PROPN
ajlm-975	122	14	-	-	PUNCT
ajlm-975	122	15	cell	cell	NOUN
ajlm-975	122	16	counts	count	NOUN
ajlm-975	122	17	(	(	PUNCT
ajlm-975	122	18	p	p	X
ajlm-975	122	19	=	=	NOUN
ajlm-975	122	20	0.102	0.102	NUM
ajlm-975	122	21	;	;	PUNCT
ajlm-975	122	22	3b	3b	NUM
ajlm-975	122	23	)	)	PUNCT
ajlm-975	122	24	.	.	PUNCT
ajlm-975	123	1	higher	high	ADJ
ajlm-975	123	2	and	and	CCONJ
ajlm-975	123	3	lower	low	ADJ
ajlm-975	123	4	serum	serum	NOUN
ajlm-975	123	5	levels	level	NOUN
ajlm-975	123	6	of	of	ADP
ajlm-975	123	7	ki67	ki67	PROPN
ajlm-975	123	8	were	be	AUX
ajlm-975	123	9	observed	observe	VERB
ajlm-975	123	10	in	in	ADP
ajlm-975	123	11	hpv	hpv	NOUN
ajlm-975	123	12	and	and	CCONJ
ajlm-975	123	13	hsv-2	hsv-2	PUNCT
ajlm-975	123	14	mono	mono	NOUN
ajlm-975	123	15	-	-	PUNCT
ajlm-975	123	16	infections	infection	NOUN
ajlm-975	123	17	(	(	PUNCT
ajlm-975	123	18	p	p	NOUN
ajlm-975	123	19	=	=	NOUN
ajlm-975	123	20	0.208	0.208	NUM
ajlm-975	123	21	)	)	PUNCT
ajlm-975	123	22	,	,	PUNCT
ajlm-975	123	23	when	when	SCONJ
ajlm-975	123	24	compared	compare	VERB
ajlm-975	123	25	with	with	ADP
ajlm-975	123	26	those	those	PRON
ajlm-975	123	27	who	who	PRON
ajlm-975	123	28	were	be	AUX
ajlm-975	123	29	seronegative	seronegative	ADJ
ajlm-975	123	30	for	for	ADP
ajlm-975	123	31	the	the	DET
ajlm-975	123	32	three	three	NUM
ajlm-975	123	33	viruses	virus	NOUN
ajlm-975	123	34	(	(	PUNCT
ajlm-975	123	35	figure	figure	NOUN
ajlm-975	123	36	3c	3c	NUM
ajlm-975	123	37	)	)	PUNCT
ajlm-975	123	38	.	.	PUNCT
ajlm-975	124	1	lower	low	ADJ
ajlm-975	124	2	serum	serum	NOUN
ajlm-975	124	3	level	level	NOUN
ajlm-975	124	4	of	of	ADP
ajlm-975	124	5	scca1	scca1	NOUN
ajlm-975	124	6	was	be	AUX
ajlm-975	124	7	observed	observe	VERB
ajlm-975	124	8	in	in	ADP
ajlm-975	124	9	ebv	ebv	NOUN
ajlm-975	124	10	mono	mono	NOUN
ajlm-975	124	11	-	-	PUNCT
ajlm-975	124	12	infection	infection	NOUN
ajlm-975	124	13	compared	compare	VERB
ajlm-975	124	14	with	with	ADP
ajlm-975	124	15	other	other	ADJ
ajlm-975	124	16	groups	group	NOUN
ajlm-975	124	17	(	(	PUNCT
ajlm-975	124	18	p	p	X
ajlm-975	124	19	=	=	NOUN
ajlm-975	124	20	0.005	0.005	NUM
ajlm-975	124	21	;	;	PUNCT
ajlm-975	124	22	figure	figure	NOUN
ajlm-975	124	23	3d	3d	NUM
ajlm-975	124	24	)	)	PUNCT
ajlm-975	124	25	.	.	PUNCT
ajlm-975	125	1	expression	expression	NOUN
ajlm-975	125	2	of	of	ADP
ajlm-975	125	3	biomarkers	biomarker	NOUN
ajlm-975	125	4	in	in	ADP
ajlm-975	125	5	viral	viral	ADJ
ajlm-975	125	6	mono	mono	NOUN
ajlm-975	125	7	-	-	PUNCT
ajlm-975	125	8	infection	infection	NOUN
ajlm-975	125	9	and	and	CCONJ
ajlm-975	125	10	co	co	NOUN
ajlm-975	125	11	-	-	NOUN
ajlm-975	125	12	infection	infection	NOUN
ajlm-975	125	13	data	datum	NOUN
ajlm-975	125	14	analysis	analysis	NOUN
ajlm-975	125	15	showed	show	VERB
ajlm-975	125	16	a	a	DET
ajlm-975	125	17	higher	high	ADJ
ajlm-975	125	18	expression	expression	NOUN
ajlm-975	125	19	of	of	ADP
ajlm-975	125	20	the	the	DET
ajlm-975	125	21	mir-21	mir-21	PROPN
ajlm-975	125	22	,	,	PUNCT
ajlm-975	125	23	mir-155	mir-155	NOUN
ajlm-975	125	24	,	,	PUNCT
ajlm-975	125	25	mir-200c	mir-200c	NOUN
ajlm-975	125	26	and	and	CCONJ
ajlm-975	125	27	p53	p53	NOUN
ajlm-975	125	28	gene	gene	NOUN
ajlm-975	125	29	among	among	ADP
ajlm-975	125	30	those	those	PRON
ajlm-975	125	31	with	with	ADP
ajlm-975	125	32	viral	viral	ADJ
ajlm-975	125	33	mono	mono	NOUN
ajlm-975	125	34	-	-	PUNCT
ajlm-975	125	35	infection	infection	NOUN
ajlm-975	125	36	while	while	SCONJ
ajlm-975	125	37	a	a	DET
ajlm-975	125	38	higher	high	ADJ
ajlm-975	125	39	expression	expression	NOUN
ajlm-975	125	40	of	of	ADP
ajlm-975	125	41	mir-182	mir-182	NOUN
ajlm-975	125	42	and	and	CCONJ
ajlm-975	125	43	lower	low	ADJ
ajlm-975	125	44	cd4	cd4	PROPN
ajlm-975	125	45	+	+	PROPN
ajlm-975	125	46	t	t	PROPN
ajlm-975	125	47	-	-	PUNCT
ajlm-975	125	48	cell	cell	NOUN
ajlm-975	125	49	counts	count	NOUN
ajlm-975	125	50	were	be	AUX
ajlm-975	125	51	observed	observe	VERB
ajlm-975	125	52	among	among	ADP
ajlm-975	125	53	those	those	PRON
ajlm-975	125	54	with	with	ADP
ajlm-975	125	55	viral	viral	ADJ
ajlm-975	125	56	co	co	NOUN
ajlm-975	125	57	-	-	NOUN
ajlm-975	125	58	infection	infection	NOUN
ajlm-975	125	59	when	when	SCONJ
ajlm-975	125	60	compared	compare	VERB
ajlm-975	125	61	with	with	ADP
ajlm-975	125	62	the	the	DET
ajlm-975	125	63	control	control	NOUN
ajlm-975	125	64	group	group	NOUN
ajlm-975	125	65	(	(	PUNCT
ajlm-975	125	66	figure	figure	NOUN
ajlm-975	125	67	4	4	NUM
ajlm-975	125	68	)	)	PUNCT
ajlm-975	125	69	.	.	PUNCT
ajlm-975	126	1	the	the	DET
ajlm-975	126	2	expression	expression	NOUN
ajlm-975	126	3	of	of	ADP
ajlm-975	126	4	mir-155	mir-155	NOUN
ajlm-975	126	5	and	and	CCONJ
ajlm-975	126	6	mir-200c	mir-200c	X
ajlm-975	126	7	among	among	ADP
ajlm-975	126	8	women	woman	NOUN
ajlm-975	126	9	with	with	ADP
ajlm-975	126	10	a	a	DET
ajlm-975	126	11	viral	viral	ADJ
ajlm-975	126	12	co	co	NOUN
ajlm-975	126	13	-	-	NOUN
ajlm-975	126	14	infection	infection	NOUN
ajlm-975	126	15	were	be	AUX
ajlm-975	126	16	insignificantly	insignificantly	ADV
ajlm-975	126	17	higher	high	ADJ
ajlm-975	126	18	when	when	SCONJ
ajlm-975	126	19	compared	compare	VERB
ajlm-975	126	20	with	with	ADP
ajlm-975	126	21	their	their	PRON
ajlm-975	126	22	expression	expression	NOUN
ajlm-975	126	23	in	in	ADP
ajlm-975	126	24	non	non	ADJ
ajlm-975	126	25	-	-	ADJ
ajlm-975	126	26	infected	infected	ADJ
ajlm-975	126	27	women	woman	NOUN
ajlm-975	126	28	.	.	PUNCT
ajlm-975	127	1	individuals	individual	NOUN
ajlm-975	127	2	with	with	ADP
ajlm-975	127	3	a	a	DET
ajlm-975	127	4	viral	viral	ADJ
ajlm-975	127	5	mono	mono	NOUN
ajlm-975	127	6	-	-	PUNCT
ajlm-975	127	7	infection	infection	NOUN
ajlm-975	127	8	had	have	VERB
ajlm-975	127	9	a	a	DET
ajlm-975	127	10	higher	high	ADJ
ajlm-975	127	11	mir-145	mir-145	NOUN
ajlm-975	127	12	expression	expression	NOUN
ajlm-975	127	13	,	,	PUNCT
ajlm-975	127	14	while	while	SCONJ
ajlm-975	127	15	those	those	PRON
ajlm-975	127	16	with	with	ADP
ajlm-975	127	17	viral	viral	ADJ
ajlm-975	127	18	co	co	NOUN
ajlm-975	127	19	-	-	NOUN
ajlm-975	127	20	infection	infection	NOUN
ajlm-975	127	21	had	have	VERB
ajlm-975	127	22	a	a	DET
ajlm-975	127	23	lower	low	ADJ
ajlm-975	127	24	expression	expression	NOUN
ajlm-975	127	25	of	of	ADP
ajlm-975	127	26	mir-145	mir-145	NOUN
ajlm-975	127	27	when	when	SCONJ
ajlm-975	127	28	compared	compare	VERB
ajlm-975	127	29	with	with	ADP
ajlm-975	127	30	participants	participant	NOUN
ajlm-975	127	31	who	who	PRON
ajlm-975	127	32	were	be	AUX
ajlm-975	127	33	without	without	ADP
ajlm-975	127	34	any	any	DET
ajlm-975	127	35	viral	viral	ADJ
ajlm-975	127	36	infections	infection	NOUN
ajlm-975	127	37	(	(	PUNCT
ajlm-975	127	38	p	p	X
ajlm-975	127	39	=	=	NOUN
ajlm-975	127	40	0.015	0.015	NUM
ajlm-975	127	41	;	;	PUNCT
ajlm-975	127	42	figure	figure	NOUN
ajlm-975	127	43	4	4	NUM
ajlm-975	127	44	)	)	PUNCT
ajlm-975	127	45	.	.	PUNCT
ajlm-975	128	1	figure	figure	VERB
ajlm-975	128	2	4	4	NUM
ajlm-975	128	3	:	:	PUNCT
ajlm-975	128	4	expression	expression	NOUN
ajlm-975	128	5	of	of	ADP
ajlm-975	128	6	biomarkers	biomarker	NOUN
ajlm-975	128	7	among	among	ADP
ajlm-975	128	8	individuals	individual	NOUN
ajlm-975	128	9	with	with	ADP
ajlm-975	128	10	viral	viral	ADJ
ajlm-975	128	11	mono	mono	NOUN
ajlm-975	128	12	-	-	PUNCT
ajlm-975	128	13	infection	infection	NOUN
ajlm-975	128	14	or	or	CCONJ
ajlm-975	128	15	co	co	NOUN
ajlm-975	128	16	-	-	NOUN
ajlm-975	128	17	infection	infection	NOUN
ajlm-975	128	18	,	,	PUNCT
ajlm-975	128	19	in	in	ADP
ajlm-975	128	20	the	the	DET
ajlm-975	128	21	absence	absence	NOUN
ajlm-975	128	22	of	of	ADP
ajlm-975	128	23	the	the	DET
ajlm-975	128	24	target	target	NOUN
ajlm-975	128	25	viruses	virus	NOUN
ajlm-975	128	26	,	,	PUNCT
ajlm-975	128	27	ogun	ogun	PROPN
ajlm-975	128	28	state	state	PROPN
ajlm-975	128	29	,	,	PUNCT
ajlm-975	128	30	nigeria	nigeria	PROPN
ajlm-975	128	31	,	,	PUNCT
ajlm-975	128	32	2018	2018	NUM
ajlm-975	128	33	.	.	PUNCT
ajlm-975	129	1	expression	expression	NOUN
ajlm-975	129	2	of	of	ADP
ajlm-975	129	3	mir-21	mir-21	PROPN
ajlm-975	129	4	,	,	PUNCT
ajlm-975	129	5	mir-155	mir-155	NOUN
ajlm-975	129	6	,	,	PUNCT
ajlm-975	129	7	mir-200c	mir-200c	NOUN
ajlm-975	129	8	,	,	PUNCT
ajlm-975	129	9	p53	p53	NOUN
ajlm-975	129	10	gene	gene	NOUN
ajlm-975	129	11	and	and	CCONJ
ajlm-975	129	12	ki67	ki67	PROPN
ajlm-975	129	13	were	be	AUX
ajlm-975	129	14	higher	high	ADJ
ajlm-975	129	15	among	among	ADP
ajlm-975	129	16	participants	participant	NOUN
ajlm-975	129	17	with	with	ADP
ajlm-975	129	18	viral	viral	ADJ
ajlm-975	129	19	mono	mono	NOUN
ajlm-975	129	20	-	-	PUNCT
ajlm-975	129	21	infection	infection	NOUN
ajlm-975	129	22	than	than	ADP
ajlm-975	129	23	among	among	ADP
ajlm-975	129	24	those	those	PRON
ajlm-975	129	25	with	with	ADP
ajlm-975	129	26	viral	viral	ADJ
ajlm-975	129	27	co	co	NOUN
ajlm-975	129	28	-	-	NOUN
ajlm-975	129	29	infection	infection	NOUN
ajlm-975	129	30	;	;	PUNCT
ajlm-975	129	31	mir-182	mir-182	NOUN
ajlm-975	129	32	and	and	CCONJ
ajlm-975	129	33	mir-143	mir-143	NOUN
ajlm-975	129	34	were	be	AUX
ajlm-975	129	35	higher	high	ADJ
ajlm-975	129	36	among	among	ADP
ajlm-975	129	37	participants	participant	NOUN
ajlm-975	129	38	with	with	ADP
ajlm-975	129	39	viral	viral	ADJ
ajlm-975	129	40	co	co	NOUN
ajlm-975	129	41	-	-	NOUN
ajlm-975	129	42	infection	infection	NOUN
ajlm-975	129	43	than	than	ADP
ajlm-975	129	44	among	among	ADP
ajlm-975	129	45	those	those	PRON
ajlm-975	129	46	with	with	ADP
ajlm-975	129	47	mono	mono	NOUN
ajlm-975	129	48	-	-	PUNCT
ajlm-975	129	49	infections	infection	NOUN
ajlm-975	129	50	;	;	PUNCT
ajlm-975	129	51	mir	mir	NOUN
ajlm-975	129	52	-	-	PUNCT
ajlm-975	129	53	let-7b	let-7b	PROPN
ajlm-975	129	54	was	be	AUX
ajlm-975	129	55	lower	low	ADJ
ajlm-975	129	56	among	among	ADP
ajlm-975	129	57	participants	participant	NOUN
ajlm-975	129	58	with	with	ADP
ajlm-975	129	59	viral	viral	ADJ
ajlm-975	129	60	co	co	NOUN
ajlm-975	129	61	-	-	NOUN
ajlm-975	129	62	infection	infection	NOUN
ajlm-975	129	63	than	than	ADP
ajlm-975	129	64	among	among	ADP
ajlm-975	129	65	those	those	PRON
ajlm-975	129	66	with	with	ADP
ajlm-975	129	67	mono	mono	NOUN
ajlm-975	129	68	-	-	PUNCT
ajlm-975	129	69	infections	infection	NOUN
ajlm-975	129	70	;	;	PUNCT
ajlm-975	129	71	mir-125b	mir-125b	NOUN
ajlm-975	129	72	expression	expression	NOUN
ajlm-975	129	73	was	be	AUX
ajlm-975	129	74	higher	high	ADJ
ajlm-975	129	75	among	among	ADP
ajlm-975	129	76	participants	participant	NOUN
ajlm-975	129	77	with	with	ADP
ajlm-975	129	78	viral	viral	ADJ
ajlm-975	129	79	mono	mono	NOUN
ajlm-975	129	80	-	-	PUNCT
ajlm-975	129	81	infection	infection	NOUN
ajlm-975	129	82	than	than	ADP
ajlm-975	129	83	among	among	ADP
ajlm-975	129	84	those	those	PRON
ajlm-975	129	85	with	with	ADP
ajlm-975	129	86	viral	viral	ADJ
ajlm-975	129	87	co	co	NOUN
ajlm-975	129	88	-	-	NOUN
ajlm-975	129	89	infection	infection	NOUN
ajlm-975	129	90	;	;	PUNCT
ajlm-975	129	91	mir-145	mir-145	NOUN
ajlm-975	129	92	expression	expression	NOUN
ajlm-975	129	93	was	be	AUX
ajlm-975	129	94	higher	high	ADJ
ajlm-975	129	95	among	among	ADP
ajlm-975	129	96	participants	participant	NOUN
ajlm-975	129	97	with	with	ADP
ajlm-975	129	98	viral	viral	ADJ
ajlm-975	129	99	mono	mono	NOUN
ajlm-975	129	100	-	-	PUNCT
ajlm-975	129	101	infection	infection	NOUN
ajlm-975	129	102	and	and	CCONJ
ajlm-975	129	103	lower	low	ADJ
ajlm-975	129	104	among	among	ADP
ajlm-975	129	105	those	those	PRON
ajlm-975	129	106	with	with	ADP
ajlm-975	129	107	viral	viral	ADJ
ajlm-975	129	108	co	co	NOUN
ajlm-975	129	109	-	-	NOUN
ajlm-975	129	110	infection	infection	NOUN
ajlm-975	129	111	,	,	PUNCT
ajlm-975	129	112	cd4	cd4	PROPN
ajlm-975	129	113	+	+	PROPN
ajlm-975	129	114	t	t	PROPN
ajlm-975	129	115	-	-	PUNCT
ajlm-975	129	116	cell	cell	NOUN
ajlm-975	129	117	counts	count	NOUN
ajlm-975	129	118	was	be	AUX
ajlm-975	129	119	lower	low	ADJ
ajlm-975	129	120	among	among	ADP
ajlm-975	129	121	participants	participant	NOUN
ajlm-975	129	122	with	with	ADP
ajlm-975	129	123	viral	viral	ADJ
ajlm-975	129	124	co	co	NOUN
ajlm-975	129	125	-	-	NOUN
ajlm-975	129	126	infection	infection	NOUN
ajlm-975	129	127	than	than	ADP
ajlm-975	129	128	among	among	ADP
ajlm-975	129	129	those	those	PRON
ajlm-975	129	130	with	with	ADP
ajlm-975	129	131	viral	viral	ADJ
ajlm-975	129	132	mono	mono	NOUN
ajlm-975	129	133	-	-	PUNCT
ajlm-975	129	134	infection	infection	NOUN
ajlm-975	129	135	;	;	PUNCT
ajlm-975	129	136	scca1	scca1	NOUN
ajlm-975	129	137	level	level	NOUN
ajlm-975	129	138	was	be	AUX
ajlm-975	129	139	higher	high	ADJ
ajlm-975	129	140	among	among	ADP
ajlm-975	129	141	participants	participant	NOUN
ajlm-975	129	142	with	with	ADP
ajlm-975	129	143	viral	viral	ADJ
ajlm-975	129	144	co	co	NOUN
ajlm-975	129	145	-	-	NOUN
ajlm-975	129	146	infection	infection	NOUN
ajlm-975	129	147	and	and	CCONJ
ajlm-975	129	148	lower	low	ADJ
ajlm-975	129	149	among	among	ADP
ajlm-975	129	150	those	those	PRON
ajlm-975	129	151	with	with	ADP
ajlm-975	129	152	viral	viral	ADJ
ajlm-975	129	153	mono	mono	NOUN
ajlm-975	129	154	-	-	PUNCT
ajlm-975	129	155	infection	infection	NOUN
ajlm-975	129	156	;	;	PUNCT
ajlm-975	129	157	when	when	SCONJ
ajlm-975	129	158	compared	compare	VERB
ajlm-975	129	159	with	with	ADP
ajlm-975	129	160	those	those	PRON
ajlm-975	129	161	who	who	PRON
ajlm-975	129	162	had	have	VERB
ajlm-975	129	163	no	no	DET
ajlm-975	129	164	viral	viral	ADJ
ajlm-975	129	165	infections	infection	NOUN
ajlm-975	129	166	.	.	PUNCT
ajlm-975	130	1	discussion	discussion	NOUN
ajlm-975	130	2	this	this	DET
ajlm-975	130	3	study	study	NOUN
ajlm-975	130	4	estimated	estimate	VERB
ajlm-975	130	5	the	the	DET
ajlm-975	130	6	expression	expression	NOUN
ajlm-975	130	7	of	of	ADP
ajlm-975	130	8	normally	normally	ADV
ajlm-975	130	9	downregulated	downregulate	VERB
ajlm-975	130	10	biomarkers	biomarker	NOUN
ajlm-975	130	11	(	(	PUNCT
ajlm-975	130	12	mir-21	mir-21	PROPN
ajlm-975	130	13	,	,	PUNCT
ajlm-975	130	14	mir-155	mir-155	NOUN
ajlm-975	130	15	,	,	PUNCT
ajlm-975	130	16	mir-182	mir-182	PROPN
ajlm-975	130	17	,	,	PUNCT
ajlm-975	130	18	mir-200	mir-200	X
ajlm-975	130	19	,	,	PUNCT
ajlm-975	130	20	p53	p53	NOUN
ajlm-975	130	21	gene	gene	NOUN
ajlm-975	130	22	,	,	PUNCT
ajlm-975	130	23	ki67	ki67	PROPN
ajlm-975	130	24	and	and	CCONJ
ajlm-975	130	25	scca1	scca1	NOUN
ajlm-975	130	26	)	)	PUNCT
ajlm-975	130	27	and	and	CCONJ
ajlm-975	130	28	normally	normally	ADV
ajlm-975	130	29	upregulated	upregulated	ADJ
ajlm-975	130	30	biomarkers	biomarker	NOUN
ajlm-975	130	31	(	(	PUNCT
ajlm-975	130	32	mir	mir	NOUN
ajlm-975	130	33	-	-	ADJ
ajlm-975	130	34	let-7b	let-7b	ADJ
ajlm-975	130	35	,	,	PUNCT
ajlm-975	130	36	mir-125b	mir-125b	PROPN
ajlm-975	130	37	,	,	PUNCT
ajlm-975	130	38	mir-143	mir-143	PROPN
ajlm-975	130	39	,	,	PUNCT
ajlm-975	130	40	mir-145	mir-145	NOUN
ajlm-975	130	41	and	and	CCONJ
ajlm-975	130	42	cd4	cd4	PROPN
ajlm-975	130	43	+	+	PROPN
ajlm-975	130	44	t	t	PROPN
ajlm-975	130	45	-	-	PUNCT
ajlm-975	130	46	cells	cell	NOUN
ajlm-975	130	47	)	)	PUNCT
ajlm-975	130	48	in	in	ADP
ajlm-975	130	49	viral	viral	ADJ
ajlm-975	130	50	mono	mono	NOUN
ajlm-975	130	51	-	-	PUNCT
ajlm-975	130	52	infection	infection	NOUN
ajlm-975	130	53	through	through	ADP
ajlm-975	130	54	tri	tri	NOUN
ajlm-975	130	55	-	-	NOUN
ajlm-975	130	56	infection.6	infection.6	NOUN
ajlm-975	130	57	since	since	SCONJ
ajlm-975	130	58	overexpression	overexpression	NOUN
ajlm-975	130	59	of	of	ADP
ajlm-975	130	60	oncomirs	oncomir	NOUN
ajlm-975	130	61	and	and	CCONJ
ajlm-975	130	62	underexpression	underexpression	NOUN
ajlm-975	130	63	of	of	ADP
ajlm-975	130	64	tumour	tumour	NOUN
ajlm-975	130	65	suppressors	suppressor	NOUN
ajlm-975	130	66	are	be	AUX
ajlm-975	130	67	usually	usually	ADV
ajlm-975	130	68	found	find	VERB
ajlm-975	130	69	in	in	ADP
ajlm-975	130	70	all	all	DET
ajlm-975	130	71	cancers	cancer	NOUN
ajlm-975	130	72	,	,	PUNCT
ajlm-975	130	73	especially	especially	ADV
ajlm-975	130	74	cervical	cervical	ADJ
ajlm-975	130	75	cancer,17,18,19,20	cancer,17,18,19,20	NOUN
ajlm-975	130	76	this	this	DET
ajlm-975	130	77	study	study	NOUN
ajlm-975	130	78	compared	compare	VERB
ajlm-975	130	79	the	the	DET
ajlm-975	130	80	level	level	NOUN
ajlm-975	130	81	of	of	ADP
ajlm-975	130	82	biomarkers	biomarker	NOUN
ajlm-975	130	83	in	in	ADP
ajlm-975	130	84	groups	group	NOUN
ajlm-975	130	85	1	1	NUM
ajlm-975	130	86	to	to	PART
ajlm-975	130	87	8	8	NUM
ajlm-975	130	88	in	in	ADP
ajlm-975	130	89	a	a	DET
ajlm-975	130	90	bid	bid	NOUN
ajlm-975	130	91	to	to	PART
ajlm-975	130	92	identify	identify	VERB
ajlm-975	130	93	the	the	DET
ajlm-975	130	94	biomarkers	biomarker	NOUN
ajlm-975	130	95	that	that	PRON
ajlm-975	130	96	are	be	AUX
ajlm-975	130	97	severely	severely	ADV
ajlm-975	130	98	affected	affect	VERB
ajlm-975	130	99	by	by	ADP
ajlm-975	130	100	viral	viral	ADJ
ajlm-975	130	101	co	co	NOUN
ajlm-975	130	102	-	-	NOUN
ajlm-975	130	103	infection	infection	NOUN
ajlm-975	130	104	.	.	PUNCT
ajlm-975	131	1	although	although	SCONJ
ajlm-975	131	2	higher	high	ADJ
ajlm-975	131	3	expression	expression	NOUN
ajlm-975	131	4	of	of	ADP
ajlm-975	131	5	mir-21	mir-21	PROPN
ajlm-975	131	6	was	be	AUX
ajlm-975	131	7	observed	observe	VERB
ajlm-975	131	8	among	among	ADP
ajlm-975	131	9	participants	participant	NOUN
ajlm-975	131	10	with	with	ADP
ajlm-975	131	11	hpv	hpv	ADJ
ajlm-975	131	12	mono	mono	NOUN
ajlm-975	131	13	-	-	PUNCT
ajlm-975	131	14	infection	infection	NOUN
ajlm-975	131	15	,	,	PUNCT
ajlm-975	131	16	overexpression	overexpression	NOUN
ajlm-975	131	17	of	of	ADP
ajlm-975	131	18	mir-21	mir-21	PROPN
ajlm-975	131	19	among	among	ADP
ajlm-975	131	20	participants	participant	NOUN
ajlm-975	131	21	with	with	ADP
ajlm-975	131	22	ebv	ebv	NOUN
ajlm-975	131	23	mono	mono	NOUN
ajlm-975	131	24	-	-	PUNCT
ajlm-975	131	25	infection	infection	NOUN
ajlm-975	131	26	suggests	suggest	VERB
ajlm-975	131	27	that	that	SCONJ
ajlm-975	131	28	the	the	DET
ajlm-975	131	29	virus	virus	NOUN
ajlm-975	131	30	could	could	AUX
ajlm-975	131	31	play	play	VERB
ajlm-975	131	32	an	an	DET
ajlm-975	131	33	active	active	ADJ
ajlm-975	131	34	role	role	NOUN
ajlm-975	131	35	in	in	ADP
ajlm-975	131	36	emt	emt	PROPN
ajlm-975	131	37	as	as	ADV
ajlm-975	131	38	well	well	ADV
ajlm-975	131	39	.	.	PUNCT
ajlm-975	132	1	ebv	ebv	NOUN
ajlm-975	132	2	-	-	PUNCT
ajlm-975	132	3	hpv	hpv	NOUN
ajlm-975	132	4	bi	bi	NOUN
ajlm-975	132	5	-	-	NOUN
ajlm-975	132	6	infection	infection	NOUN
ajlm-975	132	7	was	be	AUX
ajlm-975	132	8	not	not	PART
ajlm-975	132	9	associated	associate	VERB
ajlm-975	132	10	with	with	ADP
ajlm-975	132	11	higher	high	ADJ
ajlm-975	132	12	expressed	express	VERB
ajlm-975	132	13	mir-21	mir-21	PROPN
ajlm-975	132	14	beyond	beyond	ADP
ajlm-975	132	15	that	that	PRON
ajlm-975	132	16	observed	observe	VERB
ajlm-975	132	17	in	in	ADP
ajlm-975	132	18	any	any	PRON
ajlm-975	132	19	of	of	ADP
ajlm-975	132	20	the	the	DET
ajlm-975	132	21	individual	individual	ADJ
ajlm-975	132	22	mono	mono	NOUN
ajlm-975	132	23	-	-	PUNCT
ajlm-975	132	24	infections	infection	NOUN
ajlm-975	132	25	,	,	PUNCT
ajlm-975	132	26	however	however	ADV
ajlm-975	132	27	,	,	PUNCT
ajlm-975	132	28	it	it	PRON
ajlm-975	132	29	could	could	AUX
ajlm-975	132	30	be	be	AUX
ajlm-975	132	31	inferred	infer	VERB
ajlm-975	132	32	that	that	SCONJ
ajlm-975	132	33	both	both	DET
ajlm-975	132	34	viruses	virus	NOUN
ajlm-975	132	35	synergistically	synergistically	ADV
ajlm-975	132	36	dysregulate	dysregulate	VERB
ajlm-975	132	37	mir-21	mir-21	PROPN
ajlm-975	132	38	.	.	PUNCT
ajlm-975	133	1	the	the	DET
ajlm-975	133	2	findings	finding	NOUN
ajlm-975	133	3	of	of	ADP
ajlm-975	133	4	this	this	DET
ajlm-975	133	5	study	study	NOUN
ajlm-975	133	6	revealed	reveal	VERB
ajlm-975	133	7	that	that	SCONJ
ajlm-975	133	8	hsv-2	hsv-2	ADP
ajlm-975	133	9	mono	mono	NOUN
ajlm-975	133	10	-	-	PUNCT
ajlm-975	133	11	infection	infection	NOUN
ajlm-975	133	12	was	be	AUX
ajlm-975	133	13	associated	associate	VERB
ajlm-975	133	14	with	with	ADP
ajlm-975	133	15	minimal	minimal	ADJ
ajlm-975	133	16	mir-21	mir-21	NOUN
ajlm-975	133	17	-	-	PUNCT
ajlm-975	133	18	related	relate	VERB
ajlm-975	133	19	oncogenic	oncogenic	ADJ
ajlm-975	133	20	activity	activity	NOUN
ajlm-975	133	21	when	when	SCONJ
ajlm-975	133	22	compared	compare	VERB
ajlm-975	133	23	with	with	ADP
ajlm-975	133	24	ebv	ebv	NOUN
ajlm-975	133	25	and	and	CCONJ
ajlm-975	133	26	hpv	hpv	NOUN
ajlm-975	133	27	infection	infection	NOUN
ajlm-975	133	28	.	.	PUNCT
ajlm-975	134	1	in	in	ADP
ajlm-975	134	2	other	other	ADJ
ajlm-975	134	3	words	word	NOUN
ajlm-975	134	4	,	,	PUNCT
ajlm-975	134	5	this	this	DET
ajlm-975	134	6	study	study	NOUN
ajlm-975	134	7	suggests	suggest	VERB
ajlm-975	134	8	that	that	SCONJ
ajlm-975	134	9	hsv-2	hsv-2	ADP
ajlm-975	134	10	mono	mono	NOUN
ajlm-975	134	11	-	-	PUNCT
ajlm-975	134	12	infection	infection	NOUN
ajlm-975	134	13	or	or	CCONJ
ajlm-975	134	14	its	its	PRON
ajlm-975	134	15	co	co	NOUN
ajlm-975	134	16	-	-	NOUN
ajlm-975	134	17	infection	infection	NOUN
ajlm-975	134	18	does	do	AUX
ajlm-975	134	19	not	not	PART
ajlm-975	134	20	exert	exert	VERB
ajlm-975	134	21	substantial	substantial	ADJ
ajlm-975	134	22	oncogenic	oncogenic	ADJ
ajlm-975	134	23	activity	activity	NOUN
ajlm-975	134	24	through	through	ADP
ajlm-975	134	25	mir-21	mir-21	PROPN
ajlm-975	134	26	modulation	modulation	NOUN
ajlm-975	134	27	.	.	PUNCT
ajlm-975	135	1	additionally	additionally	ADV
ajlm-975	135	2	,	,	PUNCT
ajlm-975	135	3	we	we	PRON
ajlm-975	135	4	posit	posit	VERB
ajlm-975	135	5	that	that	SCONJ
ajlm-975	135	6	the	the	DET
ajlm-975	135	7	oncogenic	oncogenic	ADJ
ajlm-975	135	8	pathway	pathway	NOUN
ajlm-975	135	9	of	of	ADP
ajlm-975	135	10	each	each	DET
ajlm-975	135	11	virus	virus	NOUN
ajlm-975	135	12	varies	vary	VERB
ajlm-975	135	13	and	and	CCONJ
ajlm-975	135	14	may	may	AUX
ajlm-975	135	15	slightly	slightly	ADV
ajlm-975	135	16	be	be	AUX
ajlm-975	135	17	counteractive	counteractive	ADJ
ajlm-975	135	18	during	during	ADP
ajlm-975	135	19	viral	viral	ADJ
ajlm-975	135	20	co	co	NOUN
ajlm-975	135	21	-	-	NOUN
ajlm-975	135	22	infection	infection	NOUN
ajlm-975	135	23	,	,	PUNCT
ajlm-975	135	24	hence	hence	ADV
ajlm-975	135	25	the	the	DET
ajlm-975	135	26	less	less	ADJ
ajlm-975	135	27	expression	expression	NOUN
ajlm-975	135	28	of	of	ADP
ajlm-975	135	29	mir-21	mir-21	PROPN
ajlm-975	135	30	and	and	CCONJ
ajlm-975	135	31	mir-155c	mir-155c	PROPN
ajlm-975	135	32	in	in	ADP
ajlm-975	135	33	viral	viral	ADJ
ajlm-975	135	34	co	co	NOUN
ajlm-975	135	35	-	-	NOUN
ajlm-975	135	36	infection	infection	NOUN
ajlm-975	135	37	.	.	PUNCT
ajlm-975	136	1	this	this	DET
ajlm-975	136	2	warrants	warrant	NOUN
ajlm-975	136	3	more	more	ADJ
ajlm-975	136	4	study	study	NOUN
ajlm-975	136	5	.	.	PUNCT
ajlm-975	137	1	in	in	ADP
ajlm-975	137	2	this	this	DET
ajlm-975	137	3	study	study	NOUN
ajlm-975	137	4	,	,	PUNCT
ajlm-975	137	5	the	the	DET
ajlm-975	137	6	overexpression	overexpression	NOUN
ajlm-975	137	7	of	of	ADP
ajlm-975	137	8	mir-200c	mir-200c	NOUN
ajlm-975	137	9	in	in	ADP
ajlm-975	137	10	ebv	ebv	NOUN
ajlm-975	137	11	mono	mono	NOUN
ajlm-975	137	12	-	-	PUNCT
ajlm-975	137	13	infection	infection	NOUN
ajlm-975	137	14	,	,	PUNCT
ajlm-975	137	15	agrees	agree	VERB
ajlm-975	137	16	with	with	ADP
ajlm-975	137	17	the	the	DET
ajlm-975	137	18	findings	finding	NOUN
ajlm-975	137	19	of	of	ADP
ajlm-975	137	20	motch	motch	PROPN
ajlm-975	137	21	et	et	PROPN
ajlm-975	137	22	al	al	PROPN
ajlm-975	137	23	.	.	PROPN
ajlm-975	137	24	which	which	PRON
ajlm-975	137	25	show	show	VERB
ajlm-975	137	26	higher	high	ADJ
ajlm-975	137	27	mir-200c	mir-200c	NOUN
ajlm-975	137	28	expression	expression	NOUN
ajlm-975	137	29	in	in	ADP
ajlm-975	137	30	ebv	ebv	NOUN
ajlm-975	137	31	-	-	PUNCT
ajlm-975	137	32	positive	positive	ADJ
ajlm-975	137	33	tumours	tumour	NOUN
ajlm-975	137	34	than	than	ADP
ajlm-975	137	35	in	in	ADP
ajlm-975	137	36	ebv	ebv	NOUN
ajlm-975	137	37	-	-	PUNCT
ajlm-975	137	38	negative	negative	ADJ
ajlm-975	137	39	tumours.17	tumours.17	NOUN
ajlm-975	137	40	the	the	DET
ajlm-975	137	41	expression	expression	NOUN
ajlm-975	137	42	of	of	ADP
ajlm-975	137	43	mir-200c	mir-200c	NOUN
ajlm-975	137	44	was	be	AUX
ajlm-975	137	45	insignificantly	insignificantly	ADV
ajlm-975	137	46	higher	high	ADJ
ajlm-975	137	47	in	in	ADP
ajlm-975	137	48	women	woman	NOUN
ajlm-975	137	49	with	with	ADP
ajlm-975	137	50	viral	viral	ADJ
ajlm-975	137	51	co	co	NOUN
ajlm-975	137	52	-	-	NOUN
ajlm-975	137	53	infection	infection	NOUN
ajlm-975	137	54	than	than	ADP
ajlm-975	137	55	in	in	ADP
ajlm-975	137	56	those	those	PRON
ajlm-975	137	57	who	who	PRON
ajlm-975	137	58	were	be	AUX
ajlm-975	137	59	uninfected	uninfected	ADJ
ajlm-975	137	60	.	.	PUNCT
ajlm-975	138	1	additionally	additionally	ADV
ajlm-975	138	2	,	,	PUNCT
ajlm-975	138	3	the	the	DET
ajlm-975	138	4	expression	expression	NOUN
ajlm-975	138	5	of	of	ADP
ajlm-975	138	6	mir200c	mir200c	PROPN
ajlm-975	138	7	was	be	AUX
ajlm-975	138	8	significantly	significantly	ADV
ajlm-975	138	9	higher	high	ADJ
ajlm-975	138	10	in	in	ADP
ajlm-975	138	11	women	woman	NOUN
ajlm-975	138	12	with	with	ADP
ajlm-975	138	13	hpv	hpv	ADJ
ajlm-975	138	14	mono	mono	NOUN
ajlm-975	138	15	-	-	PUNCT
ajlm-975	138	16	infection	infection	NOUN
ajlm-975	138	17	than	than	ADP
ajlm-975	138	18	in	in	ADP
ajlm-975	138	19	women	woman	NOUN
ajlm-975	138	20	with	with	ADP
ajlm-975	138	21	co	co	NOUN
ajlm-975	138	22	-	-	NOUN
ajlm-975	138	23	infection	infection	NOUN
ajlm-975	138	24	,	,	PUNCT
ajlm-975	138	25	including	include	VERB
ajlm-975	138	26	hsv-2	hsv-2	X
ajlm-975	138	27	mono	mono	NOUN
ajlm-975	138	28	-	-	PUNCT
ajlm-975	138	29	infection	infection	NOUN
ajlm-975	138	30	.	.	PUNCT
ajlm-975	139	1	this	this	PRON
ajlm-975	139	2	also	also	ADV
ajlm-975	139	3	suggests	suggest	VERB
ajlm-975	139	4	that	that	SCONJ
ajlm-975	139	5	mir-200c	mir-200c	NOUN
ajlm-975	139	6	does	do	AUX
ajlm-975	139	7	not	not	PART
ajlm-975	139	8	play	play	VERB
ajlm-975	139	9	any	any	DET
ajlm-975	139	10	active	active	ADJ
ajlm-975	139	11	roles	role	NOUN
ajlm-975	139	12	in	in	ADP
ajlm-975	139	13	oncogenicity	oncogenicity	NOUN
ajlm-975	139	14	associated	associate	VERB
ajlm-975	139	15	with	with	ADP
ajlm-975	139	16	viral	viral	ADJ
ajlm-975	139	17	co	co	NOUN
ajlm-975	139	18	-	-	NOUN
ajlm-975	139	19	infection	infection	NOUN
ajlm-975	139	20	.	.	PUNCT
ajlm-975	140	1	the	the	DET
ajlm-975	140	2	reason	reason	NOUN
ajlm-975	140	3	for	for	ADP
ajlm-975	140	4	this	this	PRON
ajlm-975	140	5	is	be	AUX
ajlm-975	140	6	still	still	ADV
ajlm-975	140	7	unknown	unknown	ADJ
ajlm-975	140	8	,	,	PUNCT
ajlm-975	140	9	but	but	CCONJ
ajlm-975	140	10	it	it	PRON
ajlm-975	140	11	could	could	AUX
ajlm-975	140	12	be	be	AUX
ajlm-975	140	13	related	relate	VERB
ajlm-975	140	14	to	to	ADP
ajlm-975	140	15	differences	difference	NOUN
ajlm-975	140	16	in	in	ADP
ajlm-975	140	17	the	the	DET
ajlm-975	140	18	mirna	mirna	PROPN
ajlm-975	140	19	regulatory	regulatory	ADJ
ajlm-975	140	20	pathway	pathway	NOUN
ajlm-975	140	21	or	or	CCONJ
ajlm-975	140	22	the	the	DET
ajlm-975	140	23	targeted	target	VERB
ajlm-975	140	24	protein	protein	NOUN
ajlm-975	140	25	of	of	ADP
ajlm-975	140	26	the	the	DET
ajlm-975	140	27	investigated	investigate	VERB
ajlm-975	140	28	viruses	virus	NOUN
ajlm-975	140	29	.	.	PUNCT
ajlm-975	141	1	the	the	DET
ajlm-975	141	2	high	high	ADJ
ajlm-975	141	3	expression	expression	NOUN
ajlm-975	141	4	of	of	ADP
ajlm-975	141	5	mir-200c	mir-200c	NOUN
ajlm-975	141	6	in	in	ADP
ajlm-975	141	7	hpv	hpv	ADJ
ajlm-975	141	8	mono	mono	NOUN
ajlm-975	141	9	-	-	PUNCT
ajlm-975	141	10	infection	infection	NOUN
ajlm-975	141	11	could	could	AUX
ajlm-975	141	12	be	be	AUX
ajlm-975	141	13	due	due	ADJ
ajlm-975	141	14	to	to	ADP
ajlm-975	141	15	its	its	PRON
ajlm-975	141	16	tumourigenic	tumourigenic	NOUN
ajlm-975	141	17	e6	e6	PROPN
ajlm-975	141	18	/	/	SYM
ajlm-975	141	19	e7	e7	PROPN
ajlm-975	141	20	protein.18	protein.18	NOUN
ajlm-975	141	21	again	again	ADV
ajlm-975	141	22	,	,	PUNCT
ajlm-975	141	23	hsv-2	hsv-2	PUNCT
ajlm-975	141	24	infection	infection	NOUN
ajlm-975	141	25	was	be	AUX
ajlm-975	141	26	not	not	PART
ajlm-975	141	27	associated	associate	VERB
ajlm-975	141	28	with	with	ADP
ajlm-975	141	29	substantial	substantial	ADJ
ajlm-975	141	30	dysregulation	dysregulation	NOUN
ajlm-975	141	31	of	of	ADP
ajlm-975	141	32	mir-200c	mir-200c	NOUN
ajlm-975	141	33	.	.	PUNCT
ajlm-975	142	1	thus	thus	ADV
ajlm-975	142	2	,	,	PUNCT
ajlm-975	142	3	it	it	PRON
ajlm-975	142	4	could	could	AUX
ajlm-975	142	5	be	be	AUX
ajlm-975	142	6	inferred	infer	VERB
ajlm-975	142	7	that	that	SCONJ
ajlm-975	142	8	mir-200c	mir-200c	NOUN
ajlm-975	142	9	is	be	AUX
ajlm-975	142	10	not	not	PART
ajlm-975	142	11	directly	directly	ADV
ajlm-975	142	12	involved	involve	VERB
ajlm-975	142	13	in	in	ADP
ajlm-975	142	14	hsv-2	hsv-2	ADV
ajlm-975	142	15	-	-	ADJ
ajlm-975	142	16	associated	associated	ADJ
ajlm-975	142	17	cervical	cervical	ADJ
ajlm-975	142	18	carcinogenesis	carcinogenesis	NOUN
ajlm-975	142	19	.	.	PUNCT
ajlm-975	143	1	in	in	ADP
ajlm-975	143	2	this	this	DET
ajlm-975	143	3	study	study	NOUN
ajlm-975	143	4	,	,	PUNCT
ajlm-975	143	5	the	the	DET
ajlm-975	143	6	significant	significant	ADJ
ajlm-975	143	7	overexpression	overexpression	NOUN
ajlm-975	143	8	of	of	ADP
ajlm-975	143	9	mir-155	mir-155	NOUN
ajlm-975	143	10	only	only	ADV
ajlm-975	143	11	in	in	ADP
ajlm-975	143	12	ebv	ebv	NOUN
ajlm-975	143	13	mono	mono	NOUN
ajlm-975	143	14	-	-	PUNCT
ajlm-975	143	15	infection	infection	NOUN
ajlm-975	143	16	suggests	suggest	VERB
ajlm-975	143	17	that	that	SCONJ
ajlm-975	143	18	the	the	DET
ajlm-975	143	19	mirna	mirna	PROPN
ajlm-975	143	20	expression	expression	NOUN
ajlm-975	143	21	could	could	AUX
ajlm-975	143	22	be	be	AUX
ajlm-975	143	23	virus	virus	NOUN
ajlm-975	143	24	dependent	dependent	ADJ
ajlm-975	143	25	and	and	CCONJ
ajlm-975	143	26	also	also	ADV
ajlm-975	143	27	could	could	AUX
ajlm-975	143	28	be	be	AUX
ajlm-975	143	29	an	an	DET
ajlm-975	143	30	early	early	ADJ
ajlm-975	143	31	indication	indication	NOUN
ajlm-975	143	32	of	of	ADP
ajlm-975	143	33	ebv	ebv	NOUN
ajlm-975	143	34	infection	infection	NOUN
ajlm-975	143	35	,	,	PUNCT
ajlm-975	143	36	immune	immune	ADJ
ajlm-975	143	37	activation	activation	NOUN
ajlm-975	143	38	,	,	PUNCT
ajlm-975	143	39	genetic	genetic	ADJ
ajlm-975	143	40	instability	instability	NOUN
ajlm-975	143	41	or	or	CCONJ
ajlm-975	143	42	imminent	imminent	ADJ
ajlm-975	143	43	tumourigenesis.19,20	tumourigenesis.19,20	NOUN
ajlm-975	143	44	an	an	DET
ajlm-975	143	45	inverse	inverse	NOUN
ajlm-975	143	46	relationship	relationship	NOUN
ajlm-975	143	47	was	be	AUX
ajlm-975	143	48	observed	observe	VERB
ajlm-975	143	49	between	between	ADP
ajlm-975	143	50	mir-155	mir-155	NOUN
ajlm-975	143	51	and	and	CCONJ
ajlm-975	143	52	mir	mir	ADJ
ajlm-975	143	53	-	-	ADJ
ajlm-975	143	54	let-7b	let-7b	ADJ
ajlm-975	143	55	expression	expression	NOUN
ajlm-975	143	56	in	in	ADP
ajlm-975	143	57	ebv	ebv	NOUN
ajlm-975	143	58	mono	mono	NOUN
ajlm-975	143	59	-	-	PUNCT
ajlm-975	143	60	infection	infection	NOUN
ajlm-975	143	61	.	.	PUNCT
ajlm-975	144	1	this	this	PRON
ajlm-975	144	2	is	be	AUX
ajlm-975	144	3	in	in	ADP
ajlm-975	144	4	line	line	NOUN
ajlm-975	144	5	with	with	ADP
ajlm-975	144	6	the	the	DET
ajlm-975	144	7	findings	finding	NOUN
ajlm-975	144	8	of	of	ADP
ajlm-975	144	9	an	an	DET
ajlm-975	144	10	earlier	early	ADJ
ajlm-975	144	11	study	study	NOUN
ajlm-975	144	12	which	which	PRON
ajlm-975	144	13	show	show	VERB
ajlm-975	144	14	that	that	SCONJ
ajlm-975	144	15	the	the	DET
ajlm-975	144	16	expression	expression	NOUN
ajlm-975	144	17	of	of	ADP
ajlm-975	144	18	the	the	DET
ajlm-975	144	19	let-7	let-7	ADJ
ajlm-975	144	20	family	family	NOUN
ajlm-975	144	21	is	be	AUX
ajlm-975	144	22	suppressed	suppress	VERB
ajlm-975	144	23	in	in	ADP
ajlm-975	144	24	ebv	ebv	NOUN
ajlm-975	144	25	-	-	PUNCT
ajlm-975	144	26	associated	associate	VERB
ajlm-975	144	27	cervical	cervical	ADJ
ajlm-975	144	28	cancer.21	cancer.21	NOUN
ajlm-975	144	29	since	since	SCONJ
ajlm-975	144	30	studies	study	NOUN
ajlm-975	144	31	have	have	AUX
ajlm-975	144	32	shown	show	VERB
ajlm-975	144	33	that	that	SCONJ
ajlm-975	144	34	hpv	hpv	PROPN
ajlm-975	144	35	induces	induce	VERB
ajlm-975	144	36	genetic	genetic	ADJ
ajlm-975	144	37	instability	instability	NOUN
ajlm-975	144	38	and	and	CCONJ
ajlm-975	144	39	emt	emt	PROPN
ajlm-975	144	40	by	by	ADP
ajlm-975	144	41	upregulating	upregulating	ADJ
ajlm-975	144	42	mir-182	mir-182	NOUN
ajlm-975	144	43	,	,	PUNCT
ajlm-975	144	44	it	it	PRON
ajlm-975	144	45	could	could	AUX
ajlm-975	144	46	be	be	AUX
ajlm-975	144	47	inferred	infer	VERB
ajlm-975	144	48	that	that	SCONJ
ajlm-975	144	49	hsv-2	hsv-2	PRON
ajlm-975	144	50	plays	play	VERB
ajlm-975	144	51	a	a	DET
ajlm-975	144	52	similar	similar	ADJ
ajlm-975	144	53	role	role	NOUN
ajlm-975	144	54	in	in	ADP
ajlm-975	144	55	cervical	cervical	ADJ
ajlm-975	144	56	carcinogenesis	carcinogenesis	NOUN
ajlm-975	144	57	by	by	ADP
ajlm-975	144	58	upregulating	upregulating	NOUN
ajlm-975	144	59	mir-182.18,22	mir-182.18,22	PROPN
ajlm-975	144	60	the	the	DET
ajlm-975	144	61	higher	high	ADJ
ajlm-975	144	62	upregulation	upregulation	NOUN
ajlm-975	144	63	of	of	ADP
ajlm-975	144	64	mir-182	mir-182	NOUN
ajlm-975	144	65	in	in	ADP
ajlm-975	144	66	viral	viral	ADJ
ajlm-975	144	67	co	co	NOUN
ajlm-975	144	68	-	-	NOUN
ajlm-975	144	69	infection	infection	NOUN
ajlm-975	144	70	when	when	SCONJ
ajlm-975	144	71	compared	compare	VERB
ajlm-975	144	72	with	with	ADP
ajlm-975	144	73	viral	viral	ADJ
ajlm-975	144	74	mono	mono	NOUN
ajlm-975	144	75	-	-	PUNCT
ajlm-975	144	76	infection	infection	NOUN
ajlm-975	144	77	suggests	suggest	VERB
ajlm-975	144	78	that	that	SCONJ
ajlm-975	144	79	ebv	ebv	NOUN
ajlm-975	144	80	,	,	PUNCT
ajlm-975	144	81	hpv	hpv	NOUN
ajlm-975	144	82	and	and	CCONJ
ajlm-975	144	83	hsv-2	hsv-2	PUNCT
ajlm-975	144	84	co	co	NOUN
ajlm-975	144	85	-	-	NOUN
ajlm-975	144	86	infection	infection	NOUN
ajlm-975	144	87	synergistically	synergistically	ADV
ajlm-975	144	88	modulates	modulate	VERB
ajlm-975	144	89	the	the	DET
ajlm-975	144	90	biomarker	biomarker	NOUN
ajlm-975	144	91	,	,	PUNCT
ajlm-975	144	92	possibly	possibly	ADV
ajlm-975	144	93	through	through	ADP
ajlm-975	144	94	a	a	DET
ajlm-975	144	95	similar	similar	ADJ
ajlm-975	144	96	target	target	NOUN
ajlm-975	144	97	protein	protein	NOUN
ajlm-975	144	98	.	.	PUNCT
ajlm-975	145	1	the	the	DET
ajlm-975	145	2	triple	triple	ADJ
ajlm-975	145	3	impact	impact	NOUN
ajlm-975	145	4	of	of	ADP
ajlm-975	145	5	the	the	DET
ajlm-975	145	6	viruses	virus	NOUN
ajlm-975	145	7	also	also	ADV
ajlm-975	145	8	suggests	suggest	VERB
ajlm-975	145	9	that	that	SCONJ
ajlm-975	145	10	the	the	DET
ajlm-975	145	11	rate	rate	NOUN
ajlm-975	145	12	of	of	ADP
ajlm-975	145	13	emt	emt	PROPN
ajlm-975	145	14	could	could	AUX
ajlm-975	145	15	be	be	AUX
ajlm-975	145	16	faster	fast	ADJ
ajlm-975	145	17	in	in	ADP
ajlm-975	145	18	women	woman	NOUN
ajlm-975	145	19	with	with	ADP
ajlm-975	145	20	viral	viral	ADJ
ajlm-975	145	21	co	co	NOUN
ajlm-975	145	22	-	-	NOUN
ajlm-975	145	23	infection	infection	NOUN
ajlm-975	145	24	than	than	ADP
ajlm-975	145	25	in	in	ADP
ajlm-975	145	26	women	woman	NOUN
ajlm-975	145	27	with	with	ADP
ajlm-975	145	28	mono	mono	NOUN
ajlm-975	145	29	-	-	PUNCT
ajlm-975	145	30	infection	infection	NOUN
ajlm-975	145	31	.	.	PUNCT
ajlm-975	146	1	again	again	ADV
ajlm-975	146	2	,	,	PUNCT
ajlm-975	146	3	further	further	ADJ
ajlm-975	146	4	studies	study	NOUN
ajlm-975	146	5	are	be	AUX
ajlm-975	146	6	required	require	VERB
ajlm-975	146	7	.	.	PUNCT
ajlm-975	147	1	the	the	DET
ajlm-975	147	2	findings	finding	NOUN
ajlm-975	147	3	of	of	ADP
ajlm-975	147	4	the	the	DET
ajlm-975	147	5	current	current	ADJ
ajlm-975	147	6	study	study	NOUN
ajlm-975	147	7	also	also	ADV
ajlm-975	147	8	revealed	reveal	VERB
ajlm-975	147	9	that	that	SCONJ
ajlm-975	147	10	,	,	PUNCT
ajlm-975	147	11	although	although	SCONJ
ajlm-975	147	12	not	not	PART
ajlm-975	147	13	statistically	statistically	ADV
ajlm-975	147	14	significant	significant	ADJ
ajlm-975	147	15	,	,	PUNCT
ajlm-975	147	16	the	the	DET
ajlm-975	147	17	expression	expression	NOUN
ajlm-975	147	18	of	of	ADP
ajlm-975	147	19	ki67	ki67	PROPN
ajlm-975	147	20	and	and	CCONJ
ajlm-975	147	21	scca1	scca1	NOUN
ajlm-975	147	22	was	be	AUX
ajlm-975	147	23	relatively	relatively	ADV
ajlm-975	147	24	higher	high	ADJ
ajlm-975	147	25	among	among	ADP
ajlm-975	147	26	participants	participant	NOUN
ajlm-975	147	27	with	with	ADP
ajlm-975	147	28	a	a	DET
ajlm-975	147	29	viral	viral	ADJ
ajlm-975	147	30	infection	infection	NOUN
ajlm-975	147	31	and	and	CCONJ
ajlm-975	147	32	that	that	SCONJ
ajlm-975	147	33	a	a	DET
ajlm-975	147	34	significant	significant	ADJ
ajlm-975	147	35	increase	increase	NOUN
ajlm-975	147	36	in	in	ADP
ajlm-975	147	37	these	these	DET
ajlm-975	147	38	biomarkers	biomarker	NOUN
ajlm-975	147	39	could	could	AUX
ajlm-975	147	40	be	be	AUX
ajlm-975	147	41	indicative	indicative	ADJ
ajlm-975	147	42	of	of	ADP
ajlm-975	147	43	cancer	cancer	NOUN
ajlm-975	147	44	.	.	PUNCT
ajlm-975	148	1	viruses	virus	NOUN
ajlm-975	148	2	,	,	PUNCT
ajlm-975	148	3	individually	individually	ADV
ajlm-975	148	4	or	or	CCONJ
ajlm-975	148	5	synergistically	synergistically	ADV
ajlm-975	148	6	,	,	PUNCT
ajlm-975	148	7	have	have	AUX
ajlm-975	148	8	developed	develop	VERB
ajlm-975	148	9	unique	unique	ADJ
ajlm-975	148	10	mechanisms	mechanism	NOUN
ajlm-975	148	11	for	for	ADP
ajlm-975	148	12	hijacking	hijacking	NOUN
ajlm-975	148	13	or	or	CCONJ
ajlm-975	148	14	inhibiting	inhibit	VERB
ajlm-975	148	15	the	the	DET
ajlm-975	148	16	tumour	tumour	ADJ
ajlm-975	148	17	suppressive	suppressive	ADJ
ajlm-975	148	18	functions	function	NOUN
ajlm-975	148	19	of	of	ADP
ajlm-975	148	20	wildtype	wildtype	NOUN
ajlm-975	148	21	p53.23	p53.23	PROPN
ajlm-975	148	22	since	since	SCONJ
ajlm-975	148	23	there	there	PRON
ajlm-975	148	24	were	be	VERB
ajlm-975	148	25	direct	direct	ADJ
ajlm-975	148	26	relationships	relationship	NOUN
ajlm-975	148	27	between	between	ADP
ajlm-975	148	28	the	the	DET
ajlm-975	148	29	p53	p53	NOUN
ajlm-975	148	30	gene	gene	NOUN
ajlm-975	148	31	,	,	PUNCT
ajlm-975	148	32	mir-21	mir-21	PROPN
ajlm-975	148	33	and	and	CCONJ
ajlm-975	148	34	mir-200c	mir-200c	NOUN
ajlm-975	148	35	in	in	ADP
ajlm-975	148	36	terms	term	NOUN
ajlm-975	148	37	of	of	ADP
ajlm-975	148	38	viral	viral	ADJ
ajlm-975	148	39	infection	infection	NOUN
ajlm-975	148	40	,	,	PUNCT
ajlm-975	148	41	the	the	DET
ajlm-975	148	42	higher	high	ADJ
ajlm-975	148	43	expression	expression	NOUN
ajlm-975	148	44	of	of	ADP
ajlm-975	148	45	the	the	DET
ajlm-975	148	46	p53	p53	NOUN
ajlm-975	148	47	gene	gene	NOUN
ajlm-975	148	48	(	(	PUNCT
ajlm-975	148	49	tumour	tumour	NOUN
ajlm-975	148	50	suppressor	suppressor	NOUN
ajlm-975	148	51	)	)	PUNCT
ajlm-975	148	52	in	in	ADP
ajlm-975	148	53	participants	participant	NOUN
ajlm-975	148	54	with	with	ADP
ajlm-975	148	55	ebv	ebv	NOUN
ajlm-975	148	56	and	and	CCONJ
ajlm-975	148	57	hpv	hpv	NOUN
ajlm-975	148	58	mono	mono	NOUN
ajlm-975	148	59	-	-	PUNCT
ajlm-975	148	60	infections	infection	NOUN
ajlm-975	148	61	could	could	AUX
ajlm-975	148	62	be	be	AUX
ajlm-975	148	63	an	an	DET
ajlm-975	148	64	immunologic	immunologic	ADJ
ajlm-975	148	65	response	response	NOUN
ajlm-975	148	66	to	to	ADP
ajlm-975	148	67	higher	high	ADJ
ajlm-975	148	68	mir-21	mir-21	PROPN
ajlm-975	148	69	and	and	CCONJ
ajlm-975	148	70	mir-200c	mir-200c	PROPN
ajlm-975	148	71	(	(	PUNCT
ajlm-975	148	72	oncogenes	oncogene	NOUN
ajlm-975	148	73	)	)	PUNCT
ajlm-975	148	74	among	among	ADP
ajlm-975	148	75	participants	participant	NOUN
ajlm-975	148	76	with	with	ADP
ajlm-975	148	77	mono	mono	NOUN
ajlm-975	148	78	-	-	PUNCT
ajlm-975	148	79	infection	infection	NOUN
ajlm-975	148	80	.	.	PUNCT
ajlm-975	149	1	this	this	PRON
ajlm-975	149	2	could	could	AUX
ajlm-975	149	3	be	be	AUX
ajlm-975	149	4	an	an	DET
ajlm-975	149	5	early	early	ADJ
ajlm-975	149	6	indicator	indicator	NOUN
ajlm-975	149	7	of	of	ADP
ajlm-975	149	8	cell	cell	NOUN
ajlm-975	149	9	cycle	cycle	NOUN
ajlm-975	149	10	dysregulation	dysregulation	NOUN
ajlm-975	149	11	.	.	PUNCT
ajlm-975	150	1	this	this	DET
ajlm-975	150	2	higher	high	ADJ
ajlm-975	150	3	expression	expression	NOUN
ajlm-975	150	4	of	of	ADP
ajlm-975	150	5	the	the	DET
ajlm-975	150	6	p53	p53	NOUN
ajlm-975	150	7	gene	gene	NOUN
ajlm-975	150	8	in	in	ADP
ajlm-975	150	9	hpv	hpv	ADJ
ajlm-975	150	10	mono	mono	NOUN
ajlm-975	150	11	-	-	PUNCT
ajlm-975	150	12	infection	infection	NOUN
ajlm-975	150	13	was	be	AUX
ajlm-975	150	14	also	also	ADV
ajlm-975	150	15	observed	observe	VERB
ajlm-975	150	16	by	by	ADP
ajlm-975	150	17	zatonski	zatonski	PROPN
ajlm-975	150	18	et	et	PROPN
ajlm-975	150	19	al.24	al.24	PROPN
ajlm-975	150	20	continual	continual	ADJ
ajlm-975	150	21	reduction	reduction	NOUN
ajlm-975	150	22	in	in	ADP
ajlm-975	150	23	its	its	PRON
ajlm-975	150	24	expression	expression	NOUN
ajlm-975	150	25	or	or	CCONJ
ajlm-975	150	26	its	its	PRON
ajlm-975	150	27	mutation	mutation	NOUN
ajlm-975	150	28	during	during	ADP
ajlm-975	150	29	viral	viral	ADJ
ajlm-975	150	30	co	co	NOUN
ajlm-975	150	31	-	-	NOUN
ajlm-975	150	32	infection	infection	NOUN
ajlm-975	150	33	due	due	ADP
ajlm-975	150	34	to	to	ADP
ajlm-975	150	35	immune	immune	ADJ
ajlm-975	150	36	exhaustion	exhaustion	NOUN
ajlm-975	150	37	,	,	PUNCT
ajlm-975	150	38	as	as	SCONJ
ajlm-975	150	39	seen	see	VERB
ajlm-975	150	40	in	in	ADP
ajlm-975	150	41	this	this	DET
ajlm-975	150	42	study	study	NOUN
ajlm-975	150	43	,	,	PUNCT
ajlm-975	150	44	or	or	CCONJ
ajlm-975	150	45	underexpression	underexpression	NOUN
ajlm-975	150	46	may	may	AUX
ajlm-975	150	47	trigger	trigger	VERB
ajlm-975	150	48	cervical	cervical	ADJ
ajlm-975	150	49	carcinogenesis	carcinogenesis	NOUN
ajlm-975	150	50	.	.	PUNCT
ajlm-975	151	1	microrna-125b	microrna-125b	PROPN
ajlm-975	151	2	is	be	AUX
ajlm-975	151	3	abundantly	abundantly	ADV
ajlm-975	151	4	expressed	express	VERB
ajlm-975	151	5	in	in	ADP
ajlm-975	151	6	the	the	DET
ajlm-975	151	7	healthy	healthy	ADJ
ajlm-975	151	8	cervix	cervix	NOUN
ajlm-975	151	9	.	.	PUNCT
ajlm-975	152	1	it	it	PRON
ajlm-975	152	2	increases	increase	VERB
ajlm-975	152	3	shortly	shortly	ADV
ajlm-975	152	4	after	after	ADP
ajlm-975	152	5	hpv	hpv	ADJ
ajlm-975	152	6	infection	infection	NOUN
ajlm-975	152	7	and	and	CCONJ
ajlm-975	152	8	is	be	AUX
ajlm-975	152	9	inactivated	inactivate	VERB
ajlm-975	152	10	or	or	CCONJ
ajlm-975	152	11	relatively	relatively	ADV
ajlm-975	152	12	decreased	decrease	VERB
ajlm-975	152	13	as	as	SCONJ
ajlm-975	152	14	cancer	cancer	NOUN
ajlm-975	152	15	develops.25,26	develops.25,26	NOUN
ajlm-975	152	16	decreases	decrease	VERB
ajlm-975	152	17	in	in	ADP
ajlm-975	152	18	mir-125b	mir-125b	NOUN
ajlm-975	152	19	expression	expression	NOUN
ajlm-975	152	20	and	and	CCONJ
ajlm-975	152	21	the	the	DET
ajlm-975	152	22	development	development	NOUN
ajlm-975	152	23	of	of	ADP
ajlm-975	152	24	cancer	cancer	NOUN
ajlm-975	152	25	may	may	AUX
ajlm-975	152	26	occur	occur	VERB
ajlm-975	152	27	due	due	ADJ
ajlm-975	152	28	to	to	ADP
ajlm-975	152	29	viral	viral	ADJ
ajlm-975	152	30	co	co	NOUN
ajlm-975	152	31	-	-	NOUN
ajlm-975	152	32	infection	infection	NOUN
ajlm-975	152	33	,	,	PUNCT
ajlm-975	152	34	especially	especially	ADV
ajlm-975	152	35	ebv	ebv	NOUN
ajlm-975	152	36	-	-	PUNCT
ajlm-975	152	37	hpv	hpv	NOUN
ajlm-975	152	38	-	-	PUNCT
ajlm-975	152	39	hsv-2	hsv-2	PRON
ajlm-975	152	40	co	co	NOUN
ajlm-975	152	41	-	-	NOUN
ajlm-975	152	42	presence	presence	NOUN
ajlm-975	152	43	.	.	PUNCT
ajlm-975	153	1	underexpression	underexpression	NOUN
ajlm-975	153	2	of	of	ADP
ajlm-975	153	3	mir-143	mir-143	PROPN
ajlm-975	153	4	and	and	CCONJ
ajlm-975	153	5	mir-145	mir-145	PROPN
ajlm-975	153	6	has	have	AUX
ajlm-975	153	7	also	also	ADV
ajlm-975	153	8	been	be	AUX
ajlm-975	153	9	reported	report	VERB
ajlm-975	153	10	in	in	ADP
ajlm-975	153	11	cervical	cervical	ADJ
ajlm-975	153	12	cancer	cancer	NOUN
ajlm-975	153	13	,	,	PUNCT
ajlm-975	153	14	especially	especially	ADV
ajlm-975	153	15	in	in	ADP
ajlm-975	153	16	the	the	DET
ajlm-975	153	17	presence	presence	NOUN
ajlm-975	153	18	of	of	ADP
ajlm-975	153	19	hpv	hpv	PROPN
ajlm-975	153	20	type	type	NOUN
ajlm-975	153	21	31	31	NUM
ajlm-975	153	22	e7	e7	PROPN
ajlm-975	153	23	oncoprotein.18,27,28,29	oncoprotein.18,27,28,29	ADV
ajlm-975	153	24	in	in	ADP
ajlm-975	153	25	this	this	DET
ajlm-975	153	26	study	study	NOUN
ajlm-975	153	27	,	,	PUNCT
ajlm-975	153	28	while	while	SCONJ
ajlm-975	153	29	mir-143	mir-143	PROPN
ajlm-975	153	30	overexpression	overexpression	NOUN
ajlm-975	153	31	was	be	AUX
ajlm-975	153	32	associated	associate	VERB
ajlm-975	153	33	with	with	ADP
ajlm-975	153	34	viral	viral	ADJ
ajlm-975	153	35	co	co	NOUN
ajlm-975	153	36	-	-	NOUN
ajlm-975	153	37	infection	infection	NOUN
ajlm-975	153	38	,	,	PUNCT
ajlm-975	153	39	mir-145	mir-145	PROPN
ajlm-975	153	40	underexpression	underexpression	NOUN
ajlm-975	153	41	was	be	AUX
ajlm-975	153	42	associated	associate	VERB
ajlm-975	153	43	with	with	ADP
ajlm-975	153	44	viral	viral	ADJ
ajlm-975	153	45	co	co	NOUN
ajlm-975	153	46	-	-	NOUN
ajlm-975	153	47	infection	infection	NOUN
ajlm-975	153	48	,	,	PUNCT
ajlm-975	153	49	irrespective	irrespective	ADV
ajlm-975	153	50	of	of	ADP
ajlm-975	153	51	hsv-2	hsv-2	X
ajlm-975	153	52	status	status	NOUN
ajlm-975	153	53	.	.	PUNCT
ajlm-975	154	1	this	this	PRON
ajlm-975	154	2	suggests	suggest	VERB
ajlm-975	154	3	that	that	SCONJ
ajlm-975	154	4	mir-143	mir-143	PROPN
ajlm-975	154	5	overexpression	overexpression	NOUN
ajlm-975	154	6	and	and	CCONJ
ajlm-975	154	7	mir-145	mir-145	NOUN
ajlm-975	154	8	underexpression	underexpression	NOUN
ajlm-975	154	9	could	could	AUX
ajlm-975	154	10	be	be	AUX
ajlm-975	154	11	early	early	ADJ
ajlm-975	154	12	indicators	indicator	NOUN
ajlm-975	154	13	of	of	ADP
ajlm-975	154	14	viral	viral	ADJ
ajlm-975	154	15	co	co	NOUN
ajlm-975	154	16	-	-	NOUN
ajlm-975	154	17	infection	infection	NOUN
ajlm-975	154	18	and	and	CCONJ
ajlm-975	154	19	emt	emt	PROPN
ajlm-975	154	20	.	.	PUNCT
ajlm-975	155	1	it	it	PRON
ajlm-975	155	2	also	also	ADV
ajlm-975	155	3	suggests	suggest	VERB
ajlm-975	155	4	that	that	SCONJ
ajlm-975	155	5	ebv	ebv	NOUN
ajlm-975	155	6	and	and	CCONJ
ajlm-975	155	7	hpv	hpv	NOUN
ajlm-975	155	8	may	may	AUX
ajlm-975	155	9	synergistically	synergistically	ADV
ajlm-975	155	10	and	and	CCONJ
ajlm-975	155	11	more	more	ADV
ajlm-975	155	12	aggressively	aggressively	ADV
ajlm-975	155	13	promote	promote	VERB
ajlm-975	155	14	emt	emt	NOUN
ajlm-975	155	15	than	than	ADP
ajlm-975	155	16	either	either	PRON
ajlm-975	155	17	of	of	ADP
ajlm-975	155	18	them	they	PRON
ajlm-975	155	19	could	could	AUX
ajlm-975	155	20	have	have	AUX
ajlm-975	155	21	done	do	VERB
ajlm-975	155	22	unilaterally	unilaterally	ADV
ajlm-975	155	23	.	.	PUNCT
ajlm-975	156	1	although	although	SCONJ
ajlm-975	156	2	mir143	mir143	PROPN
ajlm-975	156	3	and	and	CCONJ
ajlm-975	156	4	mir145	mir145	PROPN
ajlm-975	156	5	are	be	AUX
ajlm-975	156	6	tumour	tumour	ADJ
ajlm-975	156	7	suppressors	suppressor	NOUN
ajlm-975	156	8	,	,	PUNCT
ajlm-975	156	9	the	the	DET
ajlm-975	156	10	divergent	divergent	ADJ
ajlm-975	156	11	expression	expression	NOUN
ajlm-975	156	12	of	of	ADP
ajlm-975	156	13	both	both	DET
ajlm-975	156	14	mirnas	mirna	NOUN
ajlm-975	156	15	in	in	ADP
ajlm-975	156	16	different	different	ADJ
ajlm-975	156	17	viral	viral	ADJ
ajlm-975	156	18	status	status	NOUN
ajlm-975	156	19	suggests	suggest	VERB
ajlm-975	156	20	that	that	SCONJ
ajlm-975	156	21	they	they	PRON
ajlm-975	156	22	may	may	AUX
ajlm-975	156	23	have	have	VERB
ajlm-975	156	24	dual	dual	ADJ
ajlm-975	156	25	functions	function	NOUN
ajlm-975	156	26	.	.	PUNCT
ajlm-975	157	1	the	the	DET
ajlm-975	157	2	latter	latter	ADJ
ajlm-975	157	3	may	may	AUX
ajlm-975	157	4	be	be	AUX
ajlm-975	157	5	an	an	DET
ajlm-975	157	6	explanation	explanation	NOUN
ajlm-975	157	7	for	for	ADP
ajlm-975	157	8	the	the	DET
ajlm-975	157	9	discordant	discordant	ADJ
ajlm-975	157	10	reports	report	NOUN
ajlm-975	157	11	on	on	ADP
ajlm-975	157	12	the	the	DET
ajlm-975	157	13	expression	expression	NOUN
ajlm-975	157	14	of	of	ADP
ajlm-975	157	15	both	both	DET
ajlm-975	157	16	biomarkers	biomarker	NOUN
ajlm-975	157	17	in	in	ADP
ajlm-975	157	18	cervical	cervical	ADJ
ajlm-975	157	19	cancer.18,22,30,31	cancer.18,22,30,31	PROPN
ajlm-975	157	20	furthermore	furthermore	ADV
ajlm-975	157	21	,	,	PUNCT
ajlm-975	157	22	the	the	DET
ajlm-975	157	23	higher	high	ADJ
ajlm-975	157	24	expression	expression	NOUN
ajlm-975	157	25	of	of	ADP
ajlm-975	157	26	mir-143	mir-143	NOUN
ajlm-975	157	27	and	and	CCONJ
ajlm-975	157	28	mir-145	mir-145	PROPN
ajlm-975	157	29	,	,	PUNCT
ajlm-975	157	30	including	include	VERB
ajlm-975	157	31	mir	mir	NOUN
ajlm-975	157	32	-	-	ADJ
ajlm-975	157	33	let-7b	let-7b	NOUN
ajlm-975	157	34	and	and	CCONJ
ajlm-975	157	35	mir-125b	mir-125b	NOUN
ajlm-975	157	36	,	,	PUNCT
ajlm-975	157	37	among	among	ADP
ajlm-975	157	38	women	woman	NOUN
ajlm-975	157	39	with	with	ADP
ajlm-975	157	40	hsv-2	hsv-2	PUNCT
ajlm-975	157	41	mono	mono	NOUN
ajlm-975	157	42	-	-	PUNCT
ajlm-975	157	43	infection	infection	NOUN
ajlm-975	157	44	when	when	SCONJ
ajlm-975	157	45	compared	compare	VERB
ajlm-975	157	46	with	with	ADP
ajlm-975	157	47	the	the	DET
ajlm-975	157	48	control	control	NOUN
ajlm-975	157	49	group	group	NOUN
ajlm-975	157	50	suggests	suggest	VERB
ajlm-975	157	51	that	that	SCONJ
ajlm-975	157	52	the	the	DET
ajlm-975	157	53	mirnas	mirna	NOUN
ajlm-975	157	54	do	do	AUX
ajlm-975	157	55	not	not	PART
ajlm-975	157	56	play	play	VERB
ajlm-975	157	57	any	any	DET
ajlm-975	157	58	significant	significant	ADJ
ajlm-975	157	59	role	role	NOUN
ajlm-975	157	60	in	in	ADP
ajlm-975	157	61	hsv-2	hsv-2	ADV
ajlm-975	157	62	-	-	ADJ
ajlm-975	157	63	associated	associated	ADJ
ajlm-975	157	64	oncogenic	oncogenic	ADJ
ajlm-975	157	65	activity	activity	NOUN
ajlm-975	157	66	.	.	PUNCT
ajlm-975	158	1	however	however	ADV
ajlm-975	158	2	,	,	PUNCT
ajlm-975	158	3	it	it	PRON
ajlm-975	158	4	could	could	AUX
ajlm-975	158	5	be	be	AUX
ajlm-975	158	6	argued	argue	VERB
ajlm-975	158	7	that	that	SCONJ
ajlm-975	158	8	hsv-2	hsv-2	VERB
ajlm-975	158	9	infection	infection	NOUN
ajlm-975	158	10	contributes	contribute	VERB
ajlm-975	158	11	to	to	ADP
ajlm-975	158	12	cervical	cervical	ADJ
ajlm-975	158	13	carcinogenesis	carcinogenesis	NOUN
ajlm-975	158	14	by	by	ADP
ajlm-975	158	15	reducing	reduce	VERB
ajlm-975	158	16	cd4	cd4	PROPN
ajlm-975	158	17	+	+	PROPN
ajlm-975	158	18	t	t	PROPN
ajlm-975	158	19	-	-	PUNCT
ajlm-975	158	20	cell	cell	NOUN
ajlm-975	158	21	counts	count	NOUN
ajlm-975	158	22	.	.	PUNCT
ajlm-975	159	1	this	this	PRON
ajlm-975	159	2	is	be	AUX
ajlm-975	159	3	underscored	underscore	VERB
ajlm-975	159	4	by	by	ADP
ajlm-975	159	5	the	the	DET
ajlm-975	159	6	finding	finding	NOUN
ajlm-975	159	7	that	that	SCONJ
ajlm-975	159	8	a	a	DET
ajlm-975	159	9	decrease	decrease	NOUN
ajlm-975	159	10	in	in	ADP
ajlm-975	159	11	cd4	cd4	PROPN
ajlm-975	159	12	+	+	PROPN
ajlm-975	159	13	t	t	PROPN
ajlm-975	159	14	-	-	PUNCT
ajlm-975	159	15	cell	cell	NOUN
ajlm-975	159	16	counts	count	NOUN
ajlm-975	159	17	by	by	ADP
ajlm-975	159	18	100	100	NUM
ajlm-975	159	19	cells	cell	NOUN
ajlm-975	159	20	/	/	SYM
ajlm-975	159	21	mm3	mm3	NOUN
ajlm-975	159	22	increases	increase	VERB
ajlm-975	159	23	the	the	DET
ajlm-975	159	24	risk	risk	NOUN
ajlm-975	159	25	of	of	ADP
ajlm-975	159	26	cervical	cervical	ADJ
ajlm-975	159	27	lesions	lesion	NOUN
ajlm-975	159	28	by	by	ADP
ajlm-975	159	29	13	13	NUM
ajlm-975	159	30	%	%	NOUN
ajlm-975	159	31	to	to	ADP
ajlm-975	159	32	18%.32	18%.32	NUM
ajlm-975	159	33	limitations	limitation	NOUN
ajlm-975	159	34	the	the	DET
ajlm-975	159	35	expression	expression	NOUN
ajlm-975	159	36	of	of	ADP
ajlm-975	159	37	mirnas	mirna	NOUN
ajlm-975	159	38	in	in	ADP
ajlm-975	159	39	a	a	DET
ajlm-975	159	40	few	few	ADJ
ajlm-975	159	41	cases	case	NOUN
ajlm-975	159	42	of	of	ADP
ajlm-975	159	43	ebv	ebv	NOUN
ajlm-975	159	44	-	-	PUNCT
ajlm-975	159	45	hpv	hpv	ADJ
ajlm-975	159	46	bi	bi	NOUN
ajlm-975	159	47	-	-	NOUN
ajlm-975	159	48	infection	infection	NOUN
ajlm-975	159	49	(	(	PUNCT
ajlm-975	159	50	n	n	NOUN
ajlm-975	159	51	=	=	SYM
ajlm-975	159	52	5	5	NUM
ajlm-975	159	53	)	)	PUNCT
ajlm-975	159	54	and	and	CCONJ
ajlm-975	159	55	ebv	ebv	VERB
ajlm-975	159	56	mono	mono	NOUN
ajlm-975	159	57	-	-	PUNCT
ajlm-975	159	58	infection	infection	NOUN
ajlm-975	159	59	(	(	PUNCT
ajlm-975	159	60	n	n	NOUN
ajlm-975	159	61	=	=	SYM
ajlm-975	159	62	15	15	NUM
ajlm-975	159	63	)	)	PUNCT
ajlm-975	159	64	as	as	SCONJ
ajlm-975	159	65	seen	see	VERB
ajlm-975	159	66	in	in	ADP
ajlm-975	159	67	this	this	DET
ajlm-975	159	68	study	study	NOUN
ajlm-975	159	69	may	may	AUX
ajlm-975	159	70	not	not	PART
ajlm-975	159	71	allow	allow	VERB
ajlm-975	159	72	for	for	ADP
ajlm-975	159	73	conclusive	conclusive	ADJ
ajlm-975	159	74	generalisation	generalisation	NOUN
ajlm-975	159	75	in	in	ADP
ajlm-975	159	76	the	the	DET
ajlm-975	159	77	investigated	investigated	ADJ
ajlm-975	159	78	population	population	NOUN
ajlm-975	159	79	.	.	PUNCT
ajlm-975	160	1	in	in	ADP
ajlm-975	160	2	other	other	ADJ
ajlm-975	160	3	words	word	NOUN
ajlm-975	160	4	,	,	PUNCT
ajlm-975	160	5	a	a	DET
ajlm-975	160	6	clear	clear	ADJ
ajlm-975	160	7	and	and	CCONJ
ajlm-975	160	8	significant	significant	ADJ
ajlm-975	160	9	impact	impact	NOUN
ajlm-975	160	10	of	of	ADP
ajlm-975	160	11	ebv	ebv	NOUN
ajlm-975	160	12	-	-	PUNCT
ajlm-975	160	13	hpv	hpv	ADJ
ajlm-975	160	14	bi	bi	NOUN
ajlm-975	160	15	-	-	NOUN
ajlm-975	160	16	infection	infection	NOUN
ajlm-975	160	17	and	and	CCONJ
ajlm-975	160	18	ebv	ebv	NOUN
ajlm-975	160	19	mono	mono	NOUN
ajlm-975	160	20	-	-	PUNCT
ajlm-975	160	21	infection	infection	NOUN
ajlm-975	160	22	on	on	ADP
ajlm-975	160	23	mirnas	mirna	NOUN
ajlm-975	160	24	may	may	AUX
ajlm-975	160	25	be	be	AUX
ajlm-975	160	26	observed	observe	VERB
ajlm-975	160	27	when	when	SCONJ
ajlm-975	160	28	a	a	DET
ajlm-975	160	29	larger	large	ADJ
ajlm-975	160	30	population	population	NOUN
ajlm-975	160	31	is	be	AUX
ajlm-975	160	32	investigated	investigate	VERB
ajlm-975	160	33	.	.	PUNCT
ajlm-975	161	1	however	however	ADV
ajlm-975	161	2	,	,	PUNCT
ajlm-975	161	3	this	this	DET
ajlm-975	161	4	study	study	NOUN
ajlm-975	161	5	could	could	AUX
ajlm-975	161	6	serve	serve	VERB
ajlm-975	161	7	as	as	ADP
ajlm-975	161	8	a	a	DET
ajlm-975	161	9	baseline	baseline	NOUN
ajlm-975	161	10	for	for	ADP
ajlm-975	161	11	future	future	ADJ
ajlm-975	161	12	studies	study	NOUN
ajlm-975	161	13	.	.	PUNCT
ajlm-975	162	1	additionally	additionally	ADV
ajlm-975	162	2	,	,	PUNCT
ajlm-975	162	3	the	the	DET
ajlm-975	162	4	use	use	NOUN
ajlm-975	162	5	of	of	ADP
ajlm-975	162	6	conventional	conventional	ADJ
ajlm-975	162	7	reverse	reverse	ADJ
ajlm-975	162	8	transcriptase	transcriptase	NOUN
ajlm-975	162	9	pcr	pcr	NOUN
ajlm-975	162	10	in	in	ADP
ajlm-975	162	11	this	this	DET
ajlm-975	162	12	study	study	NOUN
ajlm-975	162	13	is	be	AUX
ajlm-975	162	14	a	a	DET
ajlm-975	162	15	limitation	limitation	NOUN
ajlm-975	162	16	,	,	PUNCT
ajlm-975	162	17	as	as	SCONJ
ajlm-975	162	18	expression	expression	NOUN
ajlm-975	162	19	levels	level	NOUN
ajlm-975	162	20	had	have	VERB
ajlm-975	162	21	to	to	PART
ajlm-975	162	22	be	be	AUX
ajlm-975	162	23	determined	determine	VERB
ajlm-975	162	24	by	by	ADP
ajlm-975	162	25	densitometric	densitometric	ADJ
ajlm-975	162	26	analysis	analysis	NOUN
ajlm-975	162	27	.	.	PUNCT
ajlm-975	163	1	we	we	PRON
ajlm-975	163	2	believe	believe	VERB
ajlm-975	163	3	that	that	SCONJ
ajlm-975	163	4	the	the	DET
ajlm-975	163	5	use	use	NOUN
ajlm-975	163	6	of	of	ADP
ajlm-975	163	7	quantitative	quantitative	ADJ
ajlm-975	163	8	real	real	ADJ
ajlm-975	163	9	-	-	PUNCT
ajlm-975	163	10	time	time	NOUN
ajlm-975	163	11	pcr	pcr	NOUN
ajlm-975	163	12	could	could	AUX
ajlm-975	163	13	have	have	AUX
ajlm-975	163	14	yielded	yield	VERB
ajlm-975	163	15	superior	superior	ADJ
ajlm-975	163	16	results	result	NOUN
ajlm-975	163	17	than	than	SCONJ
ajlm-975	163	18	reverse	reverse	VERB
ajlm-975	163	19	transcriptase	transcriptase	NOUN
ajlm-975	163	20	pcr	pcr	NOUN
ajlm-975	163	21	.	.	PUNCT
ajlm-975	164	1	conclusion	conclusion	VERB
ajlm-975	164	2	the	the	DET
ajlm-975	164	3	findings	finding	NOUN
ajlm-975	164	4	of	of	ADP
ajlm-975	164	5	this	this	DET
ajlm-975	164	6	study	study	NOUN
ajlm-975	164	7	show	show	VERB
ajlm-975	164	8	that	that	SCONJ
ajlm-975	164	9	while	while	SCONJ
ajlm-975	164	10	ebv	ebv	NOUN
ajlm-975	164	11	and	and	CCONJ
ajlm-975	164	12	hpv	hpv	NOUN
ajlm-975	164	13	infections	infection	NOUN
ajlm-975	164	14	may	may	AUX
ajlm-975	164	15	synergistically	synergistically	ADV
ajlm-975	164	16	target	target	VERB
ajlm-975	164	17	mir-21	mir-21	PROPN
ajlm-975	164	18	and	and	CCONJ
ajlm-975	164	19	mir-200c	mir-200c	NOUN
ajlm-975	164	20	,	,	PUNCT
ajlm-975	164	21	hsv-2	hsv-2	PUNCT
ajlm-975	164	22	and	and	CCONJ
ajlm-975	164	23	its	its	PRON
ajlm-975	164	24	related	related	ADJ
ajlm-975	164	25	co	co	NOUN
ajlm-975	164	26	-	-	NOUN
ajlm-975	164	27	infections	infection	NOUN
ajlm-975	164	28	may	may	AUX
ajlm-975	164	29	target	target	VERB
ajlm-975	164	30	mir-182	mir-182	NOUN
ajlm-975	164	31	and	and	CCONJ
ajlm-975	164	32	cd4	cd4	PROPN
ajlm-975	164	33	+	+	PROPN
ajlm-975	164	34	t	t	PROPN
ajlm-975	164	35	-	-	PUNCT
ajlm-975	164	36	cell	cell	NOUN
ajlm-975	164	37	activity	activity	NOUN
ajlm-975	164	38	to	to	PART
ajlm-975	164	39	initiate	initiate	VERB
ajlm-975	164	40	emt	emt	PROPN
ajlm-975	164	41	.	.	PUNCT
ajlm-975	165	1	thus	thus	ADV
ajlm-975	165	2	,	,	PUNCT
ajlm-975	165	3	this	this	DET
ajlm-975	165	4	study	study	NOUN
ajlm-975	165	5	suggests	suggest	VERB
ajlm-975	165	6	that	that	SCONJ
ajlm-975	165	7	viral	viral	ADJ
ajlm-975	165	8	co	co	NOUN
ajlm-975	165	9	-	-	NOUN
ajlm-975	165	10	presence	presence	NOUN
ajlm-975	165	11	increases	increase	VERB
ajlm-975	165	12	the	the	DET
ajlm-975	165	13	risk	risk	NOUN
ajlm-975	165	14	of	of	ADP
ajlm-975	165	15	cervical	cervical	ADJ
ajlm-975	165	16	carcinogenesis	carcinogenesis	NOUN
ajlm-975	165	17	by	by	ADP
ajlm-975	165	18	downregulating	downregulating	NOUN
ajlm-975	165	19	mir-145	mir-145	NOUN
ajlm-975	165	20	,	,	PUNCT
ajlm-975	165	21	upregulating	upregulating	ADJ
ajlm-975	165	22	mir-182	mir-182	NOUN
ajlm-975	165	23	and	and	CCONJ
ajlm-975	165	24	suppressing	suppress	VERB
ajlm-975	165	25	cd4	cd4	PROPN
ajlm-975	165	26	+	+	PROPN
ajlm-975	165	27	t	t	PROPN
ajlm-975	165	28	-	-	PUNCT
ajlm-975	165	29	cell	cell	NOUN
ajlm-975	165	30	activity	activity	NOUN
ajlm-975	165	31	.	.	PUNCT
ajlm-975	166	1	acknowledgements	acknowledgement	NOUN
ajlm-975	166	2	special	special	ADJ
ajlm-975	166	3	thanks	thank	NOUN
ajlm-975	166	4	are	be	AUX
ajlm-975	166	5	extended	extend	VERB
ajlm-975	166	6	to	to	ADP
ajlm-975	166	7	staff	staff	NOUN
ajlm-975	166	8	of	of	ADP
ajlm-975	166	9	the	the	DET
ajlm-975	166	10	centre	centre	NOUN
ajlm-975	166	11	for	for	ADP
ajlm-975	166	12	biocomputing	biocomputing	NOUN
ajlm-975	166	13	and	and	CCONJ
ajlm-975	166	14	drug	drug	NOUN
ajlm-975	166	15	development	development	NOUN
ajlm-975	166	16	,	,	PUNCT
ajlm-975	166	17	adekunle	adekunle	PROPN
ajlm-975	166	18	ajasin	ajasin	VERB
ajlm-975	166	19	university	university	PROPN
ajlm-975	166	20	and	and	CCONJ
ajlm-975	166	21	hiv	hiv	PROPN
ajlm-975	166	22	counseling	counseling	NOUN
ajlm-975	166	23	and	and	CCONJ
ajlm-975	166	24	testing	testing	NOUN
ajlm-975	166	25	and	and	CCONJ
ajlm-975	167	1	family	family	NOUN
ajlm-975	167	2	planning	planning	NOUN
ajlm-975	167	3	clinics	clinic	NOUN
ajlm-975	167	4	,	,	PUNCT
ajlm-975	167	5	state	state	NOUN
ajlm-975	167	6	hospital	hospital	NOUN
ajlm-975	167	7	abeokuta	abeokuta	PROPN
ajlm-975	167	8	,	,	PUNCT
ajlm-975	167	9	for	for	ADP
ajlm-975	167	10	their	their	PRON
ajlm-975	167	11	technical	technical	ADJ
ajlm-975	167	12	assistance	assistance	NOUN
ajlm-975	167	13	.	.	PUNCT
ajlm-975	168	1	competing	compete	VERB
ajlm-975	168	2	interests	interest	NOUN
ajlm-975	168	3	the	the	DET
ajlm-975	168	4	authors	author	NOUN
ajlm-975	168	5	have	have	AUX
ajlm-975	168	6	declared	declare	VERB
ajlm-975	168	7	that	that	SCONJ
ajlm-975	168	8	no	no	DET
ajlm-975	168	9	competing	compete	VERB
ajlm-975	168	10	interests	interest	NOUN
ajlm-975	168	11	exist	exist	VERB
ajlm-975	168	12	.	.	PUNCT
ajlm-975	169	1	authors	author	NOUN
ajlm-975	169	2	’	’	PART
ajlm-975	169	3	contributions	contribution	NOUN
ajlm-975	169	4	j.o.o	j.o.o	NOUN
ajlm-975	169	5	.	.	PUNCT
ajlm-975	169	6	and	and	CCONJ
ajlm-975	169	7	a.a.n	a.a.n	PROPN
ajlm-975	169	8	.	.	PUNCT
ajlm-975	169	9	designed	design	VERB
ajlm-975	169	10	the	the	DET
ajlm-975	169	11	study	study	NOUN
ajlm-975	169	12	and	and	CCONJ
ajlm-975	169	13	wrote	write	VERB
ajlm-975	169	14	the	the	DET
ajlm-975	169	15	manuscript	manuscript	NOUN
ajlm-975	169	16	.	.	PUNCT
ajlm-975	170	1	c.c.o	c.c.o	NOUN
ajlm-975	170	2	.	.	PUNCT
ajlm-975	170	3	made	make	VERB
ajlm-975	170	4	conceptual	conceptual	ADJ
ajlm-975	170	5	contributions	contribution	NOUN
ajlm-975	170	6	.	.	PUNCT
ajlm-975	171	1	j.o.o	j.o.o	PROPN
ajlm-975	171	2	.	.	PUNCT
ajlm-975	172	1	and	and	CCONJ
ajlm-975	172	2	c.c.o	c.c.o	NOUN
ajlm-975	172	3	.	.	PUNCT
ajlm-975	173	1	carried	carry	VERB
ajlm-975	173	2	out	out	ADP
ajlm-975	173	3	elisa	elisa	NOUN
ajlm-975	173	4	investigations	investigation	NOUN
ajlm-975	173	5	and	and	CCONJ
ajlm-975	173	6	interpreted	interpret	VERB
ajlm-975	173	7	biochemical	biochemical	ADJ
ajlm-975	173	8	results	result	NOUN
ajlm-975	173	9	.	.	PUNCT
ajlm-975	174	1	j.o.o	j.o.o	PROPN
ajlm-975	174	2	.	.	PUNCT
ajlm-975	174	3	and	and	CCONJ
ajlm-975	174	4	d.i.d	d.i.d	PROPN
ajlm-975	174	5	.	.	PUNCT
ajlm-975	174	6	carried	carry	VERB
ajlm-975	174	7	out	out	ADP
ajlm-975	174	8	the	the	DET
ajlm-975	174	9	cervical	cervical	ADJ
ajlm-975	174	10	screening	screening	NOUN
ajlm-975	174	11	exercise	exercise	NOUN
ajlm-975	174	12	and	and	CCONJ
ajlm-975	174	13	literature	literature	NOUN
ajlm-975	174	14	searches	search	NOUN
ajlm-975	174	15	.	.	PUNCT
ajlm-975	175	1	j.o.o	j.o.o	PROPN
ajlm-975	175	2	.	.	PUNCT
ajlm-975	175	3	and	and	CCONJ
ajlm-975	175	4	o.o	o.o	PROPN
ajlm-975	175	5	.	.	PROPN
ajlm-975	175	6	carried	carry	VERB
ajlm-975	175	7	out	out	ADP
ajlm-975	175	8	the	the	DET
ajlm-975	175	9	mirna	mirna	PROPN
ajlm-975	175	10	laboratory	laboratory	NOUN
ajlm-975	175	11	investigations	investigation	NOUN
ajlm-975	175	12	and	and	CCONJ
ajlm-975	175	13	interpreted	interpret	VERB
ajlm-975	175	14	results	result	NOUN
ajlm-975	175	15	.	.	PUNCT
ajlm-975	176	1	sources	source	NOUN
ajlm-975	176	2	of	of	ADP
ajlm-975	176	3	support	support	NOUN
ajlm-975	176	4	this	this	DET
ajlm-975	176	5	research	research	NOUN
ajlm-975	176	6	received	receive	VERB
ajlm-975	176	7	no	no	DET
ajlm-975	176	8	specific	specific	ADJ
ajlm-975	176	9	grant	grant	NOUN
ajlm-975	176	10	from	from	ADP
ajlm-975	176	11	any	any	DET
ajlm-975	176	12	funding	funding	NOUN
ajlm-975	176	13	agency	agency	NOUN
ajlm-975	176	14	in	in	ADP
ajlm-975	176	15	the	the	DET
ajlm-975	176	16	public	public	ADJ
ajlm-975	176	17	,	,	PUNCT
ajlm-975	176	18	commercial	commercial	ADJ
ajlm-975	176	19	or	or	CCONJ
ajlm-975	176	20	not	not	PART
ajlm-975	176	21	-	-	PUNCT
ajlm-975	176	22	for	for	ADP
ajlm-975	176	23	-	-	PUNCT
ajlm-975	176	24	profit	profit	NOUN
ajlm-975	176	25	sectors	sector	NOUN
ajlm-975	176	26	.	.	PUNCT
ajlm-975	177	1	data	datum	NOUN
ajlm-975	177	2	availability	availability	NOUN
ajlm-975	177	3	statement	statement	NOUN
ajlm-975	177	4	data	datum	NOUN
ajlm-975	177	5	sharing	sharing	NOUN
ajlm-975	177	6	is	be	AUX
ajlm-975	177	7	not	not	PART
ajlm-975	177	8	applicable	applicable	ADJ
ajlm-975	177	9	to	to	ADP
ajlm-975	177	10	this	this	DET
ajlm-975	177	11	article	article	NOUN
ajlm-975	177	12	as	as	SCONJ
ajlm-975	177	13	no	no	DET
ajlm-975	177	14	new	new	ADJ
ajlm-975	177	15	data	datum	NOUN
ajlm-975	177	16	were	be	AUX
ajlm-975	177	17	created	create	VERB
ajlm-975	177	18	or	or	CCONJ
ajlm-975	177	19	analysed	analyse	VERB
ajlm-975	177	20	in	in	ADP
ajlm-975	177	21	this	this	DET
ajlm-975	177	22	study	study	NOUN
ajlm-975	177	23	.	.	PUNCT
ajlm-975	178	1	disclaimer	disclaimer	VERB
ajlm-975	178	2	the	the	DET
ajlm-975	178	3	views	view	NOUN
ajlm-975	178	4	and	and	CCONJ
ajlm-975	178	5	opinions	opinion	NOUN
ajlm-975	178	6	expressed	express	VERB
ajlm-975	178	7	in	in	ADP
ajlm-975	178	8	this	this	DET
ajlm-975	178	9	article	article	NOUN
ajlm-975	178	10	are	be	AUX
ajlm-975	178	11	those	those	PRON
ajlm-975	178	12	of	of	ADP
ajlm-975	178	13	the	the	DET
ajlm-975	178	14	authors	author	NOUN
ajlm-975	178	15	and	and	CCONJ
ajlm-975	178	16	do	do	AUX
ajlm-975	178	17	not	not	PART
ajlm-975	178	18	necessarily	necessarily	ADV
ajlm-975	178	19	reflect	reflect	VERB
ajlm-975	178	20	the	the	DET
ajlm-975	178	21	official	official	ADJ
ajlm-975	178	22	policy	policy	NOUN
ajlm-975	178	23	or	or	CCONJ
ajlm-975	178	24	position	position	NOUN
ajlm-975	178	25	of	of	ADP
ajlm-975	178	26	any	any	DET
ajlm-975	178	27	affiliated	affiliated	ADJ
ajlm-975	178	28	agency	agency	NOUN
ajlm-975	178	29	of	of	ADP
ajlm-975	178	30	the	the	DET
ajlm-975	178	31	authors	author	NOUN
ajlm-975	178	32	.	.	PUNCT
ajlm-975	179	1	references	reference	NOUN
ajlm-975	179	2	khenchouche	khenchouche	VERB
ajlm-975	179	3	a	a	PRON
ajlm-975	179	4	,	,	PUNCT
ajlm-975	179	5	sadouki	sadouki	PROPN
ajlm-975	179	6	n	n	PROPN
ajlm-975	179	7	,	,	PUNCT
ajlm-975	179	8	boudriche	boudriche	NOUN
ajlm-975	179	9	a	a	X
ajlm-975	179	10	,	,	PUNCT
ajlm-975	179	11	et	et	PROPN
ajlm-975	179	12	al	al	PROPN
ajlm-975	179	13	.	.	PROPN
ajlm-975	180	1	human	human	ADJ
ajlm-975	180	2	papillomavirus	papillomavirus	PROPN
ajlm-975	180	3	abd	abd	PROPN
ajlm-975	180	4	epstein	epstein	PROPN
ajlm-975	180	5	-	-	PUNCT
ajlm-975	180	6	barr	barr	PROPN
ajlm-975	180	7	virus	virus	PROPN
ajlm-975	180	8	co	co	NOUN
ajlm-975	180	9	-	-	NOUN
ajlm-975	180	10	infection	infection	NOUN
ajlm-975	180	11	in	in	ADP
ajlm-975	180	12	cervical	cervical	ADJ
ajlm-975	180	13	carcinoma	carcinoma	NOUN
ajlm-975	180	14	in	in	ADP
ajlm-975	180	15	algerian	algerian	ADJ
ajlm-975	180	16	women	woman	NOUN
ajlm-975	180	17	.	.	PUNCT
ajlm-975	181	1	virol	virol	PROPN
ajlm-975	181	2	j.	j.	PROPN
ajlm-975	182	1	2013;10:340	2013;10:340	PROPN
ajlm-975	182	2	.	.	PUNCT
ajlm-975	182	3	https://doi.org/10.1186/1743-422x-10-340	https://doi.org/10.1186/1743-422x-10-340	PROPN
ajlm-975	182	4	kahla	kahla	PROPN
ajlm-975	182	5	s	s	PROPN
ajlm-975	182	6	,	,	PUNCT
ajlm-975	182	7	oueslati	oueslati	NOUN
ajlm-975	182	8	s	s	PROPN
ajlm-975	182	9	,	,	PUNCT
ajlm-975	182	10	achour	achour	PROPN
ajlm-975	182	11	m	m	PROPN
ajlm-975	182	12	,	,	PUNCT
ajlm-975	182	13	et	et	PROPN
ajlm-975	182	14	al	al	PROPN
ajlm-975	182	15	.	.	PUNCT
ajlm-975	182	16	correlation	correlation	NOUN
ajlm-975	182	17	between	between	ADP
ajlm-975	182	18	ebv	ebv	NOUN
ajlm-975	182	19	co	co	NOUN
ajlm-975	182	20	-	-	NOUN
ajlm-975	182	21	infection	infection	NOUN
ajlm-975	182	22	and	and	CCONJ
ajlm-975	182	23	hpv16	hpv16	NOUN
ajlm-975	182	24	genome	genome	NOUN
ajlm-975	182	25	integrity	integrity	NOUN
ajlm-975	182	26	in	in	ADP
ajlm-975	182	27	tunisian	tunisian	ADJ
ajlm-975	182	28	cervical	cervical	ADJ
ajlm-975	182	29	cancer	cancer	NOUN
ajlm-975	182	30	patients	patient	NOUN
ajlm-975	182	31	.	.	PUNCT
ajlm-975	183	1	braz	braz	PROPN
ajlm-975	183	2	j	j	PROPN
ajlm-975	183	3	microbiol	microbiol	PROPN
ajlm-975	183	4	.	.	PUNCT
ajlm-975	184	1	2012;43(2):744–753	2012;43(2):744–753	NUM
ajlm-975	184	2	.	.	PROPN
ajlm-975	184	3	https://doi.org/10.1590/s1517-83822012000200039	https://doi.org/10.1590/s1517-83822012000200039	PROPN
ajlm-975	184	4	smith	smith	PROPN
ajlm-975	184	5	js	js	PROPN
ajlm-975	184	6	,	,	PUNCT
ajlm-975	184	7	herrero	herrero	PROPN
ajlm-975	184	8	r	r	PROPN
ajlm-975	184	9	,	,	PUNCT
ajlm-975	184	10	bosetti	bosetti	NOUN
ajlm-975	184	11	c	c	NOUN
ajlm-975	184	12	,	,	PUNCT
ajlm-975	184	13	et	et	PROPN
ajlm-975	184	14	al	al	PROPN
ajlm-975	184	15	.	.	PROPN
ajlm-975	184	16	herpes	herpe	NOUN
ajlm-975	184	17	simplex	simplex	NOUN
ajlm-975	184	18	virus-2	virus-2	NUM
ajlm-975	184	19	as	as	ADP
ajlm-975	184	20	a	a	DET
ajlm-975	184	21	human	human	ADJ
ajlm-975	184	22	papillomavirus	papillomavirus	NOUN
ajlm-975	184	23	cofactor	cofactor	NOUN
ajlm-975	184	24	in	in	ADP
ajlm-975	184	25	the	the	DET
ajlm-975	184	26	etiology	etiology	NOUN
ajlm-975	184	27	of	of	ADP
ajlm-975	184	28	invasive	invasive	ADJ
ajlm-975	184	29	cervical	cervical	ADJ
ajlm-975	184	30	cancer	cancer	NOUN
ajlm-975	184	31	.	.	PUNCT
ajlm-975	185	1	j	j	PROPN
ajlm-975	185	2	natl	natl	PROPN
ajlm-975	185	3	cancer	cancer	PROPN
ajlm-975	185	4	lnst	lnst	PROPN
ajlm-975	185	5	.	.	PUNCT
ajlm-975	186	1	2002;94(21):1604–1613	2002;94(21):1604–1613	NUM
ajlm-975	186	2	.	.	PUNCT
ajlm-975	187	1	https://doi.org/10.1093/jnci/94.21.1604	https://doi.org/10.1093/jnci/94.21.1604	PROPN
ajlm-975	187	2	elsheikh	elsheikh	PROPN
ajlm-975	187	3	ma	ma	PROPN
ajlm-975	187	4	,	,	PUNCT
ajlm-975	187	5	yousif	yousif	PROPN
ajlm-975	187	6	ib	ib	PROPN
ajlm-975	187	7	,	,	PUNCT
ajlm-975	187	8	osman	osman	PROPN
ajlm-975	187	9	mi	mi	PROPN
ajlm-975	187	10	,	,	PUNCT
ajlm-975	187	11	et	et	PROPN
ajlm-975	187	12	al	al	PROPN
ajlm-975	187	13	.	.	PROPN
ajlm-975	187	14	herpes	herpe	NOUN
ajlm-975	187	15	simplex	simplex	NOUN
ajlm-975	187	16	virus	virus	NOUN
ajlm-975	187	17	type	type	NOUN
ajlm-975	187	18	2	2	NUM
ajlm-975	187	19	,	,	PUNCT
ajlm-975	187	20	epstein	epstein	PROPN
ajlm-975	187	21	barr	barr	PROPN
ajlm-975	187	22	virus	virus	PROPN
ajlm-975	187	23	and	and	CCONJ
ajlm-975	187	24	human	human	ADJ
ajlm-975	187	25	papilloma	papilloma	PROPN
ajlm-975	187	26	virus	virus	NOUN
ajlm-975	187	27	co	co	NOUN
ajlm-975	187	28	-	-	NOUN
ajlm-975	187	29	infection	infection	NOUN
ajlm-975	187	30	in	in	ADP
ajlm-975	187	31	cervical	cervical	ADJ
ajlm-975	187	32	squamous	squamous	ADJ
ajlm-975	187	33	cell	cell	NOUN
ajlm-975	187	34	carcinoma	carcinoma	NOUN
ajlm-975	187	35	among	among	ADP
ajlm-975	187	36	sudanese	sudanese	ADJ
ajlm-975	187	37	females	female	NOUN
ajlm-975	187	38	.	.	PUNCT
ajlm-975	188	1	int	int	PROPN
ajlm-975	189	1	j	j	PROPN
ajlm-975	189	2	curr	curr	PROPN
ajlm-975	189	3	res	res	PROPN
ajlm-975	189	4	med	med	PROPN
ajlm-975	189	5	sci	sci	PROPN
ajlm-975	189	6	.	.	PUNCT
ajlm-975	190	1	2018;4:93–103	2018;4:93–103	NUM
ajlm-975	190	2	.	.	PUNCT
ajlm-975	191	1	https://doi.org/10.22192/ijcrms.2018.04.02.016	https://doi.org/10.22192/ijcrms.2018.04.02.016	PROPN
ajlm-975	191	2	lutz	lutz	PROPN
ajlm-975	191	3	g	g	PROPN
ajlm-975	191	4	,	,	PUNCT
ajlm-975	191	5	jurak	jurak	VERB
ajlm-975	191	6	i	i	PRON
ajlm-975	191	7	,	,	PUNCT
ajlm-975	191	8	kim	kim	PROPN
ajlm-975	191	9	et	et	PROPN
ajlm-975	191	10	,	,	PUNCT
ajlm-975	191	11	et	et	PROPN
ajlm-975	191	12	al	al	PROPN
ajlm-975	191	13	.	.	PROPN
ajlm-975	191	14	viral	viral	ADJ
ajlm-975	191	15	ubiquitin	ubiquitin	ADJ
ajlm-975	191	16	ligase	ligase	NOUN
ajlm-975	191	17	stimulates	stimulate	VERB
ajlm-975	191	18	selective	selective	ADJ
ajlm-975	191	19	host	host	NOUN
ajlm-975	191	20	microrna	microrna	PROPN
ajlm-975	191	21	expression	expression	NOUN
ajlm-975	191	22	by	by	ADP
ajlm-975	191	23	targeting	target	VERB
ajlm-975	191	24	zeb	zeb	PROPN
ajlm-975	191	25	transcriptional	transcriptional	NOUN
ajlm-975	191	26	repressors	repressor	NOUN
ajlm-975	191	27	.	.	PUNCT
ajlm-975	192	1	viruses	virus	NOUN
ajlm-975	192	2	.	.	PUNCT
ajlm-975	193	1	2017;9(8):210	2017;9(8):210	X
ajlm-975	193	2	.	.	PUNCT
ajlm-975	194	1	https://doi.org/10.3390/v9080210	https://doi.org/10.3390/v9080210	NUM
ajlm-975	194	2	okoye	okoye	PROPN
ajlm-975	194	3	jo	jo	PROPN
ajlm-975	194	4	,	,	PUNCT
ajlm-975	194	5	ngokere	ngokere	NOUN
ajlm-975	194	6	aa	aa	PROPN
ajlm-975	194	7	.	.	PUNCT
ajlm-975	194	8	crosstalk	crosstalk	VERB
ajlm-975	194	9	in	in	ADP
ajlm-975	194	10	tri	tri	ADJ
ajlm-975	194	11	-	-	ADJ
ajlm-975	194	12	positive	positive	ADJ
ajlm-975	194	13	cancer	cancer	NOUN
ajlm-975	194	14	:	:	PUNCT
ajlm-975	194	15	predictor	predictor	NOUN
ajlm-975	194	16	and	and	CCONJ
ajlm-975	194	17	diagnostic	diagnostic	ADJ
ajlm-975	194	18	mirnas	mirna	NOUN
ajlm-975	194	19	in	in	ADP
ajlm-975	194	20	focus	focus	NOUN
ajlm-975	194	21	.	.	PUNCT
ajlm-975	195	1	cancer	cancer	NOUN
ajlm-975	195	2	oncol	oncol	ADJ
ajlm-975	195	3	res	re	NOUN
ajlm-975	195	4	.	.	PUNCT
ajlm-975	196	1	2016;4(2):17–32	2016;4(2):17–32	X
ajlm-975	196	2	.	.	PUNCT
ajlm-975	197	1	https://doi.org/10.13189/cor.2016.040201	https://doi.org/10.13189/cor.2016.040201	PROPN
ajlm-975	197	2	united	united	PROPN
ajlm-975	197	3	state	state	PROPN
ajlm-975	197	4	centres	centre	NOUN
ajlm-975	197	5	for	for	ADP
ajlm-975	197	6	disease	disease	NOUN
ajlm-975	197	7	control	control	NOUN
ajlm-975	197	8	and	and	CCONJ
ajlm-975	197	9	prevention	prevention	NOUN
ajlm-975	197	10	(	(	PUNCT
ajlm-975	197	11	cdc	cdc	PROPN
ajlm-975	197	12	)	)	PUNCT
ajlm-975	197	13	.	.	PUNCT
ajlm-975	198	1	hiv	hiv	PROPN
ajlm-975	198	2	risk	risk	NOUN
ajlm-975	198	3	among	among	ADP
ajlm-975	198	4	persons	person	NOUN
ajlm-975	198	5	who	who	PRON
ajlm-975	198	6	exchange	exchange	VERB
ajlm-975	198	7	sex	sex	NOUN
ajlm-975	198	8	for	for	ADP
ajlm-975	198	9	money	money	NOUN
ajlm-975	198	10	or	or	CCONJ
ajlm-975	198	11	nonmonetary	nonmonetary	ADJ
ajlm-975	198	12	items	item	NOUN
ajlm-975	198	13	.	.	PUNCT
ajlm-975	199	1	2016	2016	NUM
ajlm-975	200	1	[	[	X
ajlm-975	200	2	cited	cite	VERB
ajlm-975	200	3	2016	2016	NUM
ajlm-975	200	4	nov	nov	PROPN
ajlm-975	200	5	20	20	NUM
ajlm-975	200	6	]	]	PUNCT
ajlm-975	200	7	.	.	PUNCT
ajlm-975	201	1	available	available	ADJ
ajlm-975	201	2	from	from	ADP
ajlm-975	201	3	:	:	PUNCT
ajlm-975	201	4	http://www.cdc-hiv-sex-workers.pdf	http://www.cdc-hiv-sex-workers.pdf	PROPN
ajlm-975	201	5	joint	joint	ADJ
ajlm-975	201	6	united	united	PROPN
ajlm-975	201	7	nations	nations	PROPN
ajlm-975	201	8	programme	programme	PROPN
ajlm-975	201	9	on	on	ADP
ajlm-975	201	10	hiv	hiv	PROPN
ajlm-975	201	11	/	/	SYM
ajlm-975	201	12	aids	aids	PROPN
ajlm-975	201	13	(	(	PUNCT
ajlm-975	201	14	unaids	unaid	NOUN
ajlm-975	201	15	)	)	PUNCT
ajlm-975	201	16	.	.	PUNCT
ajlm-975	202	1	unaids	unaid	NOUN
ajlm-975	202	2	guidance	guidance	NOUN
ajlm-975	202	3	note	note	NOUN
ajlm-975	202	4	on	on	ADP
ajlm-975	202	5	hiv	hiv	PROPN
ajlm-975	202	6	and	and	CCONJ
ajlm-975	202	7	sex	sex	NOUN
ajlm-975	202	8	work	work	NOUN
ajlm-975	202	9	,	,	PUNCT
ajlm-975	202	10	2009	2009	NUM
ajlm-975	203	1	[	[	X
ajlm-975	203	2	homepage	homepage	NOUN
ajlm-975	203	3	on	on	ADP
ajlm-975	203	4	the	the	DET
ajlm-975	203	5	internet	internet	NOUN
ajlm-975	203	6	]	]	PUNCT
ajlm-975	203	7	.	.	PUNCT
ajlm-975	204	1	2009	2009	NUM
ajlm-975	205	1	[	[	X
ajlm-975	205	2	cited	cite	VERB
ajlm-975	205	3	2016	2016	NUM
ajlm-975	205	4	nov	nov	PROPN
ajlm-975	205	5	29	29	NUM
ajlm-975	205	6	]	]	PUNCT
ajlm-975	205	7	.	.	PUNCT
ajlm-975	206	1	available	available	ADJ
ajlm-975	206	2	from	from	ADP
ajlm-975	206	3	:	:	PUNCT
ajlm-975	206	4	http://unaids.org/sites/default/files/sub_landing/files/jc2306_unaids-guidance-note-hiv-sex-work_en.pdf	http://unaids.org/sites/default/files/sub_landing/files/jc2306_unaids-guidance-note-hiv-sex-work_en.pdf	NOUN
ajlm-975	206	5	world	world	PROPN
ajlm-975	206	6	health	health	NOUN
ajlm-975	206	7	organization	organization	NOUN
ajlm-975	206	8	(	(	PUNCT
ajlm-975	206	9	who	who	PRON
ajlm-975	206	10	)	)	PUNCT
ajlm-975	206	11	.	.	PUNCT
ajlm-975	207	1	hiv	hiv	PROPN
ajlm-975	207	2	/	/	SYM
ajlm-975	207	3	aids	aids	PROPN
ajlm-975	207	4	and	and	CCONJ
ajlm-975	207	5	sex	sex	NOUN
ajlm-975	207	6	workers	worker	NOUN
ajlm-975	207	7	,	,	PUNCT
ajlm-975	207	8	2004	2004	NUM
ajlm-975	208	1	[	[	X
ajlm-975	208	2	homepage	homepage	NOUN
ajlm-975	208	3	on	on	ADP
ajlm-975	208	4	the	the	DET
ajlm-975	208	5	internet	internet	NOUN
ajlm-975	208	6	]	]	PUNCT
ajlm-975	208	7	.	.	PUNCT
ajlm-975	208	8	2004	2004	NUM
ajlm-975	209	1	[	[	X
ajlm-975	209	2	cited	cite	VERB
ajlm-975	209	3	2016	2016	NUM
ajlm-975	209	4	nov	nov	PROPN
ajlm-975	209	5	28	28	NUM
ajlm-975	209	6	]	]	PUNCT
ajlm-975	209	7	.	.	PUNCT
ajlm-975	210	1	available	available	ADJ
ajlm-975	210	2	from	from	ADP
ajlm-975	210	3	:	:	PUNCT
ajlm-975	210	4	http://www.who.int/hiv/topics/sex_work/en	http://www.who.int/hiv/topics/sex_work/en	PROPN
ajlm-975	210	5	wu	wu	PROPN
ajlm-975	210	6	j	j	PROPN
ajlm-975	210	7	,	,	PUNCT
ajlm-975	210	8	li	li	PROPN
ajlm-975	210	9	xj	xj	PROPN
ajlm-975	210	10	,	,	PUNCT
ajlm-975	210	11	zhu	zhu	PROPN
ajlm-975	210	12	w	w	PROPN
ajlm-975	210	13	,	,	PUNCT
ajlm-975	210	14	et	et	PROPN
ajlm-975	210	15	al	al	PROPN
ajlm-975	210	16	.	.	PUNCT
ajlm-975	210	17	detection	detection	NOUN
ajlm-975	210	18	and	and	CCONJ
ajlm-975	210	19	pathological	pathological	ADJ
ajlm-975	210	20	value	value	NOUN
ajlm-975	210	21	of	of	ADP
ajlm-975	210	22	papillomavirus	papillomavirus	NOUN
ajlm-975	210	23	dna	dna	NOUN
ajlm-975	210	24	and	and	CCONJ
ajlm-975	210	25	p16	p16	NOUN
ajlm-975	210	26	and	and	CCONJ
ajlm-975	210	27	p53	p53	NOUN
ajlm-975	210	28	protein	protein	NOUN
ajlm-975	210	29	expression	expression	NOUN
ajlm-975	210	30	in	in	ADP
ajlm-975	210	31	cervical	cervical	ADJ
ajlm-975	210	32	intraepithelial	intraepithelial	ADJ
ajlm-975	210	33	neoplasia	neoplasia	NOUN
ajlm-975	210	34	.	.	PUNCT
ajlm-975	211	1	oncol	oncol	ADJ
ajlm-975	211	2	lett	lett	PROPN
ajlm-975	211	3	.	.	PUNCT
ajlm-975	212	1	2014;7:738–744	2014;7:738–744	NUM
ajlm-975	212	2	.	.	PUNCT
ajlm-975	213	1	https://doi.org/10.3892/ol.2014.1791	https://doi.org/10.3892/ol.2014.1791	PROPN
ajlm-975	213	2	hellman	hellman	PROPN
ajlm-975	213	3	k	k	PROPN
ajlm-975	213	4	,	,	PUNCT
ajlm-975	213	5	lindquist	lindquist	PROPN
ajlm-975	213	6	d	d	PROPN
ajlm-975	213	7	,	,	PUNCT
ajlm-975	213	8	ranhem	ranhem	PROPN
ajlm-975	213	9	c	c	NOUN
ajlm-975	213	10	,	,	PUNCT
ajlm-975	213	11	et	et	PROPN
ajlm-975	213	12	al	al	PROPN
ajlm-975	213	13	.	.	PUNCT
ajlm-975	214	1	human	human	ADJ
ajlm-975	214	2	papillomavirus	papillomavirus	PROPN
ajlm-975	214	3	,	,	PUNCT
ajlm-975	214	4	p16ink4a	p16ink4a	PROPN
ajlm-975	214	5	,	,	PUNCT
ajlm-975	214	6	and	and	CCONJ
ajlm-975	214	7	ki-67	ki-67	ADJ
ajlm-975	214	8	in	in	ADP
ajlm-975	214	9	relation	relation	NOUN
ajlm-975	214	10	to	to	ADP
ajlm-975	214	11	clinicopathological	clinicopathological	ADJ
ajlm-975	214	12	variables	variable	NOUN
ajlm-975	214	13	and	and	CCONJ
ajlm-975	214	14	survival	survival	NOUN
ajlm-975	214	15	in	in	ADP
ajlm-975	214	16	primary	primary	ADJ
ajlm-975	214	17	carcinoma	carcinoma	NOUN
ajlm-975	214	18	of	of	ADP
ajlm-975	214	19	the	the	DET
ajlm-975	214	20	vagina	vagina	NOUN
ajlm-975	214	21	.	.	PUNCT
ajlm-975	215	1	br	br	PROPN
ajlm-975	215	2	j	j	PROPN
ajlm-975	215	3	cancer	cancer	NOUN
ajlm-975	215	4	.	.	PUNCT
ajlm-975	216	1	2014;110:1561–1570	2014;110:1561–1570	X
ajlm-975	216	2	.	.	PUNCT
ajlm-975	217	1	https://doi.org/10.1038/bjc.2014.32	https://doi.org/10.1038/bjc.2014.32	PROPN
ajlm-975	217	2	toni	toni	PROPN
ajlm-975	217	3	ls	ls	PROPN
ajlm-975	217	4	,	,	PUNCT
ajlm-975	217	5	garcia	garcia	PROPN
ajlm-975	217	6	am	be	AUX
ajlm-975	217	7	,	,	PUNCT
ajlm-975	217	8	jeffrey	jeffrey	PROPN
ajlm-975	217	9	da	da	PROPN
ajlm-975	217	10	,	,	PUNCT
ajlm-975	217	11	et	et	PROPN
ajlm-975	217	12	al	al	PROPN
ajlm-975	217	13	.	.	PUNCT
ajlm-975	217	14	optimization	optimization	NOUN
ajlm-975	217	15	of	of	ADP
ajlm-975	217	16	phenol	phenol	NOUN
ajlm-975	217	17	-	-	PUNCT
ajlm-975	217	18	chloroform	chloroform	NOUN
ajlm-975	217	19	rna	rna	NOUN
ajlm-975	217	20	extraction	extraction	NOUN
ajlm-975	217	21	.	.	PUNCT
ajlm-975	218	1	methodsx	methodsx	PROPN
ajlm-975	218	2	.	.	PUNCT
ajlm-975	219	1	2018;5:599–608	2018;5:599–608	NUM
ajlm-975	219	2	.	.	PUNCT
ajlm-975	220	1	https://doi.org/10.1016/j.mex.2018.05.011	https://doi.org/10.1016/j.mex.2018.05.011	PROPN
ajlm-975	220	2	yang	yang	PROPN
ajlm-975	220	3	l	l	PROPN
ajlm-975	220	4	-	-	PROPN
ajlm-975	220	5	h	h	PROPN
ajlm-975	220	6	,	,	PUNCT
ajlm-975	220	7	wang	wang	PROPN
ajlm-975	220	8	s	s	PROPN
ajlm-975	220	9	-	-	PUNCT
ajlm-975	220	10	l	l	NOUN
ajlm-975	220	11	,	,	PUNCT
ajlm-975	220	12	tang	tang	ADJ
ajlm-975	220	13	l	l	NOUN
ajlm-975	220	14	-	-	NOUN
ajlm-975	220	15	l	l	NOUN
ajlm-975	220	16	,	,	PUNCT
ajlm-975	220	17	et	et	PROPN
ajlm-975	220	18	al	al	PROPN
ajlm-975	220	19	.	.	PUNCT
ajlm-975	221	1	universal	universal	ADJ
ajlm-975	221	2	stem	stem	NOUN
ajlm-975	221	3	-	-	PUNCT
ajlm-975	221	4	loop	loop	NOUN
ajlm-975	221	5	primer	primer	NOUN
ajlm-975	221	6	method	method	NOUN
ajlm-975	221	7	for	for	ADP
ajlm-975	221	8	screening	screening	NOUN
ajlm-975	221	9	and	and	CCONJ
ajlm-975	221	10	quantification	quantification	NOUN
ajlm-975	221	11	of	of	ADP
ajlm-975	221	12	microrna	microrna	PROPN
ajlm-975	221	13	.	.	PUNCT
ajlm-975	222	1	plos	plos	PROPN
ajlm-975	222	2	one	one	NUM
ajlm-975	222	3	.	.	PUNCT
ajlm-975	223	1	2014;9(12):e115293	2014;9(12):e115293	X
ajlm-975	223	2	.	.	PUNCT
ajlm-975	224	1	https://doi.org/10.1371/journal.pone.0115293	https://doi.org/10.1371/journal.pone.0115293	PROPN
ajlm-975	224	2	dong	dong	PROPN
ajlm-975	224	3	j	j	PROPN
ajlm-975	224	4	,	,	PUNCT
ajlm-975	224	5	wang	wang	PROPN
ajlm-975	224	6	m	m	PROPN
ajlm-975	224	7	,	,	PUNCT
ajlm-975	224	8	ni	ni	PROPN
ajlm-975	224	9	d	d	PROPN
ajlm-975	224	10	,	,	PUNCT
ajlm-975	224	11	et	et	PROPN
ajlm-975	224	12	al	al	PROPN
ajlm-975	224	13	.	.	PUNCT
ajlm-975	224	14	microrna-217	microrna-217	ADJ
ajlm-975	224	15	functions	function	NOUN
ajlm-975	224	16	as	as	ADP
ajlm-975	224	17	a	a	DET
ajlm-975	224	18	tumor	tumor	NOUN
ajlm-975	224	19	suppressor	suppressor	NOUN
ajlm-975	224	20	in	in	ADP
ajlm-975	224	21	cervical	cervical	ADJ
ajlm-975	224	22	cancer	cancer	NOUN
ajlm-975	224	23	cells	cell	NOUN
ajlm-975	224	24	through	through	ADP
ajlm-975	224	25	targeting	target	VERB
ajlm-975	224	26	rho	rho	ADJ
ajlm-975	224	27	-	-	PUNCT
ajlm-975	224	28	associated	associate	VERB
ajlm-975	224	29	protein	protein	NOUN
ajlm-975	224	30	kinase	kinase	NOUN
ajlm-975	224	31	1	1	NUM
ajlm-975	224	32	.	.	PUNCT
ajlm-975	224	33	oncol	oncol	ADJ
ajlm-975	224	34	lett	lett	PROPN
ajlm-975	224	35	.	.	PUNCT
ajlm-975	225	1	2018;16(5):5535–5542	2018;16(5):5535–5542	NUM
ajlm-975	225	2	.	.	PUNCT
ajlm-975	225	3	https://doi.org/10.3892/ol.2018.9335	https://doi.org/10.3892/ol.2018.9335	PROPN
ajlm-975	225	4	okoye	okoye	PROPN
ajlm-975	225	5	jo	jo	PROPN
ajlm-975	225	6	,	,	PUNCT
ajlm-975	225	7	ngokere	ngokere	NOUN
ajlm-975	225	8	aa	aa	NOUN
ajlm-975	225	9	,	,	PUNCT
ajlm-975	225	10	onyenekwe	onyenekwe	NOUN
ajlm-975	225	11	cc	cc	NOUN
ajlm-975	225	12	,	,	PUNCT
ajlm-975	225	13	erinle	erinle	ADJ
ajlm-975	225	14	ca	ca	NOUN
ajlm-975	225	15	.	.	PUNCT
ajlm-975	225	16	comparable	comparable	ADJ
ajlm-975	225	17	expression	expression	NOUN
ajlm-975	225	18	of	of	ADP
ajlm-975	225	19	mir	mir	NOUN
ajlm-975	225	20	-	-	ADJ
ajlm-975	225	21	let-7b	let-7b	PROPN
ajlm-975	225	22	,	,	PUNCT
ajlm-975	225	23	mir-21	mir-21	PROPN
ajlm-975	225	24	,	,	PUNCT
ajlm-975	225	25	mir-182	mir-182	NOUN
ajlm-975	225	26	,	,	PUNCT
ajlm-975	225	27	mir-145	mir-145	NOUN
ajlm-975	225	28	,	,	PUNCT
ajlm-975	225	29	and	and	CCONJ
ajlm-975	225	30	p53	p53	NOUN
ajlm-975	225	31	in	in	ADP
ajlm-975	225	32	serum	serum	NOUN
ajlm-975	225	33	and	and	CCONJ
ajlm-975	225	34	cervical	cervical	ADJ
ajlm-975	225	35	cells	cell	NOUN
ajlm-975	225	36	:	:	PUNCT
ajlm-975	225	37	diagnostic	diagnostic	ADJ
ajlm-975	225	38	implications	implication	NOUN
ajlm-975	225	39	for	for	ADP
ajlm-975	225	40	early	early	ADJ
ajlm-975	225	41	detection	detection	NOUN
ajlm-975	225	42	of	of	ADP
ajlm-975	225	43	cervical	cervical	ADJ
ajlm-975	225	44	lesions	lesion	NOUN
ajlm-975	225	45	.	.	PUNCT
ajlm-975	226	1	int	int	NOUN
ajlm-975	226	2	j	j	PROPN
ajlm-975	226	3	health	health	PROPN
ajlm-975	226	4	sci	sci	PROPN
ajlm-975	226	5	(	(	PUNCT
ajlm-975	226	6	qassim	qassim	NOUN
ajlm-975	226	7	)	)	PUNCT
ajlm-975	227	1	[	[	X
ajlm-975	227	2	serial	serial	ADJ
ajlm-975	227	3	online	online	NOUN
ajlm-975	227	4	]	]	PUNCT
ajlm-975	227	5	.	.	PUNCT
ajlm-975	228	1	2019	2019	NUM
ajlm-975	229	1	[	[	X
ajlm-975	229	2	cited	cite	VERB
ajlm-975	229	3	2020	2020	NUM
ajlm-975	229	4	april	april	PROPN
ajlm-975	229	5	27];13:29–38	27];13:29–38	NUM
ajlm-975	229	6	.	.	PUNCT
ajlm-975	230	1	available	available	ADJ
ajlm-975	230	2	from	from	ADP
ajlm-975	230	3	:	:	PUNCT
ajlm-975	230	4	https://ijhs.org.sa/index.php/journal/article/view/4107	https://ijhs.org.sa/index.php/journal/article/view/4107	PROPN
ajlm-975	230	5	mitchell	mitchell	PROPN
ajlm-975	230	6	k	k	PROPN
ajlm-975	230	7	and	and	CCONJ
ajlm-975	230	8	iadarola	iadarola	PROPN
ajlm-975	230	9	mj	mj	PROPN
ajlm-975	230	10	.	.	PUNCT
ajlm-975	231	1	rt	rt	ADJ
ajlm-975	231	2	-	-	PUNCT
ajlm-975	231	3	pcr	pcr	NOUN
ajlm-975	231	4	analysis	analysis	NOUN
ajlm-975	231	5	of	of	ADP
ajlm-975	231	6	pain	pain	NOUN
ajlm-975	231	7	genes	gene	NOUN
ajlm-975	231	8	:	:	PUNCT
ajlm-975	231	9	use	use	NOUN
ajlm-975	231	10	of	of	ADP
ajlm-975	231	11	gel	gel	NOUN
ajlm-975	231	12	-	-	PUNCT
ajlm-975	231	13	based	base	VERB
ajlm-975	231	14	rt	rt	NOUN
ajlm-975	231	15	-	-	PUNCT
ajlm-975	231	16	pcr	pcr	PROPN
ajlm-975	231	17	for	for	ADP
ajlm-975	231	18	studying	study	VERB
ajlm-975	231	19	induced	induced	ADJ
ajlm-975	231	20	and	and	CCONJ
ajlm-975	231	21	tissue	tissue	NOUN
ajlm-975	231	22	-	-	PUNCT
ajlm-975	231	23	enriched	enrich	VERB
ajlm-975	231	24	gene	gene	NOUN
ajlm-975	231	25	expression	expression	NOUN
ajlm-975	231	26	.	.	PUNCT
ajlm-975	232	1	methods	method	NOUN
ajlm-975	232	2	mol	mol	ADP
ajlm-975	232	3	biol	biol	PROPN
ajlm-975	232	4	.	.	PUNCT
ajlm-975	233	1	2010;617:279–295	2010;617:279–295	NUM
ajlm-975	233	2	.	.	PUNCT
ajlm-975	234	1	https://doi.org/10.1007/978-1-60327-323-7_21	https://doi.org/10.1007/978-1-60327-323-7_21	PROPN
ajlm-975	234	2	motsch	motsch	NOUN
ajlm-975	234	3	n	n	CCONJ
ajlm-975	234	4	,	,	PUNCT
ajlm-975	234	5	alles	alle	VERB
ajlm-975	234	6	j	j	PROPN
ajlm-975	234	7	,	,	PUNCT
ajlm-975	234	8	imig	imig	PROPN
ajlm-975	234	9	j	j	PROPN
ajlm-975	234	10	,	,	PUNCT
ajlm-975	235	1	et	et	PROPN
ajlm-975	235	2	al	al	PROPN
ajlm-975	235	3	.	.	PUNCT
ajlm-975	235	4	microrna	microrna	PROPN
ajlm-975	235	5	profiling	profiling	PROPN
ajlm-975	235	6	of	of	ADP
ajlm-975	235	7	epstein	epstein	PROPN
ajlm-975	235	8	-	-	PUNCT
ajlm-975	235	9	barr	barr	PROPN
ajlm-975	235	10	virus	virus	PROPN
ajlm-975	235	11	-	-	PUNCT
ajlm-975	235	12	associated	associate	VERB
ajlm-975	235	13	nk	nk	PROPN
ajlm-975	235	14	/	/	SYM
ajlm-975	235	15	t	t	PROPN
ajlm-975	235	16	-	-	PUNCT
ajlm-975	235	17	cell	cell	NOUN
ajlm-975	235	18	lymphomas	lymphoma	NOUN
ajlm-975	235	19	by	by	ADP
ajlm-975	235	20	deep	deep	ADJ
ajlm-975	235	21	sequencing	sequencing	NOUN
ajlm-975	235	22	.	.	PUNCT
ajlm-975	236	1	plos	plos	PROPN
ajlm-975	236	2	one	one	NUM
ajlm-975	236	3	.	.	PUNCT
ajlm-975	237	1	2012;7(8):e42193	2012;7(8):e42193	X
ajlm-975	237	2	.	.	PUNCT
ajlm-975	238	1	https://doi.org/10.1371/journal.pone.0042193	https://doi.org/10.1371/journal.pone.0042193	X
ajlm-975	238	2	martinez	martinez	PROPN
ajlm-975	239	1	i	i	PROPN
ajlm-975	239	2	,	,	PUNCT
ajlm-975	239	3	gardiner	gardiner	PROPN
ajlm-975	239	4	as	as	ADP
ajlm-975	239	5	,	,	PUNCT
ajlm-975	239	6	board	board	PROPN
ajlm-975	239	7	kf	kf	PROPN
ajlm-975	239	8	,	,	PUNCT
ajlm-975	239	9	et	et	PROPN
ajlm-975	239	10	al	al	PROPN
ajlm-975	239	11	.	.	PROPN
ajlm-975	240	1	human	human	ADJ
ajlm-975	240	2	papillomavirus	papillomavirus	NOUN
ajlm-975	240	3	type	type	NOUN
ajlm-975	240	4	16	16	NUM
ajlm-975	240	5	reduces	reduce	VERB
ajlm-975	240	6	the	the	DET
ajlm-975	240	7	expression	expression	NOUN
ajlm-975	240	8	of	of	ADP
ajlm-975	240	9	microrna-218	microrna-218	NOUN
ajlm-975	240	10	in	in	ADP
ajlm-975	240	11	cervical	cervical	ADJ
ajlm-975	240	12	carcinoma	carcinoma	NOUN
ajlm-975	240	13	cells	cell	NOUN
ajlm-975	240	14	.	.	PUNCT
ajlm-975	241	1	oncogene	oncogene	NOUN
ajlm-975	241	2	.	.	PUNCT
ajlm-975	242	1	2008;27:2575–2582	2008;27:2575–2582	NUM
ajlm-975	242	2	.	.	PUNCT
ajlm-975	243	1	https://doi.org/10.1038/sj.onc.1210919	https://doi.org/10.1038/sj.onc.1210919	PROPN
ajlm-975	244	1	wang	wang	PROPN
ajlm-975	244	2	x	x	PROPN
ajlm-975	244	3	,	,	PUNCT
ajlm-975	244	4	tang	tang	PROPN
ajlm-975	244	5	s	s	PART
ajlm-975	244	6	,	,	PUNCT
ajlm-975	244	7	le	le	X
ajlm-975	244	8	sy	sy	PROPN
ajlm-975	244	9	.	.	NOUN
ajlm-975	244	10	aberrant	aberrant	ADJ
ajlm-975	244	11	expression	expression	NOUN
ajlm-975	244	12	of	of	ADP
ajlm-975	244	13	oncogenic	oncogenic	ADJ
ajlm-975	244	14	and	and	CCONJ
ajlm-975	244	15	tumor	tumor	NOUN
ajlm-975	244	16	-	-	PUNCT
ajlm-975	244	17	suppressive	suppressive	NOUN
ajlm-975	244	18	micrornas	microrna	NOUN
ajlm-975	244	19	in	in	ADP
ajlm-975	244	20	cervical	cervical	ADJ
ajlm-975	244	21	cancer	cancer	NOUN
ajlm-975	244	22	is	be	AUX
ajlm-975	244	23	required	require	VERB
ajlm-975	244	24	for	for	ADP
ajlm-975	244	25	cancer	cancer	NOUN
ajlm-975	244	26	cell	cell	NOUN
ajlm-975	244	27	growth	growth	NOUN
ajlm-975	244	28	.	.	PUNCT
ajlm-975	245	1	plos	plos	PROPN
ajlm-975	245	2	one	one	NUM
ajlm-975	245	3	.	.	PUNCT
ajlm-975	246	1	2008;3(7):e2557	2008;3(7):e2557	X
ajlm-975	246	2	.	.	PUNCT
ajlm-975	247	1	https://doi.org/10.1371/journal.pone.0002557	https://doi.org/10.1371/journal.pone.0002557	PROPN
ajlm-975	247	2	lao	lao	PROPN
ajlm-975	247	3	g	g	PROPN
ajlm-975	247	4	,	,	PUNCT
ajlm-975	247	5	liu	liu	PROPN
ajlm-975	247	6	p	p	PROPN
ajlm-975	247	7	,	,	PUNCT
ajlm-975	247	8	wu	wu	PROPN
ajlm-975	247	9	q	q	PROPN
ajlm-975	247	10	,	,	PUNCT
ajlm-975	248	1	et	et	PROPN
ajlm-975	248	2	al	al	PROPN
ajlm-975	248	3	.	.	PROPN
ajlm-975	248	4	mir-155	mir-155	AUX
ajlm-975	248	5	promotes	promote	VERB
ajlm-975	248	6	cervical	cervical	ADJ
ajlm-975	248	7	cancer	cancer	NOUN
ajlm-975	248	8	cell	cell	NOUN
ajlm-975	248	9	proliferation	proliferation	NOUN
ajlm-975	248	10	through	through	ADP
ajlm-975	248	11	suppression	suppression	NOUN
ajlm-975	248	12	of	of	ADP
ajlm-975	248	13	its	its	PRON
ajlm-975	248	14	target	target	NOUN
ajlm-975	248	15	gene	gene	NOUN
ajlm-975	248	16	lkb1	lkb1	PROPN
ajlm-975	248	17	.	.	PUNCT
ajlm-975	249	1	tumour	tumour	PROPN
ajlm-975	249	2	biol	biol	PROPN
ajlm-975	249	3	.	.	PUNCT
ajlm-975	250	1	2014;35:11933–11938	2014;35:11933–11938	X
ajlm-975	250	2	.	.	PUNCT
ajlm-975	251	1	https://doi.org/10.1007/s13277-014-2479-7	https://doi.org/10.1007/s13277-014-2479-7	CCONJ
ajlm-975	251	2	muralidhar	muralidhar	PROPN
ajlm-975	251	3	b	b	X
ajlm-975	251	4	,	,	PUNCT
ajlm-975	251	5	goldstein	goldstein	PROPN
ajlm-975	251	6	ld	ld	PROPN
ajlm-975	251	7	,	,	PUNCT
ajlm-975	251	8	ng	ng	PROPN
ajlm-975	251	9	g	g	PROPN
ajlm-975	251	10	,	,	PUNCT
ajlm-975	251	11	et	et	PROPN
ajlm-975	251	12	al	al	PROPN
ajlm-975	251	13	.	.	PROPN
ajlm-975	251	14	global	global	PROPN
ajlm-975	251	15	microrna	microrna	PROPN
ajlm-975	251	16	profiles	profile	NOUN
ajlm-975	251	17	in	in	ADP
ajlm-975	251	18	cervical	cervical	ADJ
ajlm-975	251	19	squamous	squamous	ADJ
ajlm-975	251	20	cell	cell	NOUN
ajlm-975	251	21	carcinoma	carcinoma	NOUN
ajlm-975	251	22	depend	depend	VERB
ajlm-975	251	23	on	on	ADP
ajlm-975	251	24	drosha	drosha	ADJ
ajlm-975	251	25	expression	expression	NOUN
ajlm-975	251	26	levels	level	NOUN
ajlm-975	251	27	.	.	PUNCT
ajlm-975	252	1	j	j	PROPN
ajlm-975	252	2	pathol	pathol	NOUN
ajlm-975	252	3	.	.	PUNCT
ajlm-975	253	1	2007;212:368–377	2007;212:368–377	X
ajlm-975	253	2	.	.	PUNCT
ajlm-975	254	1	https://doi.org/10.1002/path.2179	https://doi.org/10.1002/path.2179	PROPN
ajlm-975	254	2	gómez	gómez	NOUN
ajlm-975	254	3	-	-	PUNCT
ajlm-975	254	4	gómez	gómez	NOUN
ajlm-975	254	5	y	y	PROPN
ajlm-975	254	6	,	,	PUNCT
ajlm-975	254	7	organista	organista	NOUN
ajlm-975	254	8	-	-	PUNCT
ajlm-975	254	9	nava	nava	PROPN
ajlm-975	254	10	j	j	PROPN
ajlm-975	254	11	,	,	PUNCT
ajlm-975	254	12	gariglio	gariglio	NOUN
ajlm-975	254	13	p.	p.	NOUN
ajlm-975	254	14	deregulation	deregulation	NOUN
ajlm-975	254	15	of	of	ADP
ajlm-975	254	16	the	the	DET
ajlm-975	254	17	mirnas	mirna	NOUN
ajlm-975	254	18	expression	expression	NOUN
ajlm-975	254	19	in	in	ADP
ajlm-975	254	20	cervical	cervical	ADJ
ajlm-975	254	21	cancer	cancer	NOUN
ajlm-975	254	22	:	:	PUNCT
ajlm-975	254	23	human	human	ADJ
ajlm-975	254	24	papillomavirus	papillomavirus	NOUN
ajlm-975	254	25	implications	implication	NOUN
ajlm-975	254	26	.	.	PUNCT
ajlm-975	254	27	biomed	biome	VERB
ajlm-975	254	28	res	re	NOUN
ajlm-975	254	29	int	int	NOUN
ajlm-975	254	30	.	.	PUNCT
ajlm-975	255	1	2013;2013:1–15	2013;2013:1–15	NUM
ajlm-975	255	2	.	.	PUNCT
ajlm-975	256	1	https://doi.org/10.1155/2013/407052	https://doi.org/10.1155/2013/407052	PROPN
ajlm-975	256	2	park	park	NOUN
ajlm-975	256	3	bj	bj	NOUN
ajlm-975	256	4	,	,	PUNCT
ajlm-975	256	5	oh	oh	INTJ
ajlm-975	256	6	ys	ys	INTJ
ajlm-975	256	7	,	,	PUNCT
ajlm-975	256	8	park	park	NOUN
ajlm-975	256	9	sy	sy	PROPN
ajlm-975	256	10	,	,	PUNCT
ajlm-975	256	11	et	et	PROPN
ajlm-975	256	12	al	al	PROPN
ajlm-975	256	13	.	.	PUNCT
ajlm-975	256	14	aimp3	aimp3	PROPN
ajlm-975	257	1	haploinsufficiency	haploinsufficiency	PROPN
ajlm-975	257	2	disrupts	disrupt	VERB
ajlm-975	257	3	oncogene	oncogene	NOUN
ajlm-975	257	4	-	-	PUNCT
ajlm-975	257	5	induced	induce	VERB
ajlm-975	257	6	p53	p53	NOUN
ajlm-975	257	7	activation	activation	NOUN
ajlm-975	257	8	and	and	CCONJ
ajlm-975	257	9	genomic	genomic	NOUN
ajlm-975	257	10	stability	stability	NOUN
ajlm-975	257	11	.	.	PUNCT
ajlm-975	258	1	cancer	cancer	NOUN
ajlm-975	258	2	res	re	NOUN
ajlm-975	258	3	.	.	PUNCT
ajlm-975	259	1	2006;66(14):6913–6918	2006;66(14):6913–6918	NUM
ajlm-975	259	2	.	.	PUNCT
ajlm-975	260	1	https://doi.org/10.1158/0008-5472.can-05-3740	https://doi.org/10.1158/0008-5472.can-05-3740	PROPN
ajlm-975	260	2	zatonski	zatonski	PROPN
ajlm-975	260	3	t	t	PROPN
ajlm-975	260	4	,	,	PUNCT
ajlm-975	260	5	ciesielska	ciesielska	ADJ
ajlm-975	260	6	u	u	NOUN
ajlm-975	260	7	,	,	PUNCT
ajlm-975	260	8	nowinska	nowinska	PROPN
ajlm-975	260	9	k	k	PROPN
ajlm-975	260	10	,	,	PUNCT
ajlm-975	260	11	et	et	PROPN
ajlm-975	260	12	al	al	PROPN
ajlm-975	260	13	.	.	PUNCT
ajlm-975	261	1	expression	expression	NOUN
ajlm-975	261	2	of	of	ADP
ajlm-975	261	3	cell	cell	NOUN
ajlm-975	261	4	cycle	cycle	NOUN
ajlm-975	261	5	-	-	PUNCT
ajlm-975	261	6	related	relate	VERB
ajlm-975	261	7	proteins	protein	NOUN
ajlm-975	261	8	p16	p16	NOUN
ajlm-975	261	9	,	,	PUNCT
ajlm-975	261	10	p27	p27	NOUN
ajlm-975	261	11	,	,	PUNCT
ajlm-975	261	12	p53	p53	NOUN
ajlm-975	261	13	and	and	CCONJ
ajlm-975	261	14	ki-67	ki-67	ADJ
ajlm-975	261	15	in	in	ADP
ajlm-975	261	16	hpv	hpv	NOUN
ajlm-975	261	17	-	-	PUNCT
ajlm-975	261	18	positive	positive	ADJ
ajlm-975	261	19	and	and	CCONJ
ajlm-975	261	20	-negative	-negative	ADJ
ajlm-975	261	21	samples	sample	NOUN
ajlm-975	261	22	of	of	ADP
ajlm-975	261	23	papillomas	papilloma	NOUN
ajlm-975	261	24	of	of	ADP
ajlm-975	261	25	the	the	DET
ajlm-975	261	26	upper	upper	ADJ
ajlm-975	261	27	respiratory	respiratory	ADJ
ajlm-975	261	28	tract	tract	NOUN
ajlm-975	261	29	.	.	PUNCT
ajlm-975	262	1	anticancer	anticancer	NOUN
ajlm-975	262	2	res	re	NOUN
ajlm-975	262	3	[	[	X
ajlm-975	262	4	serial	serial	ADJ
ajlm-975	262	5	online	online	NOUN
ajlm-975	262	6	]	]	PUNCT
ajlm-975	262	7	.	.	PUNCT
ajlm-975	263	1	2016	2016	NUM
ajlm-975	264	1	[	[	X
ajlm-975	264	2	cited	cite	VERB
ajlm-975	264	3	2020	2020	NUM
ajlm-975	264	4	feb	feb	X
ajlm-975	264	5	26];36:3917–3924	26];36:3917–3924	NUM
ajlm-975	264	6	.	.	PUNCT
ajlm-975	265	1	available	available	ADJ
ajlm-975	265	2	from	from	ADP
ajlm-975	265	3	:	:	PUNCT
ajlm-975	265	4	http://ar.iiarjournals.org/content/36/8/3917.full.pdf	http://ar.iiarjournals.org/content/36/8/3917.full.pdf	PROPN
ajlm-975	265	5	ribeiro	ribeiro	PROPN
ajlm-975	265	6	j	j	PROPN
ajlm-975	265	7	,	,	PUNCT
ajlm-975	265	8	marinho	marinho	NOUN
ajlm-975	265	9	-	-	PUNCT
ajlm-975	265	10	dias	dias	PROPN
ajlm-975	265	11	j	j	PROPN
ajlm-975	265	12	,	,	PUNCT
ajlm-975	265	13	monteiro	monteiro	PROPN
ajlm-975	265	14	p	p	PROPN
ajlm-975	265	15	,	,	PUNCT
ajlm-975	265	16	et	et	PROPN
ajlm-975	265	17	al	al	PROPN
ajlm-975	265	18	.	.	PROPN
ajlm-975	265	19	mir-34a	mir-34a	NUM
ajlm-975	265	20	and	and	CCONJ
ajlm-975	265	21	mir-125b	mir-125b	NOUN
ajlm-975	265	22	expression	expression	NOUN
ajlm-975	265	23	in	in	ADP
ajlm-975	265	24	hpv	hpv	ADJ
ajlm-975	265	25	infection	infection	NOUN
ajlm-975	265	26	and	and	CCONJ
ajlm-975	265	27	cervical	cervical	ADJ
ajlm-975	265	28	cancer	cancer	NOUN
ajlm-975	265	29	development	development	NOUN
ajlm-975	265	30	.	.	PUNCT
ajlm-975	266	1	oncotarget	oncotarget	NOUN
ajlm-975	266	2	.	.	PUNCT
ajlm-975	267	1	2015;2015:1–6	2015;2015:1–6	NUM
ajlm-975	267	2	.	.	PUNCT
ajlm-975	268	1	https://doi.org/10.1155/2015/304584	https://doi.org/10.1155/2015/304584	PROPN
ajlm-975	268	2	nuovo	nuovo	PROPN
ajlm-975	268	3	gj	gj	PROPN
ajlm-975	268	4	,	,	PUNCT
ajlm-975	268	5	wu	wu	PROPN
ajlm-975	268	6	x	x	PROPN
ajlm-975	268	7	,	,	PUNCT
ajlm-975	268	8	volinia	volinia	NOUN
ajlm-975	268	9	s	s	PROPN
ajlm-975	268	10	,	,	PUNCT
ajlm-975	268	11	et	et	PROPN
ajlm-975	268	12	al	al	PROPN
ajlm-975	268	13	.	.	PUNCT
ajlm-975	269	1	strong	strong	ADJ
ajlm-975	269	2	inverse	inverse	NOUN
ajlm-975	269	3	correlation	correlation	NOUN
ajlm-975	269	4	between	between	ADP
ajlm-975	269	5	microrna-125b	microrna-125b	PROPN
ajlm-975	269	6	and	and	CCONJ
ajlm-975	269	7	human	human	ADJ
ajlm-975	269	8	papillomavirus	papillomavirus	NOUN
ajlm-975	269	9	dna	dna	NOUN
ajlm-975	269	10	in	in	ADP
ajlm-975	269	11	productive	productive	ADJ
ajlm-975	269	12	infection	infection	NOUN
ajlm-975	269	13	.	.	PUNCT
ajlm-975	270	1	diagn	diagn	NOUN
ajlm-975	270	2	mol	mol	ADP
ajlm-975	270	3	pathol	pathol	NOUN
ajlm-975	270	4	.	.	PUNCT
ajlm-975	271	1	2010;19(3):135–143	2010;19(3):135–143	X
ajlm-975	271	2	.	.	PUNCT
ajlm-975	271	3	https://doi.org/10.1097/pdm.0b013e3181c4daaa	https://doi.org/10.1097/pdm.0b013e3181c4daaa	NOUN
ajlm-975	271	4	banno	banno	PROPN
ajlm-975	271	5	k	k	PROPN
ajlm-975	271	6	,	,	PUNCT
ajlm-975	271	7	iida	iida	PROPN
ajlm-975	271	8	m	m	PROPN
ajlm-975	271	9	,	,	PUNCT
ajlm-975	271	10	yanokura	yanokura	NOUN
ajlm-975	271	11	m	m	PROPN
ajlm-975	271	12	,	,	PUNCT
ajlm-975	271	13	et	et	PROPN
ajlm-975	271	14	al	al	PROPN
ajlm-975	271	15	.	.	PUNCT
ajlm-975	271	16	microrna	microrna	PROPN
ajlm-975	271	17	in	in	ADP
ajlm-975	271	18	cervical	cervical	ADJ
ajlm-975	271	19	cancer	cancer	NOUN
ajlm-975	271	20	:	:	PUNCT
ajlm-975	271	21	oncomirs	oncomir	NOUN
ajlm-975	271	22	and	and	CCONJ
ajlm-975	271	23	tumor	tumor	NOUN
ajlm-975	271	24	suppressor	suppressor	NOUN
ajlm-975	271	25	mirs	mir	NOUN
ajlm-975	271	26	in	in	ADP
ajlm-975	271	27	diagnosis	diagnosis	NOUN
ajlm-975	271	28	and	and	CCONJ
ajlm-975	271	29	treatment	treatment	NOUN
ajlm-975	271	30	.	.	PUNCT
ajlm-975	272	1	sci	sci	PROPN
ajlm-975	272	2	world	world	PROPN
ajlm-975	272	3	j.	j.	PROPN
ajlm-975	272	4	2014;2014:178075	2014;2014:178075	PROPN
ajlm-975	272	5	.	.	PUNCT
ajlm-975	273	1	https://doi.org/10.1155/2014/178075	https://doi.org/10.1155/2014/178075	PROPN
ajlm-975	273	2	pereira	pereira	PROPN
ajlm-975	273	3	pm	pm	PROPN
ajlm-975	273	4	,	,	PUNCT
ajlm-975	273	5	marques	marques	PROPN
ajlm-975	273	6	jp	jp	PROPN
ajlm-975	273	7	,	,	PUNCT
ajlm-975	273	8	soares	soares	PROPN
ajlm-975	273	9	ar	ar	PROPN
ajlm-975	273	10	,	,	PUNCT
ajlm-975	274	1	et	et	PROPN
ajlm-975	274	2	al	al	PROPN
ajlm-975	274	3	.	.	PUNCT
ajlm-975	274	4	microrna	microrna	PROPN
ajlm-975	274	5	expression	expression	NOUN
ajlm-975	274	6	variability	variability	NOUN
ajlm-975	274	7	in	in	ADP
ajlm-975	274	8	human	human	ADJ
ajlm-975	274	9	cervical	cervical	ADJ
ajlm-975	274	10	tissues	tissue	NOUN
ajlm-975	274	11	.	.	PUNCT
ajlm-975	275	1	plos	plos	PROPN
ajlm-975	275	2	one	one	NUM
ajlm-975	275	3	.	.	PUNCT
ajlm-975	276	1	2010;5(7):e11780	2010;5(7):e11780	NUM
ajlm-975	276	2	.	.	PUNCT
ajlm-975	277	1	https://doi.org/10.1371/journal.pone.0011780	https://doi.org/10.1371/journal.pone.0011780	PROPN
ajlm-975	277	2	gunasekharan	gunasekharan	PROPN
ajlm-975	277	3	v	v	NOUN
ajlm-975	277	4	,	,	PUNCT
ajlm-975	277	5	laimins	laimins	PROPN
ajlm-975	277	6	la	la	PROPN
ajlm-975	277	7	.	.	PUNCT
ajlm-975	278	1	human	human	ADJ
ajlm-975	278	2	papillomaviruses	papillomaviruse	NOUN
ajlm-975	278	3	modulate	modulate	VERB
ajlm-975	278	4	microrna	microrna	PROPN
ajlm-975	278	5	145	145	NUM
ajlm-975	278	6	expressionto	expressionto	NOUN
ajlm-975	278	7	directly	directly	ADV
ajlm-975	278	8	control	control	VERB
ajlm-975	278	9	genome	genome	NOUN
ajlm-975	278	10	amplification	amplification	NOUN
ajlm-975	278	11	.	.	PUNCT
ajlm-975	279	1	j	j	PROPN
ajlm-975	279	2	virol	virol	NOUN
ajlm-975	279	3	.	.	PUNCT
ajlm-975	280	1	2013;87(10	2013;87(10	NUM
ajlm-975	280	2	):	):	PUNCT
ajlm-975	280	3	6037–6043	6037–6043	NOUN
ajlm-975	280	4	.	.	PUNCT
ajlm-975	281	1	https://doi.org/10.1128/jvi.00153-13	https://doi.org/10.1128/jvi.00153-13	PROPN
ajlm-975	281	2	lee	lee	PROPN
ajlm-975	281	3	jw	jw	PROPN
ajlm-975	281	4	,	,	PUNCT
ajlm-975	281	5	choi	choi	PROPN
ajlm-975	281	6	ch	ch	PROPN
ajlm-975	281	7	,	,	PUNCT
ajlm-975	281	8	choi	choi	PROPN
ajlm-975	281	9	jj	jj	PROPN
ajlm-975	281	10	,	,	PUNCT
ajlm-975	281	11	et	et	PROPN
ajlm-975	281	12	al	al	PROPN
ajlm-975	281	13	.	.	PROPN
ajlm-975	281	14	altered	alter	VERB
ajlm-975	281	15	microrna	microrna	PROPN
ajlm-975	281	16	expression	expression	NOUN
ajlm-975	281	17	in	in	ADP
ajlm-975	281	18	cervical	cervical	ADJ
ajlm-975	281	19	carcinomas	carcinoma	NOUN
ajlm-975	281	20	.	.	PUNCT
ajlm-975	282	1	clin	clin	PROPN
ajlm-975	282	2	cancer	cancer	NOUN
ajlm-975	282	3	res	re	NOUN
ajlm-975	282	4	.	.	PUNCT
ajlm-975	283	1	2008;14(9):2535–2325	2008;14(9):2535–2325	NUM
ajlm-975	283	2	.	.	PUNCT
ajlm-975	284	1	https://doi.org/10.1158/1078-0432.ccr-07-1231	https://doi.org/10.1158/1078-0432.ccr-07-1231	X
ajlm-975	285	1	dreher	dreher	PROPN
ajlm-975	285	2	a	a	PROPN
ajlm-975	285	3	,	,	PUNCT
ajlm-975	285	4	rossing	rosse	VERB
ajlm-975	285	5	m	m	PRON
ajlm-975	285	6	,	,	PUNCT
ajlm-975	285	7	kaczkowski	kaczkowski	PROPN
ajlm-975	285	8	b.	b.	PROPN
ajlm-975	285	9	differential	differential	PROPN
ajlm-975	285	10	expression	expression	NOUN
ajlm-975	285	11	of	of	ADP
ajlm-975	285	12	cellular	cellular	ADJ
ajlm-975	285	13	micrornas	microrna	NOUN
ajlm-975	285	14	in	in	ADP
ajlm-975	285	15	hpv	hpv	PROPN
ajlm-975	285	16	11	11	NUM
ajlm-975	285	17	,	,	PUNCT
ajlm-975	285	18	-16	-16	NUM
ajlm-975	285	19	,	,	PUNCT
ajlm-975	285	20	and	and	CCONJ
ajlm-975	285	21	-45	-45	PUNCT
ajlm-975	285	22	transfected	transfecte	VERB
ajlm-975	285	23	cells	cell	NOUN
ajlm-975	285	24	.	.	PUNCT
ajlm-975	286	1	biochem	biochem	PROPN
ajlm-975	286	2	biophys	biophys	PROPN
ajlm-975	286	3	res	re	NOUN
ajlm-975	286	4	commun	commun	PROPN
ajlm-975	286	5	.	.	PUNCT
ajlm-975	287	1	2011;412:20–25	2011;412:20–25	NUM
ajlm-975	287	2	.	.	PUNCT
ajlm-975	288	1	https://doi.org/10.1016/j.bbrc.2011.07.011	https://doi.org/10.1016/j.bbrc.2011.07.011	NUM
ajlm-975	288	2	omar	omar	PROPN
ajlm-975	288	3	t	t	PROPN
ajlm-975	288	4	,	,	PUNCT
ajlm-975	288	5	schwartz	schwartz	PROPN
ajlm-975	288	6	s	s	PROPN
ajlm-975	288	7	,	,	PUNCT
ajlm-975	288	8	hanrahan	hanrahan	PROPN
ajlm-975	288	9	c	c	PROPN
ajlm-975	288	10	,	,	PUNCT
ajlm-975	288	11	et	et	PROPN
ajlm-975	288	12	al	al	PROPN
ajlm-975	288	13	.	.	PUNCT
ajlm-975	288	14	progression	progression	NOUN
ajlm-975	288	15	and	and	CCONJ
ajlm-975	288	16	regression	regression	NOUN
ajlm-975	288	17	of	of	ADP
ajlm-975	288	18	premaligant	premaligant	NOUN
ajlm-975	288	19	cervical	cervical	ADJ
ajlm-975	288	20	lesions	lesion	NOUN
ajlm-975	288	21	in	in	ADP
ajlm-975	288	22	hiv	hiv	PROPN
ajlm-975	288	23	-	-	PUNCT
ajlm-975	288	24	infected	infect	VERB
ajlm-975	288	25	women	woman	NOUN
ajlm-975	288	26	from	from	ADP
ajlm-975	288	27	soweto	soweto	PROPN
ajlm-975	288	28	:	:	PUNCT
ajlm-975	288	29	a	a	DET
ajlm-975	288	30	prospective	prospective	ADJ
ajlm-975	288	31	cohort	cohort	NOUN
ajlm-975	288	32	.	.	PUNCT
ajlm-975	289	1	aids	aids	PROPN
ajlm-975	289	2	.	.	PUNCT
ajlm-975	290	1	2011;25(1):87–94	2011;25(1):87–94	X
ajlm-975	290	2	.	.	PUNCT
ajlm-975	291	1	https://doi.org/10.1097/qad.0b013e328340fd99	https://doi.org/10.1097/qad.0b013e328340fd99	PRON